WO2012079072A2 - Subcutaneously infusible levodopa prodrug compositions and methods of infusion - Google Patents
Subcutaneously infusible levodopa prodrug compositions and methods of infusion Download PDFInfo
- Publication number
- WO2012079072A2 WO2012079072A2 PCT/US2011/064398 US2011064398W WO2012079072A2 WO 2012079072 A2 WO2012079072 A2 WO 2012079072A2 US 2011064398 W US2011064398 W US 2011064398W WO 2012079072 A2 WO2012079072 A2 WO 2012079072A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- prodrug
- solution
- infusion
- salt
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title claims abstract description 413
- 229940002612 prodrug Drugs 0.000 title claims abstract description 413
- 238000001802 infusion Methods 0.000 title claims abstract description 259
- 238000000034 method Methods 0.000 title claims abstract description 188
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract description 409
- 229960004502 levodopa Drugs 0.000 title abstract description 406
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract description 399
- -1 levodopa amides Chemical class 0.000 claims abstract description 231
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 94
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 291
- 239000000243 solution Substances 0.000 claims description 256
- 150000003839 salts Chemical class 0.000 claims description 178
- 239000007788 liquid Substances 0.000 claims description 107
- 239000007787 solid Substances 0.000 claims description 104
- 229960004205 carbidopa Drugs 0.000 claims description 103
- 238000004599 local-density approximation Methods 0.000 claims description 88
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 85
- 239000007864 aqueous solution Substances 0.000 claims description 83
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- 229940079593 drug Drugs 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 52
- 229910052760 oxygen Inorganic materials 0.000 claims description 52
- 229910001868 water Inorganic materials 0.000 claims description 51
- 239000002253 acid Substances 0.000 claims description 50
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 50
- 239000001301 oxygen Substances 0.000 claims description 50
- 238000007920 subcutaneous administration Methods 0.000 claims description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 45
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000002585 base Substances 0.000 claims description 40
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- 239000002244 precipitate Substances 0.000 claims description 32
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 30
- 229940049918 linoleate Drugs 0.000 claims description 30
- 229960001794 melevodopa Drugs 0.000 claims description 30
- 239000003963 antioxidant agent Substances 0.000 claims description 28
- 235000006708 antioxidants Nutrition 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 26
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 25
- 239000000194 fatty acid Substances 0.000 claims description 25
- 229920002674 hyaluronan Polymers 0.000 claims description 25
- 229960003160 hyaluronic acid Drugs 0.000 claims description 25
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 24
- 229930195729 fatty acid Natural products 0.000 claims description 24
- NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical group CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 claims description 22
- 229960001820 etilevodopa Drugs 0.000 claims description 22
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 21
- 239000001509 sodium citrate Substances 0.000 claims description 20
- 230000003078 antioxidant effect Effects 0.000 claims description 19
- 206010044565 Tremor Diseases 0.000 claims description 18
- 235000012054 meals Nutrition 0.000 claims description 18
- 238000003860 storage Methods 0.000 claims description 18
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 17
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 17
- 230000002378 acidificating effect Effects 0.000 claims description 15
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 239000000839 emulsion Substances 0.000 claims description 14
- 238000007918 intramuscular administration Methods 0.000 claims description 14
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 14
- 229940038773 trisodium citrate Drugs 0.000 claims description 14
- 208000012661 Dyskinesia Diseases 0.000 claims description 13
- 230000033001 locomotion Effects 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 229940049964 oleate Drugs 0.000 claims description 13
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 12
- 230000007958 sleep Effects 0.000 claims description 12
- 206010001541 Akinesia Diseases 0.000 claims description 11
- 206010006100 Bradykinesia Diseases 0.000 claims description 11
- 208000006083 Hypokinesia Diseases 0.000 claims description 11
- 235000015165 citric acid Nutrition 0.000 claims description 11
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 11
- 238000012545 processing Methods 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- 239000001488 sodium phosphate Substances 0.000 claims description 11
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 10
- 230000000202 analgesic effect Effects 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 230000036470 plasma concentration Effects 0.000 claims description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 claims description 9
- 229940114078 arachidonate Drugs 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 210000003205 muscle Anatomy 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 8
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 8
- 229940000640 docosahexaenoate Drugs 0.000 claims description 8
- 229940066279 eicosapentaenoate Drugs 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- 229940105132 myristate Drugs 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 8
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 8
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 8
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 8
- 208000014094 Dystonic disease Diseases 0.000 claims description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 239000012298 atmosphere Substances 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003246 corticosteroid Substances 0.000 claims description 7
- 208000010118 dystonia Diseases 0.000 claims description 7
- 239000003966 growth inhibitor Substances 0.000 claims description 7
- 229960001680 ibuprofen Drugs 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 7
- 229940005657 pyrophosphoric acid Drugs 0.000 claims description 7
- 229960004889 salicylic acid Drugs 0.000 claims description 7
- 210000003491 skin Anatomy 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- 229940007079 succinylated gelatin Drugs 0.000 claims description 7
- 108010013480 succinylated gelatin Proteins 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 230000024121 nodulation Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 229920005646 polycarboxylate Polymers 0.000 claims description 6
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 claims description 6
- 229940066675 ricinoleate Drugs 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- 239000004135 Bone phosphate Substances 0.000 claims description 5
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 150000001840 cholesterol esters Chemical class 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 210000002615 epidermis Anatomy 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 229920002643 polyglutamic acid Polymers 0.000 claims description 5
- 229920001444 polymaleic acid Polymers 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 239000008159 sesame oil Substances 0.000 claims description 5
- 235000011803 sesame oil Nutrition 0.000 claims description 5
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 5
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 5
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 4
- 102000001974 Hyaluronidases Human genes 0.000 claims description 4
- 241000489861 Maximus Species 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 230000001800 adrenalinergic effect Effects 0.000 claims description 4
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002576 amiloride Drugs 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 239000002385 cottonseed oil Substances 0.000 claims description 4
- 235000012343 cottonseed oil Nutrition 0.000 claims description 4
- 229960001259 diclofenac Drugs 0.000 claims description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 229960002773 hyaluronidase Drugs 0.000 claims description 4
- 229960000905 indomethacin Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 210000000062 pectoralis major Anatomy 0.000 claims description 4
- 210000003314 quadriceps muscle Anatomy 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 229940070710 valerate Drugs 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 206010042674 Swelling Diseases 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000002111 antiemetic agent Substances 0.000 claims description 3
- 229940125683 antiemetic agent Drugs 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- GRZMOSSVIPFGFF-GNJLJDPWSA-N 2-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone;sulfuric acid Chemical compound OS(O)(=O)=O.C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1.C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 GRZMOSSVIPFGFF-GNJLJDPWSA-N 0.000 claims description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 2
- AVZIYZHXZAYGJS-UHFFFAOYSA-N Difenidol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 AVZIYZHXZAYGJS-UHFFFAOYSA-N 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 2
- 206010020651 Hyperkinesia Diseases 0.000 claims description 2
- 208000000269 Hyperkinesis Diseases 0.000 claims description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 2
- SDBHDSZKNVDKNU-UHFFFAOYSA-N buclizine dihydrochloride Chemical compound Cl.Cl.C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 SDBHDSZKNVDKNU-UHFFFAOYSA-N 0.000 claims description 2
- 229960001676 buclizine hydrochloride Drugs 0.000 claims description 2
- UKPBEPCQTDRZSE-UHFFFAOYSA-N cyclizine hydrochloride Chemical compound Cl.C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UKPBEPCQTDRZSE-UHFFFAOYSA-N 0.000 claims description 2
- 229960001677 cyclizine hydrochloride Drugs 0.000 claims description 2
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004993 dimenhydrinate Drugs 0.000 claims description 2
- 229960005058 diphenidol hydrochloride Drugs 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000767 metopimazine Drugs 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 229960005343 ondansetron Drugs 0.000 claims description 2
- RUPOLIZWSDDWNJ-UHFFFAOYSA-N oxypendyl Chemical compound C1CN(CCO)CCN1CCCN1C2=NC=CC=C2SC2=CC=CC=C21 RUPOLIZWSDDWNJ-UHFFFAOYSA-N 0.000 claims description 2
- 229950005217 oxypendyl Drugs 0.000 claims description 2
- OSJJYEUEJRVVOD-UHFFFAOYSA-N pipamazine Chemical compound C1CC(C(=O)N)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 OSJJYEUEJRVVOD-UHFFFAOYSA-N 0.000 claims description 2
- 229950008580 pipamazine Drugs 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 229940048084 pyrophosphate Drugs 0.000 claims description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 2
- 229960002646 scopolamine Drugs 0.000 claims description 2
- 238000011179 visual inspection Methods 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 claims 9
- 102100038889 Laforin, isoform 9 Human genes 0.000 claims 5
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 2
- 229940067596 butylparaben Drugs 0.000 claims 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 abstract description 6
- 102100035192 Laforin Human genes 0.000 description 105
- 238000009472 formulation Methods 0.000 description 52
- 230000007062 hydrolysis Effects 0.000 description 46
- 238000006460 hydrolysis reaction Methods 0.000 description 46
- 238000007254 oxidation reaction Methods 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 230000003647 oxidation Effects 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- 230000007935 neutral effect Effects 0.000 description 18
- 150000007519 polyprotic acids Polymers 0.000 description 17
- 238000001556 precipitation Methods 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 17
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 16
- 150000001450 anions Chemical class 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- IVYOMTNVXXPNCD-UHFFFAOYSA-N ethyl 3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoate Chemical compound CCOC(=O)C(C)(NN)CC1=CC=C(O)C(O)=C1 IVYOMTNVXXPNCD-UHFFFAOYSA-N 0.000 description 11
- 125000004404 heteroalkyl group Chemical group 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 239000003978 infusion fluid Substances 0.000 description 11
- 235000019263 trisodium citrate Nutrition 0.000 description 11
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000012669 liquid formulation Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 7
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000008366 buffered solution Substances 0.000 description 7
- 229920005549 butyl rubber Polymers 0.000 description 7
- 229920005556 chlorobutyl Polymers 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 150000004820 halides Chemical class 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- 238000007913 intrathecal administration Methods 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
- 102000010909 Monoamine Oxidase Human genes 0.000 description 6
- 108010062431 Monoamine oxidase Proteins 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 125000004103 aminoalkyl group Chemical group 0.000 description 6
- 125000005110 aryl thio group Chemical group 0.000 description 6
- 125000004104 aryloxy group Chemical group 0.000 description 6
- 125000004181 carboxyalkyl group Chemical group 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 229920001971 elastomer Polymers 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 125000003709 fluoroalkyl group Chemical group 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 229920002681 hypalon Polymers 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 235000010378 sodium ascorbate Nutrition 0.000 description 6
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 6
- 229960005055 sodium ascorbate Drugs 0.000 description 6
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000003929 acidic solution Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 239000003637 basic solution Substances 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 150000001735 carboxylic acids Chemical class 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- IETYBXLXKYRFEN-UHFFFAOYSA-N methyl 3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoate Chemical compound COC(=O)C(C)(NN)CC1=CC=C(O)C(O)=C1 IETYBXLXKYRFEN-UHFFFAOYSA-N 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- KZQSXALQTHVPDQ-UHFFFAOYSA-M sodium;butanedioate;hydron Chemical compound [Na+].OC(=O)CCC([O-])=O KZQSXALQTHVPDQ-UHFFFAOYSA-M 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 208000004547 Hallucinations Diseases 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 239000013011 aqueous formulation Substances 0.000 description 4
- 229920005557 bromobutyl Polymers 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 235000011083 sodium citrates Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 229920008790 Amorphous Polyethylene terephthalate Polymers 0.000 description 3
- 102100040999 Catechol O-methyltransferase Human genes 0.000 description 3
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009056 active transport Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 150000007514 bases Chemical class 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 229940050526 hydroxyethylstarch Drugs 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000005033 polyvinylidene chloride Substances 0.000 description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 3
- 229960004134 propofol Drugs 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 108090000531 Amidohydrolases Proteins 0.000 description 2
- 102000004092 Amidohydrolases Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 2
- 229960000911 benserazide Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 229960002842 clobetasol Drugs 0.000 description 2
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 239000002526 disodium citrate Substances 0.000 description 2
- 235000019262 disodium citrate Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 229940043075 fluocinolone Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229940105623 neo-synephrine Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 150000008054 sulfonate salts Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FLDCGABOSKKJQE-UHFFFAOYSA-N 1-trimethylsilylethanesulfonamide Chemical class C[Si](C)(C)C(C)S(N)(=O)=O FLDCGABOSKKJQE-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical class NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- YBVRFTBNIZWMSK-UHFFFAOYSA-N 2,2-dimethyl-1-phenylpropan-1-ol Chemical compound CC(C)(C)C(O)C1=CC=CC=C1 YBVRFTBNIZWMSK-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- GWJSQKNYHPYZRN-UHFFFAOYSA-N 2-methylpropane-2-sulfonamide Chemical class CC(C)(C)S(N)(=O)=O GWJSQKNYHPYZRN-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- WJQOZHYUIDYNHM-UHFFFAOYSA-N 2-tert-Butylphenol Chemical class CC(C)(C)C1=CC=CC=C1O WJQOZHYUIDYNHM-UHFFFAOYSA-N 0.000 description 1
- BVCOHOSEBKQIQD-UHFFFAOYSA-N 2-tert-butyl-6-methoxyphenol Chemical compound COC1=CC=CC(C(C)(C)C)=C1O BVCOHOSEBKQIQD-UHFFFAOYSA-N 0.000 description 1
- 125000006224 2-tetrahydrofuranylmethyl group Chemical group [H]C([H])(*)C1([H])OC([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- GWXXFGWOWOJEEX-UHFFFAOYSA-N 4,4,4-trihydroxy-1-phenylbutan-1-one Chemical compound OC(CCC(=O)C1=CC=CC=C1)(O)O GWXXFGWOWOJEEX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- LAAPRQODJPXAHC-UHFFFAOYSA-N Coniferyl benzoate Natural products C1=C(O)C(OC)=CC(C=CCOC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 101710096582 L-tyrosine decarboxylase Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 102000012106 Neutral Amino Acid Transport Systems Human genes 0.000 description 1
- 108010036505 Neutral Amino Acid Transport Systems Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010030312 On and off phenomenon Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229940052651 anticholinergic tertiary amines Drugs 0.000 description 1
- 229940003824 apomorphine 10 mg/ml Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- LAAPRQODJPXAHC-AATRIKPKSA-N coniferyl benzoate Chemical compound C1=C(O)C(OC)=CC(\C=C\COC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-AATRIKPKSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- XMSHRLOQLUNKSN-UHFFFAOYSA-N destosyl pyrazolate Chemical compound CC1=NN(C)C(O)=C1C(=O)C1=CC=C(Cl)C=C1Cl XMSHRLOQLUNKSN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000005057 finger movement Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 229940066963 gamma-linolenate Drugs 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229960004310 piribedil Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- CDOZDBSBBXSXLB-UHFFFAOYSA-N profenamine Chemical compound C1=CC=C2N(CC(C)N(CC)CC)C3=CC=CC=C3SC2=C1 CDOZDBSBBXSXLB-UHFFFAOYSA-N 0.000 description 1
- 229960002262 profenamine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000002398 sedimentation field-flow fractionation Methods 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical class NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
Definitions
- the invention relates to compositions, including levodopa esters, for the treatment of Parkinson's disease.
- Parkinson' s disease is characterized by the inability of the dopaminergic neurons in the substantia nigra to produce the neurotransmitter dopamine. PD impairs motor skills, cognitive processes, autonomic functions and sleep. Motor symptoms include tremor, rigidity, slow movement
- Non- motor symptoms of PD include dementia, dysphagia (difficulty swallowing), slurred speech, orthostatic hypotension, seborrheic dermatitis, urinary incontinence, constipation, mood alterations, sexual dysfunction, and sleep issues (e.g., daytime somnolence, insomnia).
- levodopa levodopa
- Levodopa is usually orally administered.
- the orally administered levodopa enters the blood and part of the levodopa in the blood crosses the blood brain barrier. It is metabolized, in part, in the brain to dopamine which temporarily diminishes the motor symptoms of PD.
- the neurodegeration underlying PD progresses, the patients require increasing doses of levodopa and the fluctuations of brain dopamine levels increase.
- DDC inhibitors such as carbidopa and benserazide
- dopamine receptor agonists such as pramipexole, ropinirole
- bromocriptine pergolide, piribedil, cabergoline, lisuride, and apomorphine
- MAO-B inhibitors such as rasagiline and selegiline
- COMT inhibitors such as entacapone and tolcapone
- anticholinergics such as trihexiphenidyl, benztropine, biperiden, and ethopropazine
- amantadine such as trihexiphenidyl, benztropine, biperiden, and ethopropazine.
- DDC-inhibitors primarily CD or benserazide.
- CD extends the plasma half-life of levodopa to approximately 90 minutes.
- Standard levodopa treatment with oral delivery typically leads to intermittent plasma levodopa levels, which are thought to contribute to motor complications.
- more continuous delivery of levodopa that provides smooth, predictable plasma levels leads to a good therapeutic response with reduced motor complications.
- Levodopa is poorly soluble in aqueous solutions near neutral pH. For example, at 25 °C and at pH 5 the solubility of levodopa is only about 2.8 g per liter, and at neutral pH it is even less soluble, only about 1.65 g per liter. A patient requiring 1 g levodopa per day would correspondingly require the daily infusion of 0.36 liters of the pH 5 solution and of 0.6 liters of the neutral pH solution. In early studies of IV levodopa infusion, volumes of over 2 L of solution (saline or dextrose and water) per day with less than 1 mg/mL of levodopa were often administered making this administration very cumbersome. The acidity of the infusion substance can create an increased risk of thrombophlebitis, and to reduce this risk, central venous access was often utilized.
- the two most widely tested levodopa prodrugs are its methyl ester, known as Melevodopa or LDME, and its ethyl ester, known as Etilevodopa or LDEE (see, for example, Stocchi et al., Mov Disord 25: 1881 (2010); Stocchi et al., Clin Neuropharmacol 33: 198 (2010); Djaldetti et al., Clin Neuropharmacol 26:322 (2003); and Blindauer et al., Arch Neurol 63:210 (2006)).
- LDME and LDEE can be unstable in solution, making them difficult to store.
- the invention features stable compositions that can permit subcutaneous administration of levodopa, or a levodopa prodrug, for the treatment of Parkinson's disease.
- CD refers to Carbidopa.
- carbidopa prodrug refers to carbidopa esters, carbidopa amides, and salts thereof, such as the hydrochloride salt of carbidopa ethyl ester, carbidopa methyl ester, or carbidopa amide.
- DDC refers to DOPA decarboxylase
- hyaluronic acid refers to hyaluronic acid and salts thereof.
- IV refers to intravenous.
- LD refers to levodopa, also known as L-DOPA, or a salt thereof.
- LD 50 refers to the median lethal oral dose of an LD prodrug in rats at 48 hours (e.g., the dose of LD prodrug required to kill half the rats within 48 hours after ingestion of the LD prodrug).
- LDA refers to an LD prodrug that is a levodopa amide of formula (III):
- each of R 5 and R 6 is, independently, selected from H, Ci_ 6 alkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, C 2 _6 heterocyclyl, C ⁇ i2 aryl, C 7 _i 4 alkaryl, C 3 _i 0 alkheterocyclyl, and Ci_ 7 heteroalkyl.
- R 5 is H or CH 3
- R 6 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , benzyl, 2-deoxy-2-glucosyl, or CH 2 CH 2 NH 2 .
- LDAs are hydrolyzed in vivo to form LD and an amine or ammonium salt.
- the LDAs of the invention and their hydrolysis products have an LD 50 in rats of greater than 3 millimoles kg.
- the LDA can be administered, for example, in its free base form, or as an acid addition salt.
- LDC refers to an LD prodrug that is a levodopa carboxamide of formula (II):
- R 2 is selected from Ci_6 alkyl, C 2 _6 alkenyl, C 2 -6 alkynyl, Ce-n aryl, C 7 _i 4 alkaryl, C 3 _i 0 alkheterocyclyl, and Ci_ 7 heteroalkyl.
- R 2 is CH 2 CH 3 , CH(OH)CH 3 , CH 2 CH 2 COOH, CH 2 CH 2 CH 3 , benzenepropenyl, phenyl, or (CHOH) 4 CH 2 OH.
- LDCs are hydrolyzed in vivo to form LD and a carboxylate or carboxylic acid.
- the LDCs of the invention and their hydrolysis products have an LD 50 in rats of greater than 3 millimoles/kg.
- the LDC can be administered, for example, in its neutral form, or as an alkali metal or alkaline earth salt.
- LDE refers to an LD prodrug that is a levodopa ester of formula (I):
- Ri is selected from Ci_6 alkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, C 2 _ 6 heterocyclyl, C ⁇ i2 aryl, C 7 _ M alkaryl, C 3 _i 0 alkheterocyclyl, and Ci_ 7 heteroalkyl.
- ORi is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH(CH 3 ) 2 ,
- LDEs are hydrolyzed in vivo to form LD and an alcohol.
- the LDEs of the invention and their hydrolysis products have an LD 50 in rats of greater than 3 millimoles/kg.
- the LDE can be administered, for example, in its free base form, or as an acid addition salt.
- LDS refers to an LD prodrug that is a levodopa sulfonamide of formula (IV):
- R 3 is selected from Ci_6 alkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, C 2 _6 heterocyclyl, Ce-n aryl, C 7 _ M alkaryl, C 3 _i 0 alkheterocyclyl, and Ci_ 7 heteroalkyl.
- R 3 is CH 3 , or 4-methylbenzyl.
- LDSs are hydrolyzed in vivo to form LD and a sulfonate.
- the LDSs of the invention and their hydrolysis products have an LD 50 in rats of greater than 3 millimoles/kg.
- the LDS can be administered, for example, in its neutral form, or as an alkali metal or alkaline earth salt.
- LEE levodopa ethyl ester, or a salt thereof.
- LDME levodopa methyl ester, or a salt thereof.
- LD prodrug refers to a pharmaceutical composition suitable for infusion, preferably for subcutaneous or intramuscular infusion, forming LD upon its hydrolysis. Examples include LDA, LDE, LDC, LDS, LDEE, and LDME, and their salts.
- the salts are usually formed, in the cases of LDEs and LDCs, by neutralizing their basic amines with an acid; and, in the cases of LDAs and LDSs, by neutralizing their carboxylic acids or sulfonic acids with a base.
- MAO-B refers to monoamine oxidase-B.
- neutral amino acid refers to an amino acid having only one carboxylic acid and only one amine function. Although phenolic amino acids like LD and OMD are partly ionized to anions and hydrated protons at neutral pH, they are classified as neutral.
- PD refers to Parkinson's disease.
- PEG refers to polyethylene glycol
- pH refers to the pH measured using a pH meter having a glass electrode connected to an electronic meter.
- polybasic acid means an acid having two or more ionizable functions and acid salts of these acids.
- examples of polybasic acids include citric acid, succinic acid and phosphoric acid and examples of their acid salts include monosodium citrate, monosodium succinate and monosodium phosphate.
- s.c refers to subcutaneous.
- administering refers to a parenteral method (e.g., infusion, injection, transdermal delivery, or buccal delivery) of giving a dosage of LD or LD prodrug (e.g., LDA, LDE, LDC, or LDS) to a subject.
- LD or LD prodrug e.g., LDA, LDE, LDC, or LDS
- the dosage form of the invention is preferably administered intramuscularly or subcutaneously, optionally using an infusion pump.
- aqueous refers to formulations of the invention including greater than 10% or 20 % (w/w) water and, optionally, a cosolvent (e.g., glycerol or ethanol).
- a cosolvent e.g., glycerol or ethanol.
- coinfused refers to two or more pharmaceutically active agents, formulated together, or separately, and infused simultaneously, either to the same site (e.g., infused via the same infusion cannula or needle), or adjacent sites (e.g., infused via separate infusion cannulae or needles within 1 cm of each other).
- continuous administration or “continuous infusion” refers to both uninterrupted administration/infusion and frequent administration/infusion. In the case of frequent
- the frequency is typically at least once per hour, preferably at least twice per hour, more preferably at least four times per hour, and most preferably at least six times per hour.
- Typical daily durations of continuous administration or infusion typically exceed 12 hours, and are usually 16 hours or 24 hours.
- the rate of administration or infusion may be reduced during intended sleep periods, optionally to nil.
- the terms "effective particle size” and “particle size” are used interchangeably and refer to a mixture of particles having a distribution in which 50% of the particles are below and 50% of the particles are above a defined measurement.
- the "effective particle size” refers to the volume- weighted median diameter as measured by a laser/light scattering method or equivalent, wherein 50% of the particles, by volume, have a smaller diameter, while 50% by volume have a larger diameter.
- the effective particle size can be measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering (e.g., with a Microtrac UPA 150), laser diffraction, and disc centrifugation.
- fatty acid salt is meant a fatty acid addition salt of LD or LD prodrug (e.g., LDE, or LDC) in which the anion is a carboxylate, R-C(0)0-, in which R is a saturated or partially- saturated straight chain or branched hydrocarbon group having between 8 and 26 carbon atoms.
- Fatty acid salts are derived from fatty acids including, without limitation, those occurring naturally in the brain, or found in blood lipids like triglycerides or cholesterol esters.
- fatty acids having 16 carbon atoms and 0, 1 or 2 double bonds (C16:0; C16: 1 and C16:2), those with 18 carbon atoms and 1, 2 or 3 double bonds (C18: 1; C18:2; and C18:3), those with 20 carbon atoms and 1, 2 or 4 double bonds (C20: l; C20:2; and C20:4) and those with 22 carbon atoms and 4, 5 or 6 double bonds (C22:4; C22:5 and C22:6).
- the fatty acids can be substituted or unsubstituted.
- Exemplary substituents include hydroxyl, halide, methyl, ethyl, propyl, isopropyl, butyl, and pentyl groups.
- the fatty acid salt is 4, 7, 10, 13, 16, 19 docosahexanoate, oleate, ricinoleate, octanoate, alpha-linoleate, eicosapentaenoate, docosahexaenoate, linoleate, gamma linoleate, palmitoleate, dihomogamma linoleate, arachidonate, myristate, palmitate, and stearate.
- infused or “infusion” includes infusion into any part of the body, including the stomach, intestines, abdominal cavity, muscles, fat, dermis, or subcutaneous tissue.
- fluid liquid crystal refers to a liquid dosage form of the invention that includes an ordered phase.
- the presence of a liquid crystal phase can be identified optically (e.g., via optical properties, such as birefringence).
- liquid salt form refers to a salt of an LD prodrug that is a liquid at 25°C.
- the liquid salt can be a thermodynamically stable liquid, or it can be a liquid that is thermodynamically metastable and, for example, because of its high viscosity, it does not readily crystallize. When metastable, it is preferred that the liquid salt be stored at about 4°C or less, where its viscosity is usually higher than it is at 25°C.
- the liquid is typically clear, although it may contain particles with a particle size smaller than about 1 ⁇ .
- liquidus refers to the temperature of a mixture not having a sharp melting point.
- the liquidus is the temperature where practically the entire mixture is liquid. While above the liquidus temperature the mixture is usually clear, below the liquidus temperature it usually includes light- scattering crystallites.
- non-aqueous refers to formulations of the invention including less than 10% (w/w) water (e.g., less than 5%, 3%, 2%, 1.5%, 1%, 0.5%, or less than 0.1% (w/w) of the formulation is water).
- shelf life means the shelf life of the inventive LD prodrug product sold for use by consumers, during which period the product is suitable for use by a subject.
- the shelf life of the LD prodrugs of the invention can be greater than 3, 6, 12, 18, or preferably 24 months.
- the shelf life may be achieved when the product is stored frozen (e.g., at about -18 °C), stored refrigerated (at about 5 + 3 °C, for example at about 4 + 2 °C), or stored at room temperature (e.g., at about 25°C).
- the LD prodrug product sold to consumers may be the solution ready for infusion, or it may be its components.
- the LD prodrug product for use by consumers may be the dry solid LD prodrug and, optionally, the solution used for its reconstitution; or the LD prodrug stored in an acidic solution and, optionally, a neutralizing basic solution; etc.
- the term "operational life” means the time period during which the infusion solution containing the LD prodrug is suitable for infusion into a subject, under actual infusion conditions.
- the operational life of the LD prodrugs of the invention can be greater than 12 hours, 24 hours, 48 hours, 72 hours, 96 hours (4 days), or 7 days. It typically requires that the product is not frozen or refrigerated.
- the product is often infused at room temperature (e.g., about 25°C), at body temperature (about 37°C), or in-between (e.g., 30 °C).
- stable refers to formulations of the invention which are “oxidatively stable” and “hydrolytically stable.” Stable formulations exhibit a reduced susceptibility to chemical transformation (e.g., oxidation and/or hydrolysis) prior to infusion into a subject. Stable dry or liquid formulations are those having a shelf life during which less than 10%, 5%, 4%, 3%, 2% or less than 1% of the LD prodrug (e.g., LDA, LDE, LDC, or LDS) is oxidized or hydrolyzed when stored for a period of 3, 6, 12, 18, or 24 months. In general, the solutions of the stable formulations remain clear, meaning that they have no substantial visible precipitate, after their storage.
- LD prodrug e.g., LDA, LDE, LDC, or LDS
- Stable liquid formulations have an operational life during which less than 10%, 5%, 4%, 3%, 2% or less than 1% of the LD prodrug (e.g., LDA, LDE, LDC, or LDS) is oxidized or hydrolyzed over a period of 8 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, or 7 days.
- An "oxidatively stable" formulation exhibits a reduced susceptibility to oxidation during its shelf life and/or its operational life, during which less than 10%, 5%, 4%, 3%, or less than 2% of the LD prodrug (e.g., LDA, LDE, LDC, or LDS) is oxidized.
- the LD prodrug e.g., LDA, LDE, LDC, or LDS
- hydrolytically stable formulation exhibits a reduced susceptibility to hydrolysis during its shelf life and/or operational life in which less than 20%, 10%, 5%, 4%, 3%, 2% or less than 1% of the LD prodrug (e.g., LDA, LDE, LDC, or LDS) is hydrolyzed.
- LD prodrug e.g., LDA, LDE, LDC, or LDS
- substantially free LD precipitate refers to formulations of the invention that are clear and without visible precipitates of LD.
- substantially free of oxygen refers to compositions of the invention packaged in a container for storage or for use wherein the packaged compositions are largely free of oxygen gas (e.g., less than 10%, or less than 5%, of the gas that is in contact with the composition is oxygen gas) or wherein the partial pressure of the oxygen is less than 15 torr, 10 torr, or 5 torr. This can be
- the composition is accomplished by, for example, replacing a part or all of the ambient air in the container with an inert atmosphere, such as nitrogen, carbon dioxide, argon, or neon, or by packaging the composition in a container under a vacuum.
- an inert atmosphere such as nitrogen, carbon dioxide, argon, or neon
- substantially free of water refers to compositions of the invention packaged in a container (e.g., a cartridge) for storage or for use wherein the packaged compositions are largely free of water (e.g., less than 2%, 1%, 0.5%, 0.1%, 0.05%, or less than 0.01% (w/w) of the composition is water). This can be accomplished by, for example, drying the constituents of the formulation prior to sealing the container.
- treating refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes.
- To “prevent disease” refers to prophylactic treatment of a subject who is not yet ill, but who is susceptible to, or otherwise at risk of, a particular disease.
- To “treat disease” or use for “therapeutic treatment” refers to administering treatment to a subject already suffering from a disease to ameliorate the disease and improve the subject's condition.
- the term “treating” also comprises treating a subject to delay progression of a disease or its symptoms. Thus, in the claims and embodiments, treating is the administration to a subject either for therapeutic or prophylactic purposes.
- alkyl and the prefix “alk-” are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e., cycloalkyl.
- Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 6 ring carbon atoms, inclusive.
- Exemplary cyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups.
- Ci_6 alkyl is meant a branched or unbranched hydrocarbon group having from 1 to 6 carbon atoms.
- a Ci_6 alkyl may be substituted or unsubstituted, may optionally include monocyclic or polycyclic rings.
- Exemplary substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxyl, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
- Ci_6 alkyls include, without limitation, methyl, ethyl, n-propyl, isopropyl, cyclopropyl,
- cyclopropylmethyl n-butyl, iso-butyl, sec-butyl, tert-butyl, and cyclobutyl.
- C 2 -6 alkenyl is meant a branched or unbranched hydrocarbon group containing one or more double bonds and having from 2 to 6 carbon atoms.
- a C 2 _ 6 alkenyl may be substituted or unsubstituted, may optionally include monocyclic or polycyclic rings.
- Exemplary substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxyl, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
- C 2 _i 2 alkenyls include, without limitation, vinyl, allyl, 2-cyclopropyl-l-ethenyl, 1-propenyl, 1-butenyl, 2-butenyl, 3- butenyl, 2-methyl- 1-propenyl, and 2-methyl-2-propenyl.
- C 2 -6 alkynyl is meant a branched or unbranched hydrocarbon group containing one or more triple bonds and having from 2 to 12 carbon atoms.
- a C 2 -6 alkynyl may be substituted or unsubstituted, may optionally include monocyclic or polycyclic rings.
- Exemplary substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxy, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
- C 2 -6 alkynyls include, without limitation, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, and 3-butynyl.
- Ce-12 aryl is meant an aromatic group having a ring system comprised of carbon atoms with conjugated ⁇ electrons (e.g., phenyl).
- the aryl group has from 6 to 12 carbon atoms.
- Aryl groups may optionally include monocyclic, bicyclic, or tricyclic rings, in which each ring desirably has five or six members.
- the aryl group may be substituted or unsubstituted.
- substituents include alkyl, hydroxy, alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, fluoroalkyl, carboxyl, hydroxyalkyl, carboxyalkyl, amino, aminoalkyl, monosubstituted amino, disubstituted amino, and quaternary amino groups.
- C 7 _i4 alkaryl is meant an alkyl or heteroalkyl substituted by an aryl group (e.g., benzyl, phenethyl, phenoxyethyl, or 3,4-dichlorophenethyl) having from 7 to 14 carbon atoms.
- aryl group e.g., benzyl, phenethyl, phenoxyethyl, or 3,4-dichlorophenethyl
- Ci_7 heteroalkyl is meant a branched or unbranched alkyl, alkenyl, or alkynyl group having from 1 to 7 carbon atoms in addition to 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O, S, and P.
- Heteroalkyls include, without limitation, saccharide radicals, tertiary amines, secondary amines, ethers, thioethers, amides, thioamides, carbamates, thiocarbamates, hydrazones, imines, phosphodiesters, phosphoramidates, sulfonamides, and disulfides.
- a heteroalkyl may optionally include monocyclic, bicyclic, or tricyclic rings, in which each ring desirably has three to six members.
- the heteroalkyl group may be substituted or unsubstituted.
- substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxyl, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
- Examples of Ci_ 7 heteroalkyls include, without limitation, methoxymethyl and ethoxy ethyl.
- C 2 -6 heterocyclyl is meant a stable 5- to 7-membered monocyclic or 7- to 14-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists of 2 to 6 carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
- the heterocyclyl group may be substituted or unsubstituted.
- substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxy, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
- the nitrogen and sulfur heteroatoms may optionally be oxidized.
- the heterocyclic ring may be covalently attached via any heteroatom or carbon atom which results in a stable structure, e.g., an imidazolinyl ring may be linked at either of the ring-carbon atom positions or at the nitrogen atom.
- a nitrogen atom in the heterocycle may optionally be quaternized.
- Heterocycles include, without limitation, saccharide radicals.
- C 3 _io alkheterocyclyl is meant an alkyl or heteroalkyl substituted heterocyclic group having from 3 to 10 carbon atoms in addition to one or more heteroatoms (e.g., 3-furanylmethyl, 2- furanylmethyl, 3-tetrahydrofuranylmethyl, or 2-tetrahydrofuranylmethyl).
- the invention features pharmaceutical compositions, devices and methods for the management of PD. Specifically, it features compositions, devices and methods for maintaining plasma LD
- This invention features stable aqueous solutions in which the concentration of a levodopa prodrug can be high enough to allow subcutaneous administration of the typical daily dose of about 5 millimoles to Parkinson's disease patients, usually in a volume of less than about 20 mL, preferably less than 15 mL. It also features LD prodrug compositions that can be subcutaneously infused, without nodule formation, and that are sufficiently stable at body temperature to allow their infusion.
- the compositions are generally solutions of levodopa esters, carboxamides, sulfonamides or amides. These can be rapidly hydrolyzed by enzymes of the body to levodopa and respectively to an alcohol.
- the invention also features stable aqueous and non-aqueous compositions in which the concentration of a levodopa prodrug can be high enough to allow intragastric, intraduodenal or intrajejunal administration of the typical daily dose of about 5 millimoles to Parkinson' s disease patients, usually in a volume of less than about 5 mL, preferably less than 3 mL. They form infusible solutions that can be stable at about 37°C for at least 16 hours, 1 day or 2 days.
- the compositions are generally solutions of salts of levodopa esters, carboxamides, sulfonamides or amides.
- the LD-prodrugs can be rapidly hydrolyzed by enzymes of the body to levodopa and respectively to an alcohol, a carboxylate salt, e.g., a sodium carboxylate; a sulfonate salt, e.g., a sodium sulfonate; or an ammonium salt, e.g., an ammonium chloride.
- a carboxylate salt e.g., a sodium carboxylate
- a sulfonate salt e.g., a sodium sulfonate
- an ammonium salt e.g., an ammonium chloride.
- Advanced PD patients require daily typically about 1 + 0.5 g, or about 5.0 + 2.5 millimoles of LD.
- the LD-prodrug solutions of this invention are concentrated, such that a daily subcutaneously or intramuscularly infused liquid volume can typically be less than 20 mL, less than 15 mL, less than 10 mL or less than 5 mL per infusion site.
- one or more skin-attached patch pumps is/are used for the infusion.
- the subcutaneously or intramuscularly infused solutions can be stored refrigerated for a period that can be longer than a year.
- the stored LD-prodrug solutions typically have a pH of 2.5 + 0.5.
- the ready-to- infuse solutions Prior to their subcutaneous or intramuscular infusion, their pH is increased typically to 5.0 + 0.5, the ready-to- infuse solutions being typically stable at 37°C for at least 24 hrs. Even more concentrated and therefore smaller daily volumes, typically of less than 5 mL or preferably less than 3 mL, can be intragastrically, intraduodenally or intrajejunally infused in a subject requiring about 1 g or about 5 millimoles of LD per day.
- the solutions can be hydrolytically and oxidatively stable. They can be stored refrigerated for periods typically longer than a year. The most preferred solutions are those including LDEE salts.
- the invention features a method for treating Parkinson's disease in a subject with an infusion of LD prodrug by subcutaneously infusing into the subject an LD prodrug solution at such a rate that: (a) the circulating plasma concentration of the LD prodrug during the infusion does not exceed 100 ng/mL; and (b) a circulating plasma LD concentration greater than 400 ng/mL is continuously maintained for a period of at least 8 hours during the infusion.
- the LD prodrug solution is subcutaneously infused at such a rate that a circulating plasma LD concentration greater than 800 ng/mL, 1,200 ng/mL, or 1,600 ng/mL (e.g., from 300 to 1,200, from 400 to 800, or from 1,000 to 2,000 ng/mL, depending upon the condition of the subject) is continuously maintained for a period of at least 2 hours, 3 hours, 4 hours, or 8 hours during the infusion.
- the LD prodrug solution is subcutaneously infused at such a rate that a circulating plasma LD concentration greater than 400 ng/mL, 800 ng/mL, 1,200 ng/mL, or 1,600 ng/mL (e.g., from 300 to 1,200, from 400 to 800, or from 1,000 to 2,000 ng/mL, depending upon the condition of the subject) is achieved within 60 minutes of the initiation of the infusion.
- the LD prodrug solution can be subcutaneously infused at such a rate that the circulating plasma concentration of the LD prodrug during the infusion does not exceed 50 ng/mL, 30 ng/mL, or 10 ng/mL.
- the LD prodrug solution can be subcutaneously infused at such a rate that a circulating plasma LD concentration less than 7,500 ng/mL, 5,000 ng/mL, 2,500 ng/mL, or 2,000 ng/mL is continuously maintained for a period of at least 8 hours during the infusion.
- the subject receives an average daily dose of less than 20 mL, 18 mL, 16 mL, 14 mL, 12 mL,10 mL, 9 mL, 8 mL, 7 mL, 6 mL, or 5 mL of the infusible LD prodrug solution.
- the LD prodrug solution can be
- the method can further include the administration of an effective amount of carbidopa or carbidopa prodrug (e.g., administered orally, transcutaneously by a skin-adhered dermal patch, or by infusion).
- an effective amount of carbidopa or carbidopa prodrug e.g., administered orally, transcutaneously by a skin-adhered dermal patch, or by infusion.
- Carbidopa can be administered, e.g., by subcutaneous co-infusion, as a solution of one of its highly water soluble prodrug salts, exemplified by carbidopa ethyl ester hydrochloride, by carbidopa methyl ester hydrochloride or by carbidopa amide hydrochloride.
- the molar amount of the co-administered carbidopa prodrug can be between one-tenth and one-half of the molar amount of LD, preferably about 1 ⁇ 4 + l/8th of the molar amount of LD.
- the LD prodrug solution includes a greater than 0.3M LD prodrug (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.5 + 0.5, 2.0 + 0.5, 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter moles per liter) and is substantially free of precipitated solid LD when stored for 24 hours at about 25 °C.
- a greater than 0.3M LD prodrug e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.5 + 0.5, 2.0 + 0.5, 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5,
- the LD prodrug can be selected from LDAs, LDEs, LDCs, LDSs, and salts thereof.
- the LD prodrug is LDEE, LDME, or a salt thereof.
- the LD prodrug and the carbidopa or a carbidopa prodrug are coinfused as separate solutions, or are contained in a single solution and infused into the subject.
- the co- infused, or orally administered, carbidopa or a carbidopa prodrug can be administered in a systemically sub-therapeutic amount (e.g., in an amount sufficient to reduce swelling, inflammation, erythema, or nodule formation at the site of administration) or, optionally, administered in a systemically therapeutic amount in order to reduce the systemic L-DOPA decarboxylase activity on the blood side of the blood brain barrier, e.g. in the kidneys, liver and red blood cells, so as to inhibit the decarboxylase and to increase thereby the half-life of L-DOPA.
- the daily infused molar amount of the LD prodrug dose can be less than 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0 or 2.2 times of the orally taken molar amount of LD.
- the infused LD prodrug solution can have a pH of from 4.0 to 6.0 (e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5 or 5.0 + 0.5) and includes from 0.3 M to 4.0 M LDEE (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.25 + 0.25, 1.5 + 0.25, 1.75 + 0.25, 2.0 + 0.25, 2.5 + 0.25, 2.75 + 0.25, 3.0 + 0.5, or 3.5 + 0.5 M LDEE).
- the LD prodrug solution includes a buffer, such as citrate, succinate, pyrophosphate, or phosphate buffer.
- the LD prodrug solution can be any buffer, such as citrate, succinate, pyrophosphate, or phosphate buffer.
- the method further includes the steps of: (i) providing a solution including greater than 0.3M LD prodrug (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.5 + 0.5, 2.0 + 0.5, 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter moles per liter) and having a pH of 2.3 + 0.7 (e.g., 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3), wherein less than 3% of the LD prod
- a solution including greater than 0.3M LD prodrug e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.5 + 0.5
- Step (iii) is optionally performed within 72 hours, 48 hours, or 24 hours of performing step (ii).
- the method can alleviate a motor or non-motor complication in a subject afflicted with Parkinson' s disease, such as tremor, akinesia, bradykinesia, dyskinesia, dystonia, cognitive impairment, and disordered sleep.
- the LD prodrug solution is optionally coinfused with hyaluronidase and/or an analgesic (e.g., salicylic acid, or a salt thereof; indomethacin; ibuprofen; amiloride; diclofenac; or calcium salts), or, optionally, an analgesic is topically administered to the subject at the site of injection.
- an analgesic e.g., salicylic acid, or a salt thereof; indomethacin; ibuprofen; amiloride; diclofenac; or calcium salts
- the LD prodrug solution can be infused proximate a large muscle (e.g., the diaphragm, trapezius, deltoid, pectoralis major, triceps brachii, biceps, gluteus maximus, sartorius, biceps femoris, rectus femoris, and gastrocnemius) at a depth between 4 mm and 15 mm below the epidermis of the subject.
- a large muscle e.g., the diaphragm, trapezius, deltoid, pectoralis major, triceps brachii, biceps, gluteus maximus, sartorius, biceps femoris, rectus femoris, and gastrocnemius
- the invention features a method of treating a patient with Parkinson' s disease, including subcutaneously infusing into the patient an aqueous solution including a LD prodrug (such as LDEE) at one or more infusion sites (e.g., one, two, three, four, or more infusion sites), wherein the volume infused at a single infusion site is less than 20 mL (e.g., between 5 - 20 mL, or 7-12 mL) per 24 hour period; the amount of drug delivered at all infusion sites is less than 10 millimoles (e.g., between 0.25 - 10 millimoles, or 0.4 - 0.6 millimoles) per 24 hour period; and the pH of the aqueous solution is between 4.0 - 6.0 (e.g., 4.0-5.3).
- a LD prodrug such as LDEE
- LD prodrug can be infused at a single infusion site during a single infusion. It has been empirically determined that infusing LDEE under these conditions reduces the incidence of pain, inflammation, swelling, and subcutaneous nodule formation, while providing adequate operational stability.
- the invention also features a kit including: (i) a first container including a sterile aqueous solution, and (ii) a second container including a sterile, dry, reconstitutable solid, wherein either the first container or the second container includes LDEE or a salt thereof.
- the kit further includes (iii) instructions for combining the contents of the first container with the contents of the second container to form a solution suitable for subcutaneous infusion into a subject and for infusing said solution into a subject for the treatment of Parkinson' s disease; wherein said solid fully dissolves in said solution in less than 5 minutes at 25 °C; said infusible solution includes LDEE, or a salt thereof, and has a pH of from 4.0 to 6.0; wherein less than 3% of the LDEE is hydrolyzed when said first container and said second container are stored at 5 + 3 °C for a period of 3 months.
- the infusible solution remains substantially free of precipitated LD when kept at about 37°C for at least 24 hours.
- the pH of the infusible solution may be from about pH 4.0 to pH 5.0, or from pH 5.0 to pH 5.5.
- the sterile, dry, reconstitutable solid of the kit may include LDEE.
- the aqueous solution of the kit, stored in a first container that is substantially impermeable to oxygen and under an atmosphere substantially free of oxygen can include 0.3 M to 4.0 M LDEE or LDEE'HCl and have a pH from 1.0 to 3.5; the second container of the kit can include sterile a solid base.
- This invention also features a method of forming, in 5 minutes or less at about 25°C, an infusible, preferably subcutaneously infusible, solution by mixing solid LDE or LDA stored in a first container with an aqueous solution of HCl of a concentration of less than 2 M, 1.5 M, 1M, 0.75M, 0.6 M or 0.5 M, the HCl solution stored in a second container, the HCl solution also including a polybasic acid at a concentration of less than about l/10 th the concentration of the HCl; such that the pH of the infusible solution formed upon mixing all or part of the contents of the two containers is 5.5 + 0.5, 5.0 + 0.5 or 4.5 + 0.5, the solution remaining clear, i.e., precipitate- free, when kept at about 25°C for 48 hours or longer, or at 37°C for 16, 24 or 48 hours or longer.
- Exemplary LDEs include LDEE and LDME.
- Exemplary polybasic acids include citric acid or
- This invention also features a kit including solid LDE or LDA in one container; and a second container including aqueous HCl of a concentration less than 2 M, 1.5 M, 1 M, 0.75 M, 0.6 M or 0.5 M HCl and additionally including a polybasic acid at a concentration of less than l/10 th the concentration of the HCl; such that the pH of the infusible, preferably subcutaneously infusible, solution formed upon mixing in 5 minutes or less at about 25 °C part or all the contents of the two containers produces a solution of pH 5.5 + 0.5, 5.0 + 0.5 or 4.5 + 0.5, which remains clear, i.e., precipitate-free, when kept at about 25°C for more than 48 hours or longer, or at 37°C for more than 16, 24 or 48 hours, the kit also including instructions for mixing the components.
- Exemplary LDEs include LDEE and LDME.
- Exemplary polybasic acids include citric acid and phosphoric acid and their acid salts.
- This invention further features a method of forming an infusible, preferably subcutaneously infusible, solution by dissolving in 5 minutes or less at about 25°C solid LDE or LDA and a solid salt of a polybasic acid of an at least tenfold lesser molar amount than the molar amount of the LDE or the LDA stored in a first container; by adding to the solid mixture HC1 of a concentration of less than 2 M, 1.5 M, 1M, 0.75M, 0.6 M or 0.5 M stored in a second container, such that the pH of the resulting solution is 5.5 + 0.5, 5.0 + 0.5 or 4.5 + 0.5, and the solution remains clear, i.e., precipitate-free, when kept at about 25°C for more than 48 hours or longer or at 37 °C for more than 16 hours.
- Exemplary LDEs include LDEE and LDME.
- This invention additionally features a kit including solid LDE or LDA and a solid salt of a polybasic acid of an at least tenfold lesser molar amount than the molar amount of the LDE or the LDA in a first container; and HC1 of a less than 2 M, 1.5 M, 1M, 0.75M, 0.6 M or 0.5 M concentration in a second container; such that mixing in 5 minutes or less at about 25°C part or all of the contents of the two containers results in an infusible, preferably subcutaneously infusible, solution of pH 5.5 + 0.5, 5.0 + 0.5 or 4.5 + 0.5, the solution remaining clear, i.e., precipitate-free, when kept at about 25°C for more than 48 hours or longer or at 37 °C for more than 16 hours, the kit also including instructions for mixing part or all the contents of the two containers and for infusing the solution.
- Exemplary LDEs include LDEE and LDME.
- Exemplary polybasic acid salts include trisodium cit
- the invention features a composition including: (i) a first container including a sterile aqueous solution containing about 0.3M to 4.0M (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0 .2, 1.0 + 0.3, 1.25 + 0.25, 1.5 + 0.25, 1.75 + 0.25, 2.0 + 0.25, 2.5 + 0.25, 2.75 + 0.25, 3.0 + 0.5, or 3.5 + 0.5 M) LDEE hydrochloride salt and having a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3), wherein less than 3% of the LDEE is hydrolyzed when the first container is stored at 5 + 3 °C (e.g., about 4 °C) for a period of 3 months; and (ii) a second container including a sterile basic compound (e.g.
- the first container remains substantially free of precipitated LD solids for at least 12 months when stored at about 5 + 3 °C (e.g., about 4 °C).
- the solution suitable for subcutaneous infusion remains substantially free of precipitated solid LD for at least 48 hours when stored at about 25°C.
- the solution suitable for subcutaneous infusion remains substantially free of precipitated solid LD for at least 8 hours, e.g., for 16 hours, or for 24 hours or for 48 hours when stored at about 37°C.
- the solution suitable for subcutaneous infusion remains substantially free of precipitated solid LD when thawed after being stored frozen (e.g., at about -18 °C or at about -3 °C) for at least 3 months, 6 months, 12 months, 18 months, or 24 months.
- the invention features a method for treating Parkinson's disease in a subject by (i) providing a first container including a sterile aqueous solution containing about 0.3 M M to 4.0M LDEE hydrochloride salt (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.25 + 0.25, 1.5 + 0.25, 1.75 + 0.25, 2.0 + 0.25, 2.5 + 0.25, 2.75 + 0.25, 3.0 + 0.5, or 3.5 + 0.5 M LDEE hydrochloride salt) and having a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3), wherein less than 3% of the LDEE is hydrolyzed when the first container is stored at 5 + 3 °C (e.g., about 4 °C) for a period of 3 months;
- reconstitutable base (iii) combining the contents of the first container and the second container form a solution suitable for subcutaneous infusion into a subject, having a pH of from 4.0 to 6.0 (e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5, or 5.0 + 0.5), including greater than or equal to about 0.3 M LDEE (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.5 + 0.5, 2 + 0.5, 1.5 + 0.5, 2 + 0.5, or 2.5 + 0.5 M LDEE), and substantially free of LD precipitate; and (iv) subcutaneously infusing into the subject the solution suitable for subcutaneous infusion.
- a pH of from 4.0 to 6.0 e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5, or 5.0 + 0.5
- the invention also features a kit including: (i) a first container including a sterile aqueous solution containing about 0.3 M M to 4.0M LDEE hydrochloride salt (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.25 + 0.25, 1.5 + 0.25, 1.75 + 0.25, 2.0 + 0.25, 2.5 + 0.25, 2.75 + 0.25, 3.0 + 0.5, or 3.5 + 0.5 M LDEE hydrochloride salt) and having a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3), wherein less than 3% of the LDEE is hydrolyzed when the first container is stored at 5 + 3 °C (e.g., about 4 °C) for a period of 3 months; (ii) a second container including sterile basic compound
- the invention features a container substantially impermeable to oxygen, the container including an atmosphere substantially free of oxygen and including a sterile aqueous solution containing about 0.3 M to 4.0M LDEE hydrochloride salt (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.25 + 0.25, 1.5 + 0.25, 1.75 + 0.25, 2.0 + 0.25, 2.5 + 0.25, 2.75 + 0.25, 3.0 + 0.5, or 3.5 + 0.5 M LDEE hydrochloride salt) and having a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3), wherein less than 3% of the LDEE is hydrolyzed when the first container is stored at 5 + 3 °C (e.g., about 4 °C) for a period of 3 months.
- a solution of about pH 4.0 + 0.5 could be both stored and infused.
- the LD prodrug solution could be buffered at pH 4.0 + 0.5 LD, for example with citrate. It could be, for example, an LDE solution, such as an LDEE solution, having a concentration of at least 0.5 M, 1 M, 1.5 M, 2 M, 2.5 M, 3 M. It could be stored refrigerated at 5 + 3°C, for example at about 4 + 2°C, for at least 3 months and it could also be infused for 16 hours or longer at ambient temperature, for example at 25 + 3 °C, or even at body temperature, near about 37°C.
- the invention features a pharmaceutical composition including an aqueous liquid containing greater than 0.3 M (e.g., 0.3 to 0.6, 0.6 to 1.4, 1.4 to 2.5, 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter) LD prodrug, or a salt thereof, wherein less than 3% of the LD prodrug is hydrolyzed when the pharmaceutical composition is stored at 5 + 3 °C (e.g., about 4 °C) for a period of 3 months.
- the aqueous liquid has a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3).
- the pharmaceutical composition can further include a pharmaceutically acceptable excipient, such as a crystal growth inhibitor, hyaluronic acid, and/or antioxidants.
- the LD prodrug is a hydrochloride salt.
- the liquid has a viscosity of between 1.2 cP and 2,000 cP (e.g., from 1.2 cP to 2 cP, 1.5 cP to 5 cP, 2.5 cP to 7.5 cP, 5 cP to 10 cP, 1.2 cP to 200 cP, 10 cP to 200 cP, or 200 cP to 2,000 cP).
- the pharmaceutical composition can be substantially free of oxygen.
- the liquid includes a polycarboxylate (e.g., hyaluronic acid, succinylated gelatin, poly(acrylic acid), poly(methacrylic acid), poly(glutamic acid), poly(aspartic acid), poly(maleic acid), poly(malic acid), or poly(fumaric acid)).
- the LD prodrug is an acid addition salt of of hydrochloric acid, sulfuric acid, or phosphoric acid.
- the pharmaceutical composition is a liquid that is supersaturated in LD.
- the pharmaceutical composition can remain substantially free of precipitated solid LD for at least 6 months, 12 months, or 24 months when stored at about 5 + 3 °C (e.g., about 4 °C). In still other embodiments, the pharmaceutical composition can remain substantially free of precipitated solid LD for at least 3 months, 6 months, 12 months, or 18 months when stored at about 25°C. In particular embodiments, the solubility of LD in the pharmaceutical composition is at least 5 g, lOg, or 15g per liter at about 25°C.
- the invention features a method for treating Parkinson' s disease in a subject with an infusion of LD prodrug by (i) providing a pharmaceutical composition described above; (ii) raising the pH of the pharmaceutical composition to 4.0 to 6.0 (e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5 or 5.0 + 0.5) to form an LD prodrug solution; and (iii) within 48 hours, 24 hours, or 12 hours of performing step (ii), infusing at least a portion of the LD prodrug solution into the subject in an amount sufficient to treat Parkinson' s disease.
- a pharmaceutical composition described above e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5 or 5.0 + 0.5
- the invention features a method for preparing an infusible LD prodrug solution including the steps of: (i) providing an aqueous liquid containing greater than 0.3 M (e.g. ,0.3 to 0.6, 0.6 to 1.4, 1.4 to 2.5, 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter) LD prodrug and a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3), or a salt thereof, wherein less than 3% of the LD prodrug is hydrolyzed when said pharmaceutical composition is stored at 5 + 3 °C for a period of 3 months; (ii) raising the pH of the an aqueous liquid to 4.0 - 6.0 (e.g.,0.3 to
- the aqueous liquid includes a pharmaceutical composition described above.
- the invention features a composition including: (i) a first container including a sterile aqueous solution containing about 0.3 M to 4.0M (e.g., 0.3 to 0.6 M, 0.6 to 1.4, 1.4 to 2.5, 0.6 + 0.3, 0.75 + 0.25, 1.0 ⁇ 0.3, 1.0 ⁇ 0.5, 1.5 ⁇ 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter) LD prodrug and having a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3), wherein less than 3% of the LD prodrug hydrolyzed when the first container is stored at 5 + 3 °C for a period of 3 months; and (ii) a second container including a sterile base
- the invention features a pharmaceutical composition suitable for infusion into a subject including an aqueous liquid containing greater than 0.3 M (e.g., 0.3 to 0.6, 0.6 to 1.4 to 2.5, 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter) LD prodrug, or a salt thereof, wherein the pharmaceutical composition remains substantially free of LD precipitate for at least 24 hours, e.g., for 48 hours or for 72 hours, when stored at about 25 °C, or for at least 8 hours, e.g., for 16 hours or 24 hours or 48 hours when stored at about 37 °C.
- aqueous liquid containing greater than 0.3 M (e.g., 0.3 to 0.6, 0.6 to 1.4 to 2.5, 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.3, 1.0 + 0.5,
- the aqueous liquid has a pH of from 4.0 to 6.0 (e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5, or 5.0 + 0.5).
- the pharmaceutical composition can further include a pharmaceutically acceptable excipient, such as a crystal growth inhibitor, hyaluronic acid, and/or antioxidants.
- the LD prodrug is a hydrochloride salt.
- the liquid has a viscosity of between 1.2 cP and 2,000 cP (e.g., from 1.2 cP to 2 cP, 1.5 cP to 5 cP, 2.5 cP to 7.5 cP, 5 cP to 10 cP, 1.2 cP to 200 cP, 10 cP to 200 cP, or 200 cP to 2,000 cP).
- the pharmaceutical composition can be substantially free of oxygen.
- the liquid includes a polycarboxylate (e.g., hyaluronic acid, succinylated gelatin, poly(acrylic acid), poly(methacrylic acid), poly(glutamic acid), poly(aspartic acid), poly(maleic acid), poly(malic acid), or poly(fumaric acid)).
- the LD prodrug is an acid addition salt of of hydrochloric acid, sulfuric acid, or phosphoric acid.
- the pharmaceutical composition is a liquid that is supersaturated in LD. In certain embodiments the pharmaceutical composition can remain substantially free of LD precipitate for at least 12 hours, 24 hours, 48 hours, or 72 hours when stored at about 25 °C.
- the pharmaceutical composition can remain substantially free of LD precipitate for at least 8 hours, 16 hours, for example for 24 hours or for 48 hours, when stored at about 37 °C.
- the pharmaceutical composition can be substantially free of precipitated solid LD when thawed after being stored frozen (e.g., at about -18 °C or at about -3 °C) for at least 3 months, 6 months, 12 months, 18 months, or 24 months.
- the solubility of LD in the pharmaceutical composition is at least 5 g, lOg, or 15g per liter at about 25°C.
- the invention features a method for treating Parkinson's disease in a subject by infusing into the subject a pharmaceutical composition described above in an amount sufficient to treat Parkinson' s disease.
- the invention features a pharmaceutical composition suitable for infusion into a subject including an aqueous liquid containing greater than 50 weight % of an LD prodrug salt, and containing less than about 40 weight % of water, buffered at a pH between pH 4.0 and pH 5.0, remaining essentially free of LD precipitate after being stored at 5 + 3°C (for example at 4 + 2°C) for at least 3 months (for example for at least 4 months or 6 months) and/or for at least 8, 16, 24 or 48 hours at about 37°C.
- An example of such a composition is a buffered, optionally citrate buffered, 2.7 M or greater concentration LDEE'HCl aqueous solution.
- the invention features a stable pharmaceutical composition suitable for infusion into a subject, optionally in the jejunum of a subject including greater than 0.3 M (e.g., 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter) LD prodrug, or a salt thereof, dissolved in a non-aqueous liquid, wherein the pharmaceutical composition remains substantially free of LD precipitate for at least 24 hours when stored at about 25 °C.
- M e.g., 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter
- LD prodrug or a salt thereof, dissolved in a non-aqueous liquid, wherein the pharmaceutical composition remains
- the nonaqueous liquid can be a lipid (e.g., a triglyceride, a cholesterol ester, sesame oil, castor oil, or cottonseed oil), an alcohol (e.g., ethanol, glycerol or propylene glycol), N-methyl pyrrolidone, or a mixture thereof.
- the aqueous solution can be, e.g., a solution of glucose, glycerol, poly(ethylene glycol), the weight % of the exemplary glucose or glycerol or poly(ethylene glycol) being greater than 10 %, 20%, 30%, 40%, 50%.
- the pharmaceutical composition can include an antioxidant (e.g., bisulfite, propofol, ibuprofen, salicylic acid or salicylic acid salt, a salt of ascorbic acid (such as sodium ascorbate), p-aminophenol, acetamol, a t-butyl ortho-substituted phenol, or any antioxidant described herein).
- an antioxidant e.g., bisulfite, propofol, ibuprofen, salicylic acid or salicylic acid salt, a salt of ascorbic acid (such as sodium ascorbate), p-aminophenol, acetamol, a t-butyl ortho-substituted phenol, or any antioxidant described herein.
- the pharmaceutical composition can include a fatty acid salt of the LD prodrug.
- the liquid has at about 20 ° C a viscosity of between 1.2 cP and 2,000 cP (e.g., from 1.2 cP to 2 cP, 1.5 cP to 5 cP, 2.5 cP to 7.5 cP, 5 cP to 10 cP, 1.2 cP to 200 cP, 10 cP to 100 cP, 50 cP to 500 cP, 250 cP to 750 cP, 500 cP to 1,000 cP, 750 cP to 2,000 cP, or 50 cP to 1,500 cP).
- a viscosity of between 1.2 cP and 2,000 cP (e.g., from 1.2 cP to 2 cP, 1.5 cP to 5 cP, 2.5 cP to 7.5 cP, 5 cP to 10 cP, 1.2 cP to 200 cP, 10 cP to 100 cP, 50 cP to 500 cP,
- the pharmaceutical composition can remain substantially free of LD precipitate for at least 12 hours, 24 hours, 48 hours, or 72 hours when stored at about 25 °C.
- the pharmaceutical composition can substantially free of precipitated solid LD when thawed after being stored frozen (e.g., at about -18 °C or at about -3 °C) for at least 3 months, 6 months, 12 months, 18 months, or 24 months.
- the solubility of LD in the pharmaceutical composition is at least 5 g, lOg, or 15g per liter at about 25°C.
- the pharmaceutical composition can remain substantially free of precipitated solid LD for at least 6 months, 12 months, or 24 months when stored at about 5 + 3 °C (e.g., about 4 °C). In still other embodiments, the pharmaceutical composition can remain substantially free of precipitated solid LD for at least 3 months, 6 months, 12 months, or 18 months when stored at about 25°C.
- the invention features a method for treating Parkinson's disease in a subject by infusing into the subject a pharmaceutical composition described above in an amount sufficient to treat Parkinson's disease.
- the invention features a stable pharmaceutical composition suitable for infusion into a subject including greater than 0.3 M (e.g., 0.5 + 0.2, 0.6 + 0.3, 0.75 + 0.25, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter) LD prodrug, or a salt thereof, dissolved in a liquid carrier including water and a lipid, wherein the pharmaceutical composition remains substantially free of LD precipitate for at least 24 hours when stored at about 25 °C.
- the liquid carrier includes an emulsion or liposomes.
- the pharmaceutical composition can include an antioxidant (e.g., bisulfite, propofol, ibuprofen, salicylic acid or salicylic acid salt, a salt of ascorbic acid (such as sodium ascorbate), p-aminophenol, acetamol, a t-butyl ortho-substituted phenol, or any antioxidant described herein).
- an antioxidant e.g., bisulfite, propofol, ibuprofen, salicylic acid or salicylic acid salt, a salt of ascorbic acid (such as sodium ascorbate), p-aminophenol, acetamol, a t-butyl ortho-substituted phenol, or any antioxidant described herein.
- the pharmaceutical composition can include a fatty acid salt of the LD prodrug.
- the pharmaceutical composition has at about 20 ° C a viscosity of between 1.2 cP and 2,000 cP (e.g., from 1.2 cP to 2 cP, 1.5 cP to 5 cP, 2.5 cP to 7.5 cP, 5 cP to 10 cP, 1.2 cP to 200 cP, 10 cP to 100 cP, 50 cP to 500 cP, 250 cP to 750 cP, 500 cP to 1,000 cP, 750 cP to 2,000 cP, or 50 cP to 1,500 cP).
- a viscosity of between 1.2 cP and 2,000 cP (e.g., from 1.2 cP to 2 cP, 1.5 cP to 5 cP, 2.5 cP to 7.5 cP, 5 cP to 10 cP, 1.2 cP to 200 cP, 10 cP to 100 cP, 50 cP to 500 cP
- the pharmaceutical composition can remain substantially free of LD precipitate for at least 12 hours, 24 hours, 48 hours, or 72 hours when stored at about 25 °C.
- the pharmaceutical composition can substantially free of precipitated solid LD when thawed after being stored frozen (e.g., at about -18 °C or at about -3 °C) for at least 3 months, 6 months, 12 months, 18 months, or 24 months.
- the solubility of LD in the pharmaceutical composition is at least 5 g, lOg, or 15g per liter at about 25°C.
- the pharmaceutical composition can remain substantially free of precipitated solid LD for at least 6 months, 12 months, or 24 months when stored at about 5 + 3 °C (e.g., about 4 °C). In still other embodiments, the pharmaceutical composition can remain substantially free of precipitated solid LD for at least 3 months, 6 months, 12 months, or 18 months when stored at about 25°C.
- the invention features a method for treating Parkinson's disease in a subject by infusing into the subject a pharmaceutical composition described above in an amount sufficient to treat Parkinson' s disease.
- the invention features a pharmaceutical composition including a liquid salt of levodopa methyl ester.
- the liquid salt is a fatty acid salt, such as, without limitation, levodopa methyl ester oleate, levodopa methyl ester octanoate, levodopa methyl ester alpha-linoleate, levodopa methyl ester eicosapentaenoate, levodopa methyl ester docosahexaenoate, levodopa methyl ester linoleate, levodopa methyl ester gamma linoleate, levodopa methyl ester palmitoleate, levodopa methyl ester dihomogamma linoleate, levodopa methyl ester arachidonate, levodopa methyl ester myristate, levodopa methyl methyl
- the invention features a pharmaceutical composition including a liquid salt of an LDC.
- the liquid salt is a fatty acid salt, such as, without limitation, a fatty acid salt selected from oleate, octanoate, alpha-linoleate, eicosapentaenoate, docosahexaenoate, linoleate, palmitoleate, gamma linoleate, dihomogamma linoleate, arachidonate, myristate, palmitate, and stearate salts, and mixtures thereof.
- a fatty acid salt selected from oleate, octanoate, alpha-linoleate, eicosapentaenoate, docosahexaenoate, linoleate, palmitoleate, gamma linoleate, dihomogamma linoleate, arachidonate, myristate, palmitate
- the invention features a pharmaceutical composition including a liquid salt of an LDE, wherein the salt is not levodopa ethyl ester oleate, levodopa ethyl ester ricinoleate, levodopa ethyl ester palmitate, or levodopa ethyl ester valerate.
- the liquid salt is a fatty acid salt, such as, without limitation, a fatty acid salt selected from oleate, octanoate, alpha-linoleate, eicosapentaenoate, docosahexaenoate, linoleate, palmitoleate, gamma linoleate, dihomogamma linoleate, arachidonate, myristate, palmitate, and stearate salts, and mixtures thereof.
- a fatty acid salt selected from oleate, octanoate, alpha-linoleate, eicosapentaenoate, docosahexaenoate, linoleate, palmitoleate, gamma linoleate, dihomogamma linoleate, arachidonate, myristate, palmitate, and stearate salts, and mixtures thereof.
- the invention features a stable pharmaceutical composition suitable for infusion into a subject, optionally into the stomach or duodenum or jejunum of a subject, including greater than 0.3 M (e.g., 0.6 + 0.3, 0.75 + 0.25, 1.0 ⁇ 0.5, 1.5 ⁇ 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter) LD prodrug fatty acid salt, wherein the pharmaceutical composition is substantially free of LD precipitate for at least 12 hours, 24 hours, or 48 hours when stored at about 25 °C.
- M e.g., 0.6 + 0.3, 0.75 + 0.25, 1.0 ⁇ 0.5, 1.5 ⁇ 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter
- LD prodrug fatty acid salt wherein the pharmaceutical composition is substantially free of LD precipitate for at least 12 hours, 24 hours, or 48 hours when stored
- the pharmaceutical composition can substantially free of precipitated solid LD when thawed after being stored frozen (e.g., at about -18 °C or at about -3 °C) for at least 3 months, 6 months, 12 months, 18 months, or 24 months.
- the pharmaceutical composition includes greater than 40 weight % (e.g., 40-60%, 50-70%, 60-90%, or 80-98%) (w/w) carboxylate salt of an LD prodrug dissolved in a liquid carrier.
- the liquid carrier can be a lipid (e.g., a triglyceride, a cholesterol ester, sesame oil, castor oil, or cottonseed oil), an alcohol (e.g., ethanol, glycerol or propylene glycol), N-methyl pyrrolidone, or a mixture thereof.
- the liquid carrier further includes an antioxidant.
- the liquid carrier can include water and a lipid.
- the liquid carrier includes an emulsion or liposomes.
- the pharmaceutical composition has at about 20 ° C a viscosity of between 1.2 cP and 2,000 cP (e.g., from 1.2 cP to 2 cP, 1.5 cP to 5 cP, 2.5 cP to 7.5 cP, 5 cP to 10 cP, 1.2 cP to 200 cP, 10 cP to 100 cP, 50 cP to 500 cP, 250 cP to 750 cP, 500 cP to 1,000 cP, 750 cP to 2,000 cP, or 50 cP to 1,500 cP).
- a viscosity of between 1.2 cP and 2,000 cP (e.g., from 1.2 cP to 2 cP, 1.5 cP to 5 cP, 2.5 cP to 7.5 cP, 5 cP to 10 cP, 1.2 cP to 200 cP, 10 cP to 100 cP, 50 cP to 500 cP
- the pharmaceutical composition can remain substantially free of LD precipitate for at least 12 hours, 24 hours, 48 hours, or 72 hours when stored at about 25 °C.
- the pharmaceutical composition can substantially free of precipitated solid LD when thawed after being stored frozen (e.g., at about -18 °C or at about -3 °C) for at least 3 months, 6 months, 12 months, 18 months, or 24 months.
- the solubility of LD in the pharmaceutical composition is at least 5 g, lOg, or 15g per liter at about 25°C.
- the pharmaceutical composition can remain substantially free of precipitated solid LD for at least 6 months, 12 months, or 24 months when stored at about 5 + 3 °C (e.g., about 4 °C). In still other embodiments, the pharmaceutical composition can remain substantially free of precipitated solid LD for at least 3 months, 6 months, 12 months, or 18 months when stored at about 25°C.
- the invention features a method for treating Parkinson's disease in a subject by infusing into the subject a pharmaceutical composition including a liquid salt or fatty acid salt described above in an amount sufficient to treat Parkinson' s disease.
- the invention further features a method for treating Parkinson' s disease in a subject by infusing into the subject a pharmaceutical composition including levodopa ethyl ester oleate, levodopa ethyl ester ricinoleate, levodopa ethyl ester palmitate, or levodopa ethyl ester valerate in an amount sufficient to treat Parkinson' s disease.
- the invention features a stable pharmaceutical composition suitable for injection into a subject including an aqueous liquid with LD prodrug particles, or a salt thereof, suspended therein, the LD prodrug particles having an effective particle size of from 20 nm to 1.0 ⁇ (e.g., an effective particle size of from 20 nm to 0.5 ⁇ , 100 nm to 1 ⁇ , 150 nm to 800 nm, or from 150 nm to 600 nm).
- the LD prodrug particles include an LD prodrug, or a salt thereof.
- the invention features a method for treating Parkinson's disease in a subject by infusing into the subject a pharmaceutical composition including LD prodrug particles in an amount sufficient to treat Parkinson' s disease.
- the LD prodrug can be selected from LDAs, LDEs, LDCs, LDSs, and salts thereof.
- the LD prodrug is LDEE, LDME, or a salt thereof, such as LDEE hydrochloride salt.
- the invention features a container including a pharmaceutical composition containing an LD prodrug described herein.
- the container includes an atmosphere substantially free of oxygen.
- the invention features a container including a material that is substantially impermeable to oxygen, the container containing a reconstitutable solid including an LD prodrug, or a salt thereof, wherein the container is substantially free of oxygen and wherein the reconstitutable solid, when reconstituted, is suitable for subcutaneous infusion.
- the invention also features a container including a material that is substantially impermeable to oxygen, the container containing liquid including an LD prodrug, or a salt thereof, wherein the container is substantially free of oxygen and wherein the liquid is suitable for subcutaneous infusion.
- the container can further include a pharmaceutically acceptable excipient, such as a viscosity enhancing agent, an anti oxidant, and/or a preservative.
- the container can further include from 0.5 to 4.0% (w/w) hyaluronic acid, or any other viscosity enhancing agent described herein; and/or the container can further include an antioxidant (e.g., bisulfite, propofol, ibuprofen, salicylic acid or salicylic acid salt, a salt of ascorbic acid (such as sodium ascorbate), p-aminophenol, acetamol, a t-butyl ortho-substituted phenol, or any antioxidant described herein).
- an antioxidant e.g., bisulfite, propofol, ibuprofen, salicylic acid or salicylic acid salt, a salt of ascorbic acid (such as sodium ascorbate), p-aminophenol, acetamol, a t-butyl ortho-substituted phenol, or any antioxidant described herein).
- the LD prodrug in the container is an LDE, or a salt thereof, such as an acid addition salt of LDEE (e.g., LDEE hydrochloride).
- the container is designed to hold less than 30 mL, 25 mL, 20 mL, 15 mL, 10 mL, 5 mL, 3 mL of a liquid including from 0.3 M to 4.0 M LD prodrug, or a salt thereof, (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 0.8 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, or 3.5 + 0.5 moles per liter) and having a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3
- the invention features a method for treating Parkinson's disease in a subject, the method including: (i) dissolving the solid contents of the container of the invention in buffering agent containing water to form an aqueous solution having a pH of from 4.0 to 6.0 (e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5 or 5.0 + 0.5) and an LD prodrug concentration of from 0.3 M to 4.0 M (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, , 2.5 + 0.5, , 3.0 + 0.5, or 3.5 + 0.5 moles per liter); and (ii) infusing the aqueous solution into the subject in an amount sufficient to treat Parkinson' s disease.
- aqueous solution having a pH of from 4.0 to 6.0 (e.g., 4.2 to 5.0,
- the buffered water can include a pharmaceutically acceptable potassium and/or a sodium salt of a dibasic, tribasic or tetrabasic acid, such as a salt of citric acid; pyrophosphoric acid, succinic acid, or phosphoric acid (e.g., trisodium citrate, tetrasodium pyrophosphate, disodium succinate, or trisodium phosphate).
- a pharmaceutically acceptable potassium and/or a sodium salt of a dibasic, tribasic or tetrabasic acid such as a salt of citric acid; pyrophosphoric acid, succinic acid, or phosphoric acid (e.g., trisodium citrate, tetrasodium pyrophosphate, disodium succinate, or trisodium phosphate).
- the LD prodrug is levodopa ethyl ester.
- the solution infused into the subject is substantially free of precipitated solids; has a pH of from 4.0 to 6.0 (e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5, or 5.0 + 0.25), and includes greater than 0.3 M (e.g., 0.5 + 0.2, 1.0 + 0.5 or 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter) levodopa ethyl ester.
- a pH of from 4.0 to 6.0 e.g., 4.2 to 5.0, 4.5 + 0.3, 4.4 + 0.2, 4.5 + 0.5, or 5.0 + 0.25
- greater than 0.3 M e.g., 0.5 + 0.2, 1.0 + 0.5 or 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, 3.5 + 0.5, or greater than 3.5 moles per liter
- the method can be used to alleviate a motor or non-motor complication in a subject afflicted with Parkinson's disease, such as tremor, akinesia, bradykinesia, dyskinesia, dystonia, cognitive impairment, and disordered sleep.
- the method can further include administration of an effective amount of an anti-emetic agent (e.g., nicotine, lobeline sulfate, pipamazine, oxypendyl hydrochloride, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate, scopolamine, metopimazine, or diphenidol hydrochloride).
- an anti-emetic agent e.g., nicotine, lobeline sulfate, pipamazine, oxypendyl hydrochloride, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate, scopolamine
- the methods can include administering an effective amount of carbidopa or carbidopa prodrug (e.g., orally or by infusion).
- carbidopa prodrugs include its esters, such as carbidopa ethyl ester and carbidopa methyl ester, and carbidopa amide, the highly water soluble hydrochloride salts of which are preferred as carbidopa prodrugs.
- the pharmaceutical composition can administered by subcutaneous infusion or intramuscular infusion.
- the pharmaceutical composition can be infused proximate a large muscle (e.g., the diaphragm, trapezius, deltoid, pectoralis major, triceps brachii, biceps, gluteus maximus, sartorius, biceps femoris, rectus femoris, and gastrocnemius) at a depth between 4 mm and 15 mm below the epidermis of the subject (e.g., 5 mm to 15 mm or 5 mm to 12 mm beneath the epidermis of the subject).
- a large muscle e.g., the diaphragm, trapezius, deltoid, pectoralis major, triceps brachii, biceps, gluteus maximus, sartorius, biceps femoris, rectus femoris, and gastrocnemius
- the pharmaceutical composition is coinfused with hyaluronidase and/or with an analgesic (e.g., salicylic acid, or a salt thereof; indomethacin; ibuprofen; amiloride; diclofenac; or calcium salts), or an analgesic is topically administered to the subject at the site of infusion.
- an analgesic e.g., salicylic acid, or a salt thereof; indomethacin; ibuprofen; amiloride; diclofenac; or calcium salts
- the invention features an ambulatory infusion pump system for the treatment of Parkinson's disease including: (i) a pharmaceutical composition of the invention in a drug reservoir; and (ii) a cannula or needle in fluid communication with the drug reservoir for infusing the pharmaceutical composition into a subject.
- the pump system is a patch pump including an adhesive for adherence of the patch pump directly or indirectly to the skin of a subject.
- the ambulatory infusion pump system can further include software, memory, a data processing unit, and information input/output capability, wherein the system is able to input, store and recall data including one or more of the subject's symptoms or drug responses related to Parkinson's disease, such symptoms selected from the group of tremor, hyperkinesia, dystonia, akinesia, bradykinesia, tremor, turning on, turning off, delayed time to on, and response failure.
- the ambulatory infusion pump system can further include software, memory, a data processing unit, and user input capability to input into the system information related to the ingestion of a meal, and the system thereafter adjusts the rate of infusion of the pharmaceutical composition.
- the pump system can be programmed to increase the rate of infusion after a meal including protein.
- the ambulatory infusion pump system can further include software, memory, a data processing unit, and information input/output capability, wherein the system is able to automatically increase the rate of infusion of the pharmaceutical composition, by a factor of two or more, at a preset time in the morning or after a period of at least four hours.
- the ambulatory infusion pump system can further include a data processing unit; and a motion sensor electrically connected to, or in RF communication with, the data processing unit to detect movement of the subject, wherein the system recommends a change in the infusion rate in response to the data from the motion sensor.
- the invention features an ambulatory pump system for the treatment of Parkinson's disease including: (i) a first reservoir containing an acidic aqueous solution including from 0.3 M to 4.0 M (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, or 3.5 + 0.5 moles per liter) LDEE, or a salt thereof; (ii) a second reservoir containing a basic aqueous solution; and (iii) a means for combining and a means for infusing the acidic aqueous solution and the basic aqueous solution into a subject (e.g., a cannula and/or needle in fluid communication with the first drug reservoir and the second drug reservoir for combining and infusing the acidic aqueous solution and the basic aqueous solution into a subject, optionally
- the first reservoir contains an acidic aqueous solution having a pH of from 1.0 to 3.5 (e.g., 2.3 + 0.7, 1.8 + 0.3, 2.1 + 0.3, 2.5 + 0.3, or 2.7 + 0.3), and the second reservoir contains a basic aqueous solution having a pH of greater than 7.0 (e.g., greater than 7.5, 8.0, or 8.5).
- the acidic aqueous solution can include a pharmaceutical composition described herein.
- the basic aqueous solution includes a pharmaceutically acceptable potassium and/or a sodium salt of a dibasic, tribasic or tetrabasic acid, such as a salt of citric acid; pyrophosphoric acid, succinic acid, or phosphoric acid (e.g., trisodium citrate, tetrasodium pyrophosphate, disodium succinate, or trisodium phosphate).
- a pharmaceutically acceptable potassium and/or a sodium salt of a dibasic, tribasic or tetrabasic acid such as a salt of citric acid; pyrophosphoric acid, succinic acid, or phosphoric acid (e.g., trisodium citrate, tetrasodium pyrophosphate, disodium succinate, or trisodium phosphate).
- the invention features a kit including (i) a pharmaceutical composition of the invention; and instructions for administering the composition to a subject for the treatment of Parkinson' s disease.
- the invention features a method for using the pharmaceutical composition of the invention, the method including the step of visually inspecting the composition prior to use to determine whether the pharmaceutical composition is suitable for infusion into a subject, wherein a transparent solution is suitable for infusion and a colored or opaque solution is not suitable for infusion.
- the pharmaceutical composition can be packed in a kit or container that is configured to permit visual inspection of the pharmaceutical composition.
- the invention features a hydrolytically stable, oxidatively stable, pharmaceutical composition for reconstitution, including dry solid LDEE free base crystallites in a container including substantially no water and oxygen.
- the invention features a compound of formula (II):
- R 2 is CH 2 CH 3 ,
- the invention features a compound of formula (III):
- R 5 and R 6 are as defined herein.
- R 5 is H or CH 3
- R 6 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , benzyl, 2-deoxy-2-glucosyl, or CH 2 CH 2 NH 2 .
- the invention features a compound of formula (IV):
- R 3 is CH 3 , or 4- methylbenzyl.
- the invention features a pharmaceutical composition including an aqueous liquid containing an LD prodrug, or a salt thereof, and water, wherein the weight percent of water in the pharmaceutical composition is less than the weight percent of said LD prodrug, or a salt thereof (e.g., by mass the ratio of LD prodrug, or a salt thereof, to water is from 1.05: 1.0 to 1.25: 1.0; 1.15: 1.0 to 1.55: 1.0; 1.25: 1.0 to 1.75: 1.0; 1.75: 1.0 to 2.0: 1.0; 1.85: 1.0 to 3.0: 1.0; or from 2.0: 1.0 to 4.0: 1.0).
- the invention also features a pharmaceutical composition including an aqueous liquid containing an LD prodrug, or a salt thereof, and water, wherein the aqueous liquid has a density greater than 1.15 g/mL (e.g., a density of from 1.15 to 1.45, 1.25 to 1.65, or 1.35 to 1.95 g/mL) at about 25 °C.
- a pharmaceutical composition including an aqueous liquid containing an LD prodrug, or a salt thereof, and water, wherein the aqueous liquid has a density greater than 1.15 g/mL (e.g., a density of from 1.15 to 1.45, 1.25 to 1.65, or 1.35 to 1.95 g/mL) at about 25 °C.
- the invention further features a pharmaceutical composition including great than 0.25 M LD prodrug, or a salt thereof (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, or 3.5 + 0.5 M LD prodrug); greater than 0.05 M carbidopa prodrug (e.g., 0.06 + 0.1, 0.7 + 0.1, 0.8 + 0.1, 0.9 + 0.1, 1.0 + 0.2, or 1.5 + 0.5 M carbidopa prodrug), or a salt thereof, and water.
- the pharmaceutical composition can optionally further include a vasoconstrictor.
- the LD prodrug, or a salt thereof can be infused intragastrically, intraduodenally or intrajejunally through a tube of less than about 3 mm, 2 mm, 1.5 mm, 1.0 mm outer diameter, and/or an internal diameter of less than 1 mm, 0.7 mm, 0.35 mm for a period of greater than or equal to about 12 hours, 24 hours, 48 hours, 72 hours, and most preferably 96 hours.
- the LD prodrug, or a salt thereof can be infused simultaneously at two or more infusion sites.
- the LD prodrug, or a salt thereof can be co-infused with a vasoconstrictor in an amount sufficient to reduce local swelling, inflammation, or nodule formation.
- the vasoconstrictor can be, without limtiation, a corticosteroid vasoconstrictor (e.g., dexamethasone, beclomethasone, clobetasol, betamethasone, fluocinolone, or derivatives, such as esters, thereof); or an adrenergic vasoconstrictor (e.g., neo-synephrine, phenylepinephrine, or oxymetazoline).
- a corticosteroid vasoconstrictor e.g., dexamethasone, beclomethasone, clobetasol, betamethasone, fluocinolone, or derivatives, such as esters, thereof
- an adrenergic vasoconstrictor e.g
- the vasoconstrictor is dexamethasone.
- concentration of dexamethasone in the infused solution can be between about 1 ⁇ g/mL and about 4 mg/mL, and its preferred concentration is between about 10 ⁇ g/mL and about 1 mg/mL.
- the pharmaceutical composition can include a vasoconstrictor in an amount sufficient to reduce local swelling, inflammation, or nodule formation when administered to a subject using a method described herein.
- the vasoconstrictor can be, without limtiation, a corticosteroid vasoconstrictor (e.g., dexamethasone, beclomethasone, clobetasol, betamethasone, fluocinolone, or derivatives, such as esters, thereof); or an adrenergic vasoconstrictor (e.g., neo-synephrine, phenylepinephrine, or oxymetazoline).
- a corticosteroid vasoconstrictor e.g., dexamethasone, beclomethasone, clobetasol, betamethasone, fluocinolone, or derivatives, such as esters, thereof
- an adrenergic vasoconstrictor e.g
- the invention further features a pharmaceutical composition including great than 0.25 M LD prodrug, or a salt thereof (e.g., 0.4 + 0.1, 0.5 + 0.1, 0.6 + 0.1, 0.7 + 0.1, 0.8 + 0.2, 1.0 + 0.3, 1.0 + 0.5, 1.5 + 0.5, 2.0 + 0.5, 2.5 + 0.5, 3.0 + 0.5, or 3.5 + 0.5 M LD prodrug); a vasoconstrictor (e.g., a corticosteroid vasoconstrictor or an adrenergic vasoconstrictor); and water.
- the vasoconstrictor is the corticosteroid vasoconstrictor dexamethasone.
- the pharmaceutical composition can include between about 1 ⁇ g/mL and about 4 mg/mL dexamethasone (e.g., between 1 ⁇ g/mL and 0.5 mg/mL, 10 ⁇ g/mL and 1 mg/mL, 0.5 mg/mL and 2 mg/mL, or 1 mg/mL and 4 mg/mL).
- the pharmaceutical composition can optionally further include carbidopa, or a prodrug thereof.
- the invention features pharmaceutical compositions, devices, systems, kits and methods for maintaining plasma LD concentrations in a desired therapeutic target range.
- the inventions enable PD patients to reduce the variability of their plasma and/or brain LD concentrations, e.g., reducing the magnitude and/or frequency of high or low LD excursions.
- the durations of periods and/or severities of symptoms of PD are reduced.
- the fluctuations are reduced by continuous, frequent and/or programmed, preferably subcutaneous or intramuscular, infusion of a solution of an LD prodrug.
- the concentration can be high enough to provide for daily infusion of less than 20 mL, 18mL, 16 mL, 15 mL, 14 mL, 13 mL, 12 mL, 10 mL, 9 mL, 8 mL, 7 mL, 6 mL, 5 mL, 4 mL, 3 mL, or 2 mL of the LD prodrug containing solution.
- the preferred subcutaneously infused prodrugs include highly soluble LDEs, LDCs LDAs and LDSs and their salts, which can be rapidly hydrolyzed in the body, typically in an enzyme catalyzed reaction, to form LD, yet can be stored at least for the duration of the intended infusion period, for example at least 8 hours, 16 hours, 24 hours, 48 hours, 72 hours, in a container of the infusion system.
- the infused solution can be an aqueous solution formed by mixing prior to use the storable contents of two containers or chambers.
- one container contains an aqueous solution of the LD prodrug that can be stored with refrigeration at about 5 + 3 °C, for example at about 4 + 2 °C, for more than 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months.
- the invention also features infusion pump systems for the administration of the formulations and methods of infusion.
- the invention features a pharmaceutically acceptable, LD prodrug (e.g., LDA, LDE, LDC or LDS) formulation which can be stable in solution, which can be delivered via an ambulatory infusion pump, and which can provide continuous dopaminergic stimulation to the PD patient.
- LD prodrug e.g., LDA, LDE, LDC or LDS
- the LD prodrug can be formulated to prevent rapid hydrolysis prior to its infusion, but can be rapidly hydrolyzed to form LD after its delivery into the body.
- Preferred LDEs are rapidly hydrolyzed in vivo by esterases.
- LDAs, LDCs and LDSs are rapidly hydrolyzed in vivo by amidases. Minimization of the symptoms of LD requires a relatively stable and sufficient plasma LD level, which could be achieved by careful consideration of the formulation of the LD prodrug and the rate of its continuous, or frequent or programmed infusion.
- the prodrugs of the invention can be stored in liquid forms or solid forms, which can provide upon mixing of the contents of two containers or chambers an infusible aqueous solution prior to infusion into a subject.
- the solubilities of the LDEs, LDCs, LDAs and LDSs can exceed the solubility of LD, the highest solubilities typically being observed for LD prodrug salt forms.
- the solubilities of salts of LDEE and LDME, such as the salts formed when these bases are neutralized by HC1 are much more soluble than LD.
- the high solubility of LDEE'HCl allows for aqueous solutions of greater than 2.5 M in concentration. For example, a concentration of 3.0 + 0.5 M and a pH between about 1.0 and 3.5 that can be stored for long periods of time.
- the concentrated solutions can be stored and optionally diluted with up-adjusting their pH to be subcutaneously or intramuscularly infused, providing for continuous infusion therapy of PD.
- the infused volumes are typically much smaller than those intragastrically or intrajejunally infused.
- the LD prodrugs are hydrolyzed to LD, which can be much less soluble in water or in aqueous solutions in the pH range suitable for subcutaneous or intramuscular infusion.
- the shelf life of the stored and of the infused (operational) LD prodrug solutions is usually determined by their hydrolysis, leading to LD precipitation, which can be faster than the other degradation processes, such as oxidation, particularly when oxygen is substantially excluded. For this reason, a major problem with the LD prodrug formulations, particularly of the aqueous formulations, is their hydrolytic instability.
- the rate of hydrolysis is pH and temperature dependent.
- LD is poorly soluble, and because the concentration of the LD prodrug in the small-volume subcutaneously or intramuscularly infused solution is necessarily high, even hydrolysis of a small fraction of an LD prodrug or prodrug salt may result in the precipitation of LD from the solution.
- the presence of a large amount of LD precipitate is unacceptable, as it may lead to a dosing error and because it may block or reduce the flow in the infusion system.
- the LDEs formed of LD and of different alcohols are hydrolyzed prior to their infusion at different rates.
- the rate of hydrolysis of LDEE near pH 7 and at about 37°C can be about four times faster than the rate of hydrolysis of LDME.
- the rate of hydrolysis of LDE salts also depends on the anion, i.e., on the acid forming the LDE salt.
- the rate of hydrolysis of the salt formed of LDEE and acetic acid is about 3 times faster at about pH 4.5 at about 23°C than that of LDEE'HCl, the salt formed of LDEE and HCl.
- the rate of hydrolysis at a particular pH and temperature also depends on the buffering agent, being slower at about pH 3 in citrate or phosphate buffered solutions than in the acetate buffered solution.
- the hydrolysis of LDE salts, such as LDEE'HCl is strongly pH dependent. It is usually fast near neutral pH and decreases as the pH decreases until about pH 2; below about pH 1 it increases as the pH is further decreased. In strongly acidic solutions, e.g., of about pH 0.5 or less, the rate of hydrolysis is even faster.
- the LDE salt can be stored in its dry solid form, and dissolved in water or in an aqueous solution prior to use. Alternatively and preferably, the LDE salt can be dissolved, and stored as an aqueous solution at a pH and at a temperature where the rate of hydrolysis is slow.
- the shelf life increases as the pH is lowered from neutral to the range from about pH 6 to about pH 5, increases further when the pH is lowered to the range from about pH 5 to pH 4, increases further when it is lowered from about pH 4 to about pH 3, and can be particularly long at about pH 2.3 + 0.7, for example at about pH 2.3.
- the operational life meaning the life of the infused solution, is similarly pH dependent.
- the pH of a subcutaneously infused solution can be generally greater than about 4.0.
- the preferred operational pH range is between about 4.0 and about 6.0, the range between about 4.0 and 5.3 being more preferred; for example the pH of the infused solution can be 4.5 + 0.5 or 4.2 + 0.3.
- the solution may be optionally stored at a temperature below about 25 °C, for example it may be refrigerated at about 5 + 3 °C.
- the aqueous LDE or LDC solutions may be stabilized by forming salts with polycarboxylic acids, the number of carboxylic acid functions exceeding the number of LDE or LDC amine functions.
- the aqueous liquid formulations of the invention can include an LDE or LDC formulated with one or more polycarboxylic acids (e.g., hyaluronic acid, succinylated gelatin, poly(acrylic acid), poly(methacrylic acid), poly(glutamic acid), poly(aspartic acid), poly(maleic acid), poly(malic acid), poly(fumaric acid), or a combination thereof.
- polycarboxylic acids e.g., hyaluronic acid, succinylated gelatin, poly(acrylic acid), poly(methacrylic acid), poly(glutamic acid), poly(aspartic acid), poly(maleic acid), poly(malic acid), poly(fumaric acid), or a combination thereof.
- the polycarboxylic acid and/or its sodium salt can also be added to alter the viscosity of the solution, or as a crystal growth inhibitor, of an LD prodrug formulation (e.g., LDA, LDE, LDC or LDS).
- an LD prodrug formulation e.g., LDA, LDE, LDC or LDS.
- the preferred molecular weight average of the hyaluronic acid is from about 5,000 to about 2,000,000 Daltons (e.g., from 5,000 to 1,000,000; 5,000 to 850,000; 5,000 to 500,000; 50,000 to 850,000; 50,000 to 500,000; or from 150,000 to 850,000 Daltons).
- the formulation with hyaluronic acid can stabilize the LD prodrug (e.g., LDA, LDE, LDC or LDS) against rapid oxidation and/or hydrolysis, and can also produce a slow and controlled release when complexed (as a salt) to the hyaluronic acid.
- the LD prodrug e.g., LDA, LDE, LDC or LDS
- the concentration of the LD prodrug (e.g., LDA, LDE, LDC or LDS) complexed to the hyaluronic acid in the injectable slow-release solution would be typically between 0.5 and 2 moles per liter of the complexed LD ester (e.g., 0.5 + 5 %, 1.0 + 5 %, 1.5 + 4%, 2.0 + 5% moles per liter).
- the concentration for LD prodrug (e.g., LDA, LDE, LDC or LDS) complexed to other polycarboxylic acids can be the same.
- the ratio of hyaluronate carboxyl moiety to drug is greater than 1 (e.g., from about 1.1 to about 2.0, or from about 1.2 to about 1.8).
- LDE molecule hyaluronic mer ratios
- LDC molecule hyaluronic mer ratios
- polycarboxylic acid in the formulations of the invention can reduce the local pain at the infusion site. Pain receptor controlled ion gates are opened by either high proton
- polymeric acids provide an internally strongly protonating environment, because of the high concentration of acidic functions within the macromolecule, yet they are much less ionized, because upon increasingly dissociating they acquire an increasingly negative charge, moderating the further release of protons.
- the LD prodrug e.g., LDA, LDE, LDC or LDS
- the osmotic pressure is less than it would be if the LD prodrug (e.g., LDA, LDE, LDC or LDS) molecules were unbound.
- the LD prodrug (e.g., LDA, LDE, LDC and LDS) formulations of the invention can be designed to enhance stability by reducing the rates of their hydrolysis, which usually dominates their degradation. While the dominant degradation process in the presence of water is hydrolysis, the LD prodrugs can also be oxidized by dissolved or gaseous oxygen. Exclusion of oxygen prevents such degradation. The products of the oxidation are not useful prodrugs, and in the absence of frequent monitoring (e.g., by HPLC or mass spectroscopy), oxidation makes accurate dosing difficult or impossible.
- the oxidation process is an autoxidation, meaning that a radical intermediate accelerates the oxidation, making it autocatalytic. The rate of oxidation can be reduced by several methods.
- the second is to include antioxidants, particularly pharmaceutically acceptable radical scavengers. Because ionization of catechol functions is an early step of the oxidation reaction sequence, oxidation can also be slowed or prevented by dissolving the LDA, LDE, LDS or LDC in a lipid, in which the catechol functions remain un-ionized because of the low dielectric constant.
- the third is to maintain a mildly acidic environment of a pH between about 2.3 and about 5.0, for example of about pH 4.5 + 0.5 or 4.2 + 0.3.
- the daily required amounts of LD for PD management are generally between about 1.5 millimoles and 10 millimoles, typically between about 2.5 and 7.5 millimoles, and most often of about 5 millimoles.
- the volumes can be small and can be infused subcutaneously or intramuscularly.
- Such high concentrations, particularly in non-aqueous solutions, and in emulsions, also allow reduction of the infused volume when the infusion is intragastric, intrajejunal or intraperitoneal.
- the subcutaneous or intramuscular infusion of excessively acidic solutions is painful, triggering pain signals from acid sensing ion-flux gating neuronal receptors, and can also damage cells of the infused tissue, triggering an inflammatory reaction.
- the concentrated infused LD prodrug solutions can be hypertonic. Because infusion of excessively hypertonic solutions may also cause pain and cellular damage, the present invention features aqueous and non-aqueous compositions and methods for which infusion associated pain, cellular damage and inflammation can be reduced or avoided.
- the aqueous liquid formulations of the invention can include the LD prodrug (e.g., LDA, LDE, LDC or LDS) formulated as a viscous liquid by including one or more viscosity enhancing agents in the formulation.
- the viscosity enhancing agents may also prevent or retard crystallization and precipitation of LD, e.g., from partially hydrolyzed LDA, LDE or LDC solutions. It can provide long lived, precipitate free, supersaturated LD prodrug solutions.
- the viscosity of the infusible LD prodrug (e.g., LDA, LDE, LDC or LDS) compositions can typically be between about 1.2 cP and about 2,000 cp (e.g., between about 2 cp and 50 cP), when the viscosity is measured by glass capillary (Oswald) viscometer, or a falling sphere viscometer, or by a Brookfield viscometer, such as model LVDV-E of Brookfield Engineering Laboratories (11 Commerce Boulevard, Middleboro, MA 02346-1031 USA).
- the viscosity can by adjusted by an added sugar or a polyol, such as glucose, glycerol, sucrose, mannitol, or a polymer, such as hyaluronic acid, gelatin, collagen, dextran, albumin, polyethylene glycol (e.g., polyethylene glycol 3350), glycogen, succinylated gelatin, polylactic acid, polyglycolic acid, and DL-lactic and glycolic acids copolymers.
- the viscosity enhancing polymer can have a molecular weight average of between about 5,000 and about 2,000,000 Daltons.
- the pharmaceutical compositions of the invention can include from 0.1 to 2.0% (w/w) hyaluronic acid having an average molecular weig ht of from lxlO 6 to 2xl0 6 Daltons.
- the viscosities of the hyaluronic acid solutions increase with the hyaluronic acid concentration and with the molecular weight of the hyaluronic acid.
- the preferred infused solutions including LD prodrug e.g., LDA, LDE, LDC or LDS
- the preferred infused solutions including LD prodrug have viscosities of less than about 10 4 centipoise, preferably less than about 10 3 centipoise, preferably between about 1.2 cp and about 2xl0 2 cp at about 25°C when the viscosity is measured with a glass capillary viscometer or by a falling sphere viscometer.
- aqueous liquid formulations of the invention can include the LD prodrug (e.g., LDA, LDE,
- LDC or LDS formulated with one or more crystallization inhibitors, such as a sugar (e.g., hydroxyethyl starch, dextran, albumin, polyethylene glycol, mannitol, glucose), hyaluronic acid, succinylated gelatin, or other polycarboxylic acids.
- a sugar e.g., hydroxyethyl starch, dextran, albumin, polyethylene glycol, mannitol, glucose
- hyaluronic acid e.g., succinylated gelatin, or other polycarboxylic acids.
- the crystallization inhibitor e.g., hyaluronic acid
- the crystallization inhibitor can reduce the size of the precipitated LD crystallites or prevent the precipitation of crystallites of LD from its supersaturated solution.
- the size of precipitated crystallites is defined by the ratio of two rates: the rate of formation of crystal nuclei, the nucleation rate; and the rate of diffusion of the precipitated solute to the crystallites. Because the viscosity of the polymeric acid solutions and also of the concentrated saccharide (e.g., glucose) solutions is high, increasing with concentration and molecular weight, the dimensions of the precipitated crystallites, if any, can be made small enough to allow the pumping of their suspensions.
- the preferred adsorption of macromolecules on growing faces of crystallites prevents or reduces access of molecules of the precipitated solute, often fully preventing, or slowing, growth of the crystallites to dimensions where their surface/volume ratio is high enough for thermodynamic stability, the high surface energy de- stabilizing small crystallites (i.e., slowing the rate of nucleation or preventing nucleation).
- the invention also features a formulation including a carbidopa prodrug (e.g., carbidopa ester or carbidopa amide) which can be stable in solution, which can be delivered via an ambulatory infusion pump, and which can increase the LD half-life in the PD patient and/or reduce the daily LD or LD prodrug dose. It can be optionally co-dissolved and/or co-infused with the LD-prodrug. When co- infused with the LD prodrug the carbidopa prodrug can reduce the total daily infused LD dose.
- the carbidopa prodrug can be formulated to prevent rapid hydrolysis prior to its infusion, but is rapidly hydrolyzed to form carbidopa after its delivery into the body.
- Preferred carbidopa esters are rapidly hydrolyzed in vivo by esterases and preferred carbidopa amides are rapidly hydrolyzed in vivo by amidases.
- the prodrugs of the invention can be stored in liquid forms or solid forms, which can provide upon mixing of the contents of two containers or chambers an infusible aqueous solution prior to infusion into a subject.
- solubilities of the carbidopa esters and carbidopa amides can exceed the solubility of carbidopa, the highest solubilities typically being observed for carbidopa prodrug salt forms.
- solubilities of salts of carbidopa ethyl ester and carbidopa methyl ester, such as the salts formed when these bases are neutralized by HC1 are much more soluble than carbidopa.
- the high solubility of carbidopa ethyl ester hydrochloride allows for aqueous solutions of high concentration.
- the concentrated solutions can be subcutaneously or intramuscularly infused, or they can be intragastrically or intrajejunally infused.
- the carbidopa prodrugs are hydrolyzed to carbidopa, which can be much less soluble in water or in aqueous solutions in the pH range suitable for subcutaneous or intramuscular infusion.
- the shelf life of the stored and of the infused (operational) carbidopa prodrug solutions is usually determined by their hydrolysis, leading to carbidopa precipitation, which can be faster than the other degradation processes, such as oxidation, particularly when oxygen is substantially excluded.
- a major problem with the carbidopa prodrug formulations, particularly of the aqueous formulations is their hydrolytic instability.
- the rate of hydrolysis is pH and temperature dependent.
- carbidopa is poorly soluble, and because the concentration of the carbidopa prodrug in the small-volume subcutaneously or intramuscularly infused solution is necessarily high, even hydrolysis of a small fraction of a carbidopa prodrug or prodrug salt may result in the precipitation of carbidopa from the solution.
- the presence of a large amount of carbidopa precipitate is unacceptable, as it may lead to a dosing error and because it may block or reduce the flow in the infusion system.
- the carbidopa esters formed of carbidopa and of different alcohols are hydrolyzed at different rates.
- the rate of hydrolysis of carbidopa methyl ester could be slower than the rate of hydrolysis of carbidopa ethyl ester.
- the rate of hydrolysis of carbidopa ester salts could also depend on the anion, i.e., on the acid forming the carbidopa ester salt.
- the rate of hydrolysis of the salt formed of carbidopa ethyl ester and acetic acid could be faster than the hydrolysis of the salt formed of carbidopa ethyl ester and HC1.
- the rate of hydrolysis at a particular pH and temperature also depends on the buffering agent, being slower at about pH 3 in citrate or phosphate buffered solutions than in the acetate buffered solution.
- the hydrolysis of carbidopa ester salts such as carbidopa ethyl ester hydrochloride, is expected to be strongly pH dependent. It is expected to be fast near neutral pH; to decrease as the pH decreases until about pH 2; below about pH 1 it is expected to increase as the pH is further decreased. In strongly acidic solutions, e.g., of about pH 0.5 or less, the expected rate of hydrolysis is even faster.
- the shelf life can be very short for the typical carbidopa prodrug aqueous solution at about neutral pH at an ambient temperature (e.g., 25°C).
- the carbidopa ester salt can be stored in its dry solid form, and dissolved in water or in an aqueous solution prior to use.
- the carbidopa ester salt can be dissolved, and stored as an aqueous solution at a pH and at a temperature where the rate of hydrolysis is slow.
- the shelf life is expected to increase as the pH is lowered from neutral to the range from about pH 6 to about pH 5, increase further when the pH is lowered to the range from about pH 5 to pH 4, increase further when it is lowered from about pH 4 to about pH 3, and can be particularly long at about pH 2.3 + 0.7, for example at about pH 2.3.
- the operational life meaning the life of the infused solution, is similarly pH dependent.
- the pH of a subcutaneously infused solution can be generally greater than about 4.0.
- the preferred operational pH range is between about 4.0 and about 6.0, the range between about 4.0 and 5.3 being more preferred; for example the pH of the infused solution can be 4.5 + 0.5 or 4.2 + 0.3.
- the solution may be optionally stored at a temperature below about 25°C, for example it may be refrigerated at about 5 + 3 °C.
- No carbidopa precipitation is expected in an exemplary 1.0 ⁇ 0.5 M aqueous carbidopa ethyl ester hydrochloride solution when having a pH between about 1.5 and about 3.5 and stored at about 5 + 3 °C (e.g., about 4 °C) for more than 1 year, or when having a pH of 2.5 + 0.5 and stored at about 5 + 3 °C (e.g., about 4 °C) for about 3 years.
- the daily required amounts of carbidopa for PD management are generally between about 0.3 millimoles and 3 millimoles, typically between about 0.6 and 2.0 millimoles, and most often of about 1-2 millimoles.
- concentrations of >0.3 M , >0.4 M, >0.5 M, >0.6 M, >0.8 M, >1.0 M, >1.5 M, >2 M, >2.5 M, >2.7 M in aqueous solutions or emulsions the volumes can be small and can be infused
- LD and LD prodrugs can be susceptible to oxidative degradation.
- the formulations of the invention optionally contain one or more antioxidants.
- Antioxidants that can be used in the aqueous formulations of the invention can be selected from thiols (e.g., dihydrolipoic acid, propylthiouracil, thioredoxin, glutathione, cysteine, cystine, cystamine, thiodipropionic acid), sulphoximines (e.g., buthionine-sulphoximines, homo-cysteine- sulphoximine, buthionine-sulphones, and penta-, hexa- and heptathionine-sulphoximine), metal chelators (e.g, a-hydroxy-fatty acids, lactoferrin, citric acid, lactic acid, and malic acid, EDTA, EGTA, and
- the LD prodrug can be formulated with one or more antioxidants selected from vitamin E; beta-carotene; tert-butylhydroxytoluene, tert- butylhydroxyanisole, ubiquinol, nordihydroguaiaretic acid trihydroxybutyrophenone, benzoates like coniferyl benzoate, terTBHQ (tert- butyl hydroquinone), propylgallate (3,4,5-trihydroxybenzoate), and dodecyl gallate, or a mixture thereof.
- the total amount of antioxidant included in the formulations can be from 0.01 to 2% by weight.
- the pharmaceutical formulations described herein can include non- precipitating particles of an LD prodrug (e.g., LDA, LDE, LDC or LDS), or a salt thereof typically having an effective particle size of less than about 1 micron (i.e., nanoparticulate including formulations).
- LD prodrug particles can be made by using any method known in the art for achieving the desired particle sizes.
- Useful methods include, for example, homogenization, supercritical fluid fracture, or precipitation techniques. Exemplary methods are described in U.S. Patent Nos.
- the invention features compositions, methods, and infusion pumps for infusing an LD prodrug and or its salt.
- the LDEs are hydrolyzed in vivo to an alcohol; the LDCs are hydrolyzed in vivo to LD and a salt, mostly sodium salt, of a carboxylic acid; the LDAs are hydrolyzed in vivo to LD and an ammonium salt, mostly an ammonium chloride; and the LDS are hydrolyzed in vivo to LD and a sulfonate salt, mostly sodium sulfonate salt.
- the oral, i.e., ingested LD 50 of the produced alcohol or sodium carboxylate, or ammonium chloride, or sodium sulfonate is greater than 3
- LDEE can be prepared from LD and ethanol, for example, as described in PCT Publication Nos. WO2003/042136 and WO2000027801; as described in U.S. Patent Nos. 5,525,631; 6,218,566, and/or 5,354,885; or as described by Marrel et al., European Journal of Medicinal Chemistry, 20:459 (1985), each of which is incorporated herein by reference.
- Other esters of LD can be prepared from LD and the corresponding alcohol using analogous synthetic methods.
- the hydrolysis rates generally decrease as the pH decreases, and the shelf life of the LDE salt consequently increases, unless the pH is about 1.0 + 0.5 or less.
- the pH is about 1.0 + 0.5 or less.
- the LDEE'HCl solutions are generally more stable than at about pH 3; at pH 3 the
- LDEE'HCl solution are generally more stable than at about pH 4; at about pH 4 they are generally more stable than at about pH 5; at about pH 5 they are generally more stable than at about pH 6; and at about pH 6 they are generally more stable than they are at about pH 7.
- the rates of hydrolysis of the protonated LDE cations depend on the charge-balancing anion. In general, the rates of hydrolysis for salts with anions formed by the dissociation of weak acids are greater than those formed by the dissociation of strong acids. For example, the acetate of the protonated LDEE salt may hydrolyze about three times more rapidly than its chloride salt.
- LDEE is hydrolyzed within hours or less, making the pH 7 solution unsuitable for most infusion situations.
- the rates of hydrolysis generally increase with temperature, and may at least about double or about triple for each 10°C increase, correspondingly decreasing upon cooling.
- a buffer is added to maintain a particular pH the anion or anions of the buffer affect the rate of hydrolysis.
- hydrolysis in the presence of acetate buffer is more rapid than in the presence of citrate buffer or phosphate buffer, wherefore the use of citrate buffer or phosphate buffer is preferred.
- the infused pharmaceutical compositions may include LDA, LDC and/or LDS.
- the LDCs can be synthesized using the methods described by Zhou et al., European Journal of Medicinal Chemistry, 45:4035 (2010).
- LD prodrugs can be prepared from LD in a process that may include the selective protection and deprotection of the hydroxyl, amine, and/or carboxyl functional groups of the LD.
- protecting groups for amines include carbamates, such as tert-butyl, benzyl, 2,2,2 - trichloroethyl, 2-trimethylsilylethyl, 9-fluorenylmethyl, allyl, and m-nitrophenyl.
- amides such as formamides, acetamides, trifluoroacetamides, sulfonamides, trifluoromethanesulfonyl amides, trimethylsilylethanesulfonamides, and tert-butylsulfonyl amides.
- protecting groups for carboxyls include esters, such as methyl, ethyl, tert-butyl, 9-fluorenylmethyl, 2-(trimethylsilyl)ethoxy methyl, benzyl, diphenylmethyl, O- nitrobenzyl, ortho-esters, and halo-esters.
- Examples of commonly used protecting groups for hydroxyl groups include ethers, such as methyl, methoxymethyl, methoxyethoxymethyl, methylthiomethyl, benzyloxymethyl, tetrahydropyranyl, ethoxyethyl, benzyl, 2-napthylmethyl, O-nitrobenzyl, P-nitrobenzyl, P-methoxybenzyl, 9-phenylxanthyl, trityl (including methoxy-trityls), and silyl ethers.
- ethers such as methyl, methoxymethyl, methoxyethoxymethyl, methylthiomethyl, benzyloxymethyl, tetrahydropyranyl, ethoxyethyl, benzyl, 2-napthylmethyl, O-nitrobenzyl, P-nitrobenzyl, P-methoxybenzyl, 9-phenylxanthyl, trityl (including methoxy-trity
- Protecting groups can be chosen such that selective conditions (e.g., acidic conditions, basic conditions, catalysis by a nucleophile, catalysis by a lewis acid, or hydrogenation) are required to remove each, exclusive of other protecting groups in a molecule.
- selective conditions e.g., acidic conditions, basic conditions, catalysis by a nucleophile, catalysis by a lewis acid, or hydrogenation
- the conditions required for the addition of protecting groups to amine, hydroxyl, and carboxyl functionalities and the conditions required for their removal are provided in detail in T.W. Green and P.G.M. Wuts, Protective Groups in Organic Synthesis (2nd Ed.), John Wiley & Sons, 1991 and P.J. Kocienski, Protecting Groups, Georg Thieme Verlag, 1994.
- LD-treated people with advanced PD require typically daily 0.5-1.5 g (2.5-7.5 millimoles) oral LD.
- the intent is to subcutaneously infuse the prodrug equivalent of the mid-range 1 g LD in a volume of preferably less than 20 mL, 18 mL, 16 mL, 15 mL, 14 mL, 13 mL, 12 mL, 11 mL, 10 mL, 9 mL, 8 mL, 7 mL, 6 mL, 5 mL.
- Lesser volumes of 4 mL, 3 mL, or less than 2 mL can be used when the infusion is intragastric, intraduodenal or intrajejunal.
- the respective concentration for 1 g (5 millimoles) equivalent of any LD prodrug is 0.3 M when the infused volume is 20 mL, 0.5 M when the infused volume islO mL, 1.0 M when the infused volume is 5 mL.
- the concentrations can be higher, 1.67 M when the infused volume is 3 mL, 2.5 M when the infused volume is 2 mL, and 3.0 M when the infused volume is 1.67 M.
- the weight percentage of water is less than the weight percentage of the prodrug, yet the solutions are clear, homogenous, liquids.
- the weight % of water in the 2.6 M LDEE'HCl solution is about 42 weight %, and that in the 2.9 M solution is about 36 weight %.
- Their densities can be high, in excess of 1.15 g/mL at 25°C for the more concentrated solutions.
- the density of the 2.6 M LDEE'HCl solution is about 1.17 g/mL and that of the 2.9 M
- LDEE'HCl solution it is about 1.19 g/mL.
- the preferred anion of the LDE salts or the LDC salt is the chloride ion, the only anion present in body fluids at > 0.1 M concentration, because infusion of 5 millimoles of its salt does not substantially affect its systemic concentration.
- the preferred anion is chloride, i.e., in the case of LDEE the preferred salt is LDEE'HCl.
- the preferred cation in the LDA and LDS salts is the sodium cation.
- the LD prodrug may be administered in its free base form or as a pharmaceutically acceptable salt, preferably its chloride salt. It may be administered also as a salt with an anion known to be very rapidly metabolized through cycles, such as the Krebs cycle (e.g., lactate, acetate, citrate, gluconate, malate, malonate, fumarate, succinate, isocitrate, or 1 -glycerophosphate). Of these, lactate, present in blood and interstitial fluid at > 1 mM concentrations is preferred. In certain instances the formulation of the invention includes a hydrochloride salt of an LD prodrug (e.g., LDA or LDE).
- a hydrochloride salt of an LD prodrug e.g., LDA or LDE
- the formulation is a non-aqueous formulation or emulsion of the invention that includes a carboxylate salt of an LD prodrug (e.g., LDA or LDE).
- LD prodrug e.g., LDA or LDE
- the anions of these salts are typically aliphatic or aromatic carboxylate anions, such as eicosapentaenoate, docosahexaenoate, ricinoleate, alpha-linolenate, gamma linolenate, dihomo-gamma linolenate, arachidonate, linoleate, myristate, oleate, palmitate, palmitoleate, and/or stearate and may have an odd or even number of carbon atoms.
- the preferred carboxylate anions are aliphatic and have an even number of carbon atoms between 8 and 22, more preferably between 8 and 22, e.g.
- anions include arachidonate, linoleate, palmitoleate, and/or oleate.
- the equilibrium reaction in which the free base LD prodrug is reacted with a carboxylic acid to form an acid addition salt can result in a mixture that can contain some fraction of free LDE or LDA and free carboxylic acid.
- a carboxylic acid to form an acid addition salt can be advantageous for slightly lowering the local pH and thereby stabilizing the catechol of the ester against oxidation by dissolved oxygen and also for lowering the temperature of the liquidus.
- the molar excess of the carboxylic acid is about 10 mole % or less.
- the shelf lives of the LD prodrug salts are generally limited by hydrolysis in the presence of water, e.g., in aqueous solutions and also in humid atmospheres; and by their air-oxidation.
- liquid LD prodrug salts or salt mixtures e.g., liquid salts
- the liquid LD prodrug salt formulations can be advantageously difficult to oxidize.
- the process is an autoxidation, meaning that a radical intermediate accelerates the oxidation, making it autocatalytic.
- the rate of oxidation can be reduced by several methods.
- the second is to include anti-oxidants, particularly pharmaceutically acceptable radical scavengers capturing radical intermediates involved in the oxidation of the catechol functions of the LD prodrugs. These include for example capture by the polyunsaturated aliphatic carboxylates of the composition, by added vitamin E, and by added tert-butylphenols.
- the third is to increase the viscosity (relative to that of water). At the higher viscosity of the oils (relative to water) the rate of oxidation by dissolved oxygen is reduced. The oxidation is also slowed or prevented in the liquid LD prodrug salts because their dielectric constants are lower than those of aqueous solutions. Ionization of the catechol functions is usually the first step in their oxidation; at the lower dielectric constants of the liquid LD prodrug salts, the catechol functions are less ionized.
- the acid addition salts of the invention that are of particular relevance to intragastric, intraduodenal or intrajejunal infusion, can be formulated with lipids, such as carboxylic acids, and mono, di or triglycerides of carboxylic acids, and/or other esters of C 12 -C 22 carboxylic acids, preferably esters melting below 25°C, such as ethyl myristate and ethyl oleate.
- the preferred carboxylic acids and their glycerol or ethanol esters are those with 12 and/or 14 and/or 16 and/or 18 and/or 20 carbon atoms;
- the lipid excipients are typically mixtures, i.e., like sesame oil, castor oil, or linseed oil, and/or carboxylic acids, like oleic, linoleic, or palmitoleic acid and can be combined with alcohols, such as glycerol.
- the fatty acid LD salts or the oils are metastable liquids, meaning that they are liquids that can eventually crystallize, their crystallization is retarded when the viscosity is increased.
- solubility of LD increases remarkably with the concentration of LDEE'HCl.
- concentration of LDEE'HCl we have found that in a citrate buffered solution of about pH 4.5 not containing LDEE-HCl the solubility of LD at 25°C is about 0.68 g/100 mL or 34 mM.
- a citrate buffered solution of about pH 4.5 containing 1.3 M LDEE-HCl the solubility of LD at 25°C is about 1.0 g/100 mL or 51 mM.
- solubility of LD at 25°C is about 1.7 g/100 mL or 86 mM.
- the hydrolytic stability of concentrated aqueous solutions of LDEE TC1 is best between about pll 2.0 and about pH 3, and it is preferred to store the solutions at pH 2.3 ⁇ 0.7.
- Such a pll can be maintained for example through co- dissolving citrate, e.g., as trisodium citrate, for example to about 2 -50 m ' M concentration, typically to about 10-40 mM concentration, and preferably to 20-35 mM concentration.
- citrate e.g., as trisodium citrate
- Exemplary estimated storage and operational lives are provided in Table 1 for an about 2.6 M LDEE'HCl solution. Table 1
- the burden of hypertonicity can be reduced by increasing the daily administered volume (for the administration of 1 g LD equivalent) to about 5-20 mL.
- compositions of the invention can be infused, preferably subcutaneously or intramuscularly, using an infusion pump, which can optionally be a syringe-type infusion pump.
- the pump can be configured to automatically infuse continuously or intermittently, and/or administration can be subject-controlled.
- any suitable type of infusion pump may be used to deliver the LD prodrug (e.g., LDA, LDE, LDC or LDS) including liquid composition.
- LD prodrug e.g., LDA, LDE, LDC or LDS
- These may include implantable and non-implantable pumps, pumps for intramuscular, subcutaneous, percutaneous, or intrathecal delivery, fixed position or ambulatory pumps, patch pumps and carried pumps.
- These pumps may employ any pump drive mechanism known in the art including syringe, hydraulic, gear, rotary vane, screw, bent axis, axial piston, radial piston, peristaltic, spring-driven, gas-driven, piezo-electric, electroosmotic, and wax expansion.
- an infusion pump can include a peristaltic pump.
- an infusion pump can include a computer-controlled motor, turning a screw that pushes the plunger of a syringe.
- An intrathecal pump can be used to deliver very small quantities of a pharmaceutical composition directly to the intrathecal space and cerebrospinal fluid of a subject.
- Intrathecal pumps are typically implanted in the body, with a catheter leading from the pump to the target location. Such pumps typically have a drug reservoir refillable via a drug injection, have a battery life of about six years, and have a capacity of about 20 mL or 40 mL of drug. Their pumps are typically peristaltic. Flow rates vary from about 0.048 mL/day to 24 mL/day. The flow rate accuracy of the pump is typically within +/-14.5% of the programmed flow rate at 0.048-24 mL/day at 37°C, 50% reservoir volume, and 300 meters above sea level. Such pumps are typically programmable and the infusion rates can be modified non-invasively.
- Ambulatory drug infusion pumps can be used for subcutaneous or intravenous administration of a pharmaceutical composition of the invention.
- One example of an ambulatory infusion pump used to treat PD is the Smiths Medical CADD-Legacy 1400 ambulatory pump, which is used to deliver the Duodopa gel.
- the pump is reusable and works with a disposable cassette containing the drug.
- the cassette has a 100 mL reservoir containing 20 mg/mL LD and 5 mg/mL carbidopa in a gel; carmellose sodium is used as a thickening agent.
- the shelf life is 15 weeks when refrigerated, and 24 hours at room temperature.
- the Duodopa gel is infused from the extracorporeal pump to the duodenum through a catheter that is surgically implanted through the wall of the abdomen in a percutaneous gastrostomy operation.
- the CADD-Legacy pump includes a display, cassette detection, occlusion detection, air-in-line detection, on/off key, event memory and programmable infusion rates.
- the infusion regimen suggested in the Duodopa users guide includes a morning dose (administered when the subject wakes up in order to quickly achieve the concentration required for optimal subject response); a continuous maintenance dose (administered continuously by the pump to maintain a constant circulating concentration); and extra doses (administered if the subject experiences reduced mobility during the day).
- APO-go pump for infusion of apomorphine, a dopamine agonist. It is indicated for the treatment of disabling motor fluctuations ('on- off phenomena) in subjects with PD.
- the pump infuses apomorphine 10 mg/mL solution.
- a particular class of ambulatory drug infusion pumps which can be used for the delivery of the pharmaceutical compositions of the invention, are single, two and multi-compartment pumps designed to infuse drugs, for example insulin to patients with diabetes. These can generally be broken down into two groups: skin-attached "patch pumps” and carried pumps. Examples of insulin patch pump designs by various companies include those described in U.S. Patent Nos. 7,914,499, 7,806,867; 7,740,607;
- Examples of carried pump designs by various companies include those described in U.S. Patent Nos. 6,551,276 and
- the preferred pumps are inexpensive, optionally single-use, skin attached patch pumps, optionally with two compartments.
- One, two or more inexpensive patch-pumps can be attached to the skin in order to increase the dose rate or the dose of the LD-prodrug, or to better distribute the infused volume.
- An exemplary useful pump is the Crono syringe-type programmable infusion pump of Cane s.r.l. Medical Technology Via Pavia 105/1 Rivoli (TO) Italy. Its dimensions are 77x48x29 mm (3x1.9x1.1 inch) and its weight is 115 g, its 3 Volt type 123 A lithium battery included. The capacity of its syringe is 10 or 20 mL. The delivered solution volume can be programmed from 1 to 20 mL for delivery times from 30 minutes to 99 hours, in 15 minutes steps. The accuracy is +/- 2%. The occlusion pressure is 4.5 + 1 bar.
- the pump is programmable and the data are automatically stored in the pump's memory; in the event of an anomaly, an alarm is provided and an error message is displayed.
- the pump' s functions can be "locked” such that the subject will not accidentally change a function by pushing a button.
- the pump operates accurately in the 10°C - 45°C, at 30 -75 relative humidity and through the 700 hPa-1060 hPa (hectopascal) atmospheric pressure range.
- Yet another exemplary useful pump that can be used in the methods and devices of the invention is an electro-osmotic drug pump, such as that described in PCT Publication No. WO 2011112723; W. Shin et al., Drug Delivery and Translational Research 1:342 (2011); W. Shin et al., Journal of the
- the pumps preferred are externally worn and infuse subcutaneously or intramuscularly and can infuse solutions of 1 cP, 10 cP, 100 cP, 1000 cP viscosity at about 30°C at average rates of more than 1 ⁇ ⁇ per min, preferably at least 2, 5, 10 ⁇ ⁇ per minutes.
- Infusions may be made continuously or intermittently, with sample intermittent infusion intervals being less than or equal to about every 5, 10, 15, 30, 60, 90 or 120 minutes.
- Infusion rates may be set to one or more values that equates to a rate of LD prodrug (e.g., LDA, LDE, LDC or LDS) delivery of anywhere between 1 - 200 mg/hr.
- LD prodrug e.g., LDA, LDE, LDC or LDS
- Sample infusion rates may equate to about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175 or 200 mg/hr of LD prodrug (e.g., LDA, LDE, LDC or LDS).
- Sample infusion rates may equate to less than or equal to about 10, 5, 1, 0.5 and 0.1 mg/hr of LD prodrug (e.g., LDA, LDE, LDC or LDS).
- Pump flow rates depend on the concentration of the LD prodrug (e.g., LDA, LDE, LDC or LDS) in the solution. Convenient flow rates range from less than or equal to about 1.4, 1.2, 1.0, 0.8, 0.6, 0.4, 0.3, 0.2, 0.1 or 0.04 mL/hr. For intrathecal pumps flow rates typically vary from about 0.0048 mL/day to 2.4 mL/day. Sample flow rates equate to less than about 20, 15, 10, 5, 1, 0.5, 0.1, and 0.01 mL/day.
- the concentration of the LD prodrug e.g., LDA, LDE, LDC or LDS
- Convenient flow rates range from less than or equal to about 1.4, 1.2, 1.0, 0.8, 0.6, 0.4, 0.3, 0.2, 0.1 or 0.04 mL/hr.
- flow rates typically vary from about 0.0048 mL/day to 2.4 mL/day. Sample flow rates equate to less than
- LD prodrug e.g., LDA, LDE, LDC or LDS
- LD prodrug from a single container may be infused s.c. or intramuscularly by the pump for a period of greater than or equal to about 8 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours or 96 hours.
- the container may contain the equivalent of between 0.25 - 20 g of LD prodrug (e.g., LDA, LDE, LDC or LDS), or of 1 - 6 g of LD prodrug (e.g., LDA, LDE, LDC or LDS).
- LD prodrug e.g., LDA, LDE, LDC or LDS
- Examples of the equivalent amounts of LD prodrug (e.g., LDA, LDE, LDC or LDS) that may be contained in a container are about 0.5 + 0.2, 1 + 0.3, 2 + 0.4, 3 + 0.5, 4 + 0.7, 5 + 0.8, 6 + 2, 8 + 2, 10 + 2, 12 + 2, 14 + 2, 16 + 2, 18 + 2, or 20 + 2 g.
- Implantable pumps may contain greater amounts of drug in their reservoirs.
- any suitable type of infusion pump may be used to subcutaneously or intramuscularly deliver the non-aqueous compositions or the emulsions.
- These may include implantable and non-implantable pumps, fixed position or ambulatory pumps, patch pumps and carried pumps.
- the pumps preferred are externally worn and infuse subcutaneously or intramuscularly and can infuse solutions of 1 cP, 10 cP, 100 cP, 1000 cP viscosity at about 30°C at average rates of more than 0.1 mL/hr, preferably at least 0.2 mL/hr, 0.3 mL/hr, 0.4 mL/hr, 0.5mL/hr, 0.6 mL/hr.
- Typical infused LD prodrug dose ranges are from about 10 micromoles per kg of subject weight to about 200 micromoles per kg of subject weight of LD prodrug per day.
- the typical daily dose for a subject weighing 75 kg is from about 0.75 millimoles to about 15 millimoles of LD prodrug.
- Infusion rates may be set to one or more values that equates to a rate of LD prodrug delivery of anywhere between about 30 micromoles per hour and about 600 micromoles per hour.
- concentration of the LD prodrug is 0.5 M, these values correspond to average flow rates of 60 and 1,200 microliters per hour respectively.
- the exemplary dosage/kg of LD prodrug to be administered is likely to depend on such variables as the stage of the PD of the subject, the dose/kg being higher for subjects in more advanced stages of the disease and on the particular formulation of the LD prodrug being used.
- the preferred pump flow rate is between about 0.2 mL per hour and about 1.5 mL per hour.
- the flow rate depends on the duty cycle. For example, if the pump is on for 10 min and is off for 20 min the pumping rate while the pump is on is between 0.6 mL per hour and about 4.5 mL per hour.
- LD prodrug from a container may be infused s.c.
- the container may contain between about 1 millimole and about 0.1 mole of LD prodrug.
- An about 10 mL exemplary container, typically replaced daily, may contain about 7 millimoles of the LD prodrug containing enough prodrug to form about 1350 mg LD when hydrolyzed in-vivo by an esterase.
- the flow rate is constant rather than being adjusted by the user or health care provider. Pumps with different constant flow rates are to be provided for users requiring different daily doses of the LD prodrug. In another embodiment the flow rate is constant for all users, and the users are provided with solutions of different LD-prodrug concentrations. Advantages of the fixed flow rate pumps include their low cost and the simplicity of their use.
- Pumps of the present invention can include some or all of the following elements: a pump drive mechanism; a subcutaneous or intramuscular infusion set, cannula, or needle; an intrathecal catheter (e.g., for delivering dopamine); an inserter for the subcutaneous or intramuscular infusion set, cannula, or needle; a drug reservoir; a display; an input mechanism (e.g., a keypad or touchscreen); a memory; a remote control; a data processing unit; an alarm; a battery; a transmitter; a receiver; an occlusion sensor; data download or transmission capability; the ability to input disease-related data (e.g., event markers, sensor measurements, meals, exercise, etc.); algorithms to recommend or control drug basal and/or bolus dosing; and an adhesive to attach to the skin or a clip to attach to clothes.
- the pumps can be configured to obtain data from sensors through a physical or a wireless connection, or even from physical integration of the units.
- the pump may also be configured to communicate
- the drug reservoir(s) can be equipped with a septum, which is penetrated to provide fluid contact between the reservoir and the infusion needle.
- the septum of the reservoir can be made from a polymer having low oxygen permeability, such as polyvinylidene chloride, filler loaded butyl rubber
- the infusion set's catheter can be constructed to have low permeability to oxygen.
- the catheter can, optionally, be long, e.g. 60 cm; its ID can be typically less than 1 mm (e.g., about 0.7 mm, about 0.4 mm, or less). Its wall thickness can be less than 1 mm and greater than about 0.2mm (e.g., between about 0.4 and about 0.6 mm).
- the catheter can be optionally formed from a polymer, such as polyvinylidene chloride, filler loaded butyl rubber (poly(isobutylene-co-isoprene)), filler loaded chlorobutyl rubber, chlorobutyl rubber, bromobutyl rubber, butyl rubber, chlorosulfonated polyethylene (Hypalon), or amorphous polyethylene terephthalate.
- a polymer such as polyvinylidene chloride, filler loaded butyl rubber (poly(isobutylene-co-isoprene)), filler loaded chlorobutyl rubber, chlorobutyl rubber, bromobutyl rubber, butyl rubber, chlorosulfonated polyethylene (Hypalon), or amorphous polyethylene terephthalate.
- Non-programmable pumps may be entirely or partially disposable after use.
- Non-programmable pumps may simply deliver a constant basal infusion rate; optionally, they may also have the ability to deliver a fixed bolus or multiple fixed boli on command.
- the pump can include the software, memory and hardware to enable the pump to input, store, recall, display, communicate and/or analyze event markers useful to management of PD.
- event markers can include: (i) intake of the infused medications, including dose and time; (ii) intake of other PD medications, including identification of the drug, dose and time (e.g., such medications may include DDC inhibitors, dopamine receptor agonists, MAO-B agonists, COMT enzyme inhibitors,
- symptoms and side effects e.g., on and off times, dose failures, delayed time to on, tremor, dystonia, akinesia, bradykinesia, dyskinesia, tremor, nausea, vomiting, confusion, somnolence, hallucination, insomnia, constipation, dizziness, dysphagia, moods and mood changes, and impulse control disorders
- sensor readings or data e.g., sensor readings or data
- sleep times and/or sleep quality e.g., meals and meal information, particularly of the protein content of the meal
- defecation information e.g., exercise information.
- Such event markers can also record the time of the event and additional information or notes specific to each event, such as its intensity, quality, duration, amount, or character, among other information.
- the pump may be programmed to increase the amount of drug infused following meals that contain proteins, after which the blood concentration of neutral amino acids competing with LD for active transport across the blood brain barrier increases.
- the pump may be used to infuse the LD prodrug over the entire 24 hour day.
- some physicians may prefer that the pump only infuse the LD prodrug about 12, 14, 16, 18, or 20 hours per day.
- the infusion may be stopped or reduced significantly, i.e., reduced to less than 50% of the average daytime infusion rate.
- the subject wakes up he or she may initiate the infusion at the regular basal rate or, if the subject is in the off state, at a higher "morning dose" rate, in order to turn on more quickly.
- the pump can be programmed to begin such morning infusions automatically so that the subject does not need to initiate them.
- the pump may be programmed to initiate infusion at the regular basal rate or at a higher morning dose rate at a certain hour or a certain amount of time (e.g., 4, 6, or 8 hours) after the infusion was stopped or decreased. If the pump is programmed to initiate such an infusion before the subject typically gets up in the morning, then the subject can get up in the on state rather than in the off state.
- a morning dose rate is an infusion rate that is greater than 10%, 20%, 30%, 40% or 50% greater than the basal rate or the average daytime infusion rate. When a fixed flow rate pump is used the subject may take an oral morning dose to turn on more quickly.
- Multistep inputs and those requiring fine motor skills may be particularly difficult.
- a particularly useful means of providing input to the pump is to have one, two, three, four or more large, dedicated actuators on the pump or a remote control for the subject to easily activate in order to input frequently used or critical functions or information.
- Examples of such an actuator are one, two, three, four or more large buttons or switches that may be placed on the exterior of the pump or remote control. These buttons or switches may be of any convenient size. Examples include the range of 0.1 to 2.0 inches, the range of 0.25 to 1 inch. Examples of frequently used or critical functions or information may include: deliver bolus; reduce infusion rate; increase infusion rate; or experiencing one or more of dyskinesia, bradykinesia, tremor, off state or on state.
- buttons to indicate dyskinesia are: a button to indicate bradykinesia; a button to indicate rigidity; a button to indicate off state; a button to indicate akinesia; or a button to initiate a bolus.
- a button to indicate dyskinesia When a fixed flow rate skin-adhered pump is used the flow would start e.g., upon its application to the skin.
- the pump can be integrated with a sensor to form a sensor-augmented pump.
- the pump system can include the software, memory and hardware to enable the pump to input, store, recall, display, communicate and/or analyze sensor data useful to management of PD.
- Such integration may be physical, in which case the sensor and the pump share some physical components (e.g., a housing, remote control, memory, a display, a power source). Alternatively, such integration may be through data communication in which case the sensor transmits data to the pump, the pump transmits data to the sensor, or both.
- the sensor can include a transmitter and/or a receiver.
- the sensor can be a unitary device or may be a system having physically separate components, such as a physically separate sensor component and a display, memory, data communication, analysis or other component.
- the sensor can be reusable or disposable.
- Sensors of the present invention can include any physiological, physical or chemical parameter associated with the subject.
- sensors and sensed parameters include: (i) motion sensors (e.g., accelerometers to sense movement, stillness, slowness, falling, walking, akinesia, bradykinesia, tremor, restless leg, finger movement and/or leg movement; (ii) the accelerometers may also sense posture, such as whether the subject is standing, sitting or lying down); (iii) pressure transducers or electrodes to sense cardiovascular parameters (e.g., heart rate, electrocardiogram, etc.); (iv) electrodes to sense wakefulness or sleep, and sleep parameters (these may include polysomnography, electroencephalogram, electro-oculogram, and/or electromyogram); (v) pressure sensors to measure blood pressure; (vi) acoustical or electrical sensors to detect snoring and/or sleep apnea; (vii) chemical sensors to test blood, saliva or other body fluids for the presence or concentration of specific medications or ana
- the pump system can include hardware, software and algorithms that enable the system to recognize a situation and recommend to the subject a one-time adjustment to the drug delivery regimen, e.g., to take a bolus of LD prodrug (e.g., LDA, LDE, LDC or LDS) optionally combined with a carbidopa prodrug (e.g., carbidopa ester or carbidopa amide).
- LD prodrug e.g., LDA, LDE, LDC or LDS
- carbidopa prodrug e.g., carbidopa ester or carbidopa amide
- the pump system can include hardware, software and algorithms that enable the system to recognize patterns and recommend to the subject changes in his drug delivery regimen.
- the system can utilize for this purpose data from the stored event markers and data from sensors. The changes may be to the regimen of the drug being infused by the pump or to the regimen of other PD drugs being taken by the subject.
- the system may decrease the LD prodrug (e.g., LDA, LDE, LDC or LDS) infusion rate or stop the infusion altogether;
- the system may provide a bolus of LD prodrug (e.g., LDA, LDE, LDC or LDS), increase the LD prodrug (e.g., LDA, LDE, LDC or LDS) infusion rate, or if the pump infusion had been stopped it may turn the pump infusion back on;
- the system may recommend a revised drug infusion regimen with an increase in the LD prodrug (e.g., LDA, LDE, LDC or LDS) basal infusion rate;
- the subject takes a
- the system may be programmed to recommend a one-time increase or decrease in the LD prodrug (e.g., LDA, LDE, LDC or LDS) basal infusion rate, a one-time bolus, or that a subject should skip a scheduled bolus.
- the system may also recommend a change to the LD prodrug (e.g., LDA, LDE, LDC or LDS) infusion regimen, such as increasing or decreasing the LD prodrug (e.g., LDA, LDE, LDC or LDS) basal infusion rate, increasing or decreasing the amount of a scheduled bolus, adding a new scheduled bolus, deleting a scheduled bolus, or changing the time of a scheduled bolus.
- the system may also be programmed to similarly provide for one time increases or decreases, or to change the drug intake regimen, for other PD drugs that are being taken by the subject based on analysis of the event markers and/or input from sensors. It will be appreciated that the pump system can be programmed to make some or all of these changes automatically, instead of simply recommending the changes to the subject.
- the system may also be programmed to adjust the flow rate in order to maintain a steady LD influx in the CNS following a protein-rich meal, and thus avoid the symptoms of low brain LD, such as turning off.
- LDEE is relatively rapidly hydrolyzed in vivo by abundant esterases.
- the transport to the brain is active transport, involving neutral amino acid transporters.
- the LD in the plasma competes with other neutral amino acids in the plasma for transport across the blood-brain barrier.
- the concentrations of the other neutral amino acids in plasma increase following a protein-containing meal, often reaching their peak 3-5 hours after the meal.
- the infusion rate can be adjusted to peak at about 1.7 x the base rate following consumption of a protein-rich meal.
- the system may also be programmed to adjust the flow rate to accommodate the user's sleep pattern. For example, if the user prefers not to use the infusion pump while asleep, the user can start the awake period with a higher than basal infusion rate (i.e., a bolus), optionally delivered over 10-60 minutes.
- the system may include a diurnal program that is user specific, varied for different users to account for the times of the day when they have meals, the protein-content of the individual meals, and their sleep/awake hours.
- Containers e.g., Cartridges and Vials
- the drug product or its components may be stored in one, two, three, four or more containers.
- the containers may be physically separate or they may be physically connected, e.g., separate chambers in a common housing.
- One or more of the containers may be configured to be connected to the infusion pump.
- the containers or chambers may be configured so that their contents are manually combined by the user, or so that they are automatically combined by the infusion pump.
- a metal foil or a plastic barrier separating the two chambers may be pierced or crushed when an actuator is pressed; the actuator may be automatically pressed when the container is inserted into the infusion pump.
- the contents of the containers may be combined outside the pump and then transferred to the pump' s drug reservoir.
- one of the containers or chambers may serve as the pump's drug reservoir.
- the containers may be disposable or reusable. Exemplary forms of the containers are vials and syringes.
- the storage container includes two or more sealed chambers, each chamber including a precursor solution of an infusible LD prodrug pharmaceutical composition.
- One chamber includes an acidic LD prodrug or LD prodrug and carbidopa prodrug solution.
- a second chamber includes a solution with a basic pH.
- the storage container may include a means for combining or mixing the two or more solutions to form the infusible LD prodrug pharmaceutical composition. Examples of such a storage container are a multi-chamber syringe, and a multi-chamber drug reservoir of an infusion pump.
- the storage container includes two or more sealed chambers, the first chamber including the solid LD prodrug and optionally the carbidopa prodrug.
- the second chamber includes a solution of two acids, one being preferably HC1 and the second being a polybasic acid, such as phosphoric acid.
- the storage container may include a means for combining or mixing the two or more solutions to form the infusible LD prodrug pharmaceutical composition.
- Examples of such a storage container are a multi-chamber syringe, and a multi-chamber drug reservoir of an infusion pump.
- the container or chamber may contain the LD prodrug (e.g., LDA, LDE, LDC or LDS) in liquid form or in dry solid form. It may also contain the carbidopa prodrug, e.g., its ester or amide.
- the LD prodrug e.g., LDA, LDE, LDC or LDS
- the carbidopa prodrug e.g., its ester or amide.
- the container or chamber is preferably impermeable to oxygen, e.g., constructed of glass; a non-porous ceramic; a relatively water vapor and oxygen impermeable polymer, such as polyacrylonitrile, polyvinylidene chloride, or filler loaded butyl rubber (poly(isobutylene-co-isoprene)); filler loaded chlorobutyl rubber; chlorobutyl rubber, bromobutyl rubber, butyl rubber, chlorosulfonated polyethylene (Hypalon), or amorphous polyethylene terephthalate; and metalized polymers (e.g., metalized polypropylene or polyester)).
- the container or chamber has a wall thickness of from about 0.25 mm to about 1.5 mm (e.g., 0.25 to 0.5, 0.5 tol.0, or 1.0 to 1.5 mm).
- Materials may be selected for their compatibility with the formulation components (e.g., glycerol does not attack plastics, and polymers can be selected for their compatibility with water, alcohol, and mixed solvent systems). For example, polymers that do not increase their weight by more than 5% when soaked for 24 hours in the formulation components at 25 °C would be deemed compatible.
- the container or chamber may include a vial made of glass, preferably of colored glass absorbing light of wavelengths shorter than about 450 nm.
- the vial may include a septum, made of a rubber, preferably inorganic filler loaded rubber, in which the permeability of oxygen is low, such as butyl rubber (poly(isobutylene-co-isoprene)); or chlorobutyl rubber or bromobutyl rubber.
- the container may be hard-sided or flexible, such as a polymeric bag.
- the LD prodrug e.g.,
- LDA, LDE, LDC or LDS can be placed into the container or chamber in such a manner that the contents of the container or chamber are substantially free of water and optionally, but not necessarily, also of oxygen. Methods of accomplishing this are well known in the art. They may include storing the composition under an inert gas. Alternatively, they may include using a vacuum to remove most gases from the container prior to or after pumping or injecting the dry solid LD ester into the container, and then sealing the container.
- the containers of the invention can include a connector for connection to an ambulatory infusion pump.
- the connector can be as simple as a septum, which is punctured to place the container in fluid communication with the pump cannula. More complex male-female components for establishing the connection can be used to achieve the same purpose and are well known in the art.
- the container can include multiple, individually sealed chambers containing the LD prodrug (e.g., LDA, LDE, LDC or LDS) formulation or its solid and/or liquid components and/or the carbidopa prodrug.
- Individual chambers may be opened and, if necessary, combined to provide the infused formulation.
- two, three, four, five or more separate chambers containing dry solid LD prodrug (e.g., LDA, LDE, LDC or LDS) formulation may be employed.
- It can also include multiple chambers containing aqueous solvent. Such an approach permits the drug from one chamber to be used for infusion, while the drug in the other chamber remains stable in its sealed chamber.
- the drug in another chamber may be used to create a fresh infusion solution.
- a single container can provide infusion solution for significantly longer than the stable lifetime of a single infusion solution.
- Similar manufacturing methods and methods of use taught herein may be used to make and use a container including multiple chambers containing dry solid or liquid LD prodrug and/or carbidopa prodrug.
- the LD prodrug with or without the carbidopa prodrug is stored in dry solid form.
- the present invention includes a method of preparing the infusion solution for use.
- the dry solid LD prodrug e.g., LDA, LDE, LDC or LDS
- an aqueous solution such as an HC1 and polybasic acid including aqueous solution
- the LD prodrugs and optional carbidopa prodrugs can be rapidly hydrolyzed in the body, and can be stored in the solid prodrug form at 25°C for 6 months, 12 months, 18 months, or 24 months. They form infusible solutions that can be stable at about 25°C for at least 16 hours, 1 day, 2 days, 3 days, 4 days or 7 days.
- the present invention includes a process for manufacturing a container or chamber containing the LD prodrug (e.g., LDA, LDE, LDC or LDS) formulation by placing the dry solid LD prodrug (e.g., LDA, LDE, LDC or LDS) formulation into the container.
- the container may include a material that is substantially oxygen and water vapor impermeable, eliminating substantially all of the water vapor and oxygen from the compartment, and the process may include sealing the container, and subsequently combining the dry LD prodrug (e.g., LDA, LDE, LDC or LDS) formulation with an aqueous solution to create an infusion solution.
- the container of the solid prodrug is stored in a second desiccated container and the process may include combining the dry LD prodrug (e.g., LDA, LDE), optionally containing a carbidopa prodrug, with an aqueous solution to create an infusion solution.
- the aqueous solution includes HC1 and a polybasic acid.
- the process may also include the step of adding water or an aqueous solution to a second, optional, chamber in the container and sealing the second chamber.
- the water or the aqueous solution is substantially free of dissolved oxygen and the material of the second chamber is substantially impermeable to oxygen.
- the manufacturing process includes the step of the subject, or his caregiver, adding aqueous solution to the dry solid LD prodrug (e.g., LDA, LDE, LDC or LDS) formulation.
- the dry solid LD prodrug e.g., LDA, LDE, LDC or LDS
- the step of adding the aqueous solution may include combining the dry solid LD ester with an aqueous, for example HCl and polybasic acid including, solution stored in a second chamber of the container, or it may include adding the aqueous solution to the container from a separate source.
- an aqueous for example HCl and polybasic acid including, solution stored in a second chamber of the container, or it may include adding the aqueous solution to the container from a separate source.
- concentrations of the subcutaneously infused prodrugs are in the range between about 0.25 M and about 1.5 M, e.g., between 0.3 M and 1.0 M, or between 0.4 M and 0.8 M, or between 0.4 M and 0.6 M the dissolution may require several minutes.
- the prodrug particles would require a high surface-to-volume ratio, in which case the mole % of surface adsorbed-water, not removed under acceptable drying conditions, could be high.
- the adsorbed water could hydrolyze the LDE or LDA or LDC or carbidopa ester or carbidopa amide upon its extended storage.
- the solid stored in one container or chamber may contain LDE or LDA or carbidopa prodrug crystallites, their amines or hydrazines mostly or completely un-protonated, i.e, not their salt form.
- the large basic crystallites would be, generally, advantageously less hygroscopic than the salts formed of the protonated LDE or LDA cation and the chloride, bisulfate or sulfate anion.
- the chamber containing the LDE or LDA may optionally also contain a buffer-forming base, such as trisodium citrate or trisodium phosphate, in a molar amount typically less than 2 mole %, 1 mole % of the LDE or LDC.
- the second chamber would contain an about equivalent amount of the salt-forming acid solution, such as the hydrochloric acid solution or a slight excess of the acid, typically of about 1 % of the equivalent amount or less.
- the stored basic LDE or LDC with or without the carbidopa ester or amide in one chamber and would be neutralized mostly by acid in the second chamber, e.g.
- 0.25 M-1.5 M HCl with typically 0.005 M -0.15 M of polybasicacid , e.g., about 0.3-0.8 M HCl, 0.01-0.08 M polybasic acid, or 0.4-0.8 M HCl, 0.01-0.06 M polybasic acid.
- polybasicacid typically 0.005 M -0.15 M of polybasicacid , e.g., about 0.3-0.8 M HCl, 0.01-0.08 M polybasic acid, or 0.4-0.8 M HCl, 0.01-0.06 M polybasic acid.
- the LD prodrug (e.g., LDA, LDE, LDC or LDS or respective salt) with or without the carbidopa ester or amide solid dosage form can include one or more of the following: (i) a polycarboxylic acid (with the number of carboxylic acid functions exceeding the number of amines of the LD prodrug (i.e., LDA, LDC) and when a carbidopa prodrug is added the number of LD amines plus the number of carbidopa prodrug hydrazines. The environment of the LD prodrug molecules is thereby made acidic.
- a polycarboxylic acid with the number of carboxylic acid functions exceeding the number of amines of the LD prodrug (i.e., LDA, LDC)
- a carbidopa prodrug is added the number of LD amines plus the number of carbidopa prodrug hydrazines.
- the environment of the LD prodrug molecules
- the catechol functions of the LD prodrug e.g., LDA, LDE, LDC or LDS
- carbidopa prodrug molecules are less prone to oxidation, and the prodrugs are less prone to hydrolysis
- a viscosity enhancing agent which may also inhibit crystallization resulting in precipitation of large particles, in an amount such that, reconstituted the infusible formulation has a viscosity of between about 1.2 cp and aboutl0 2 cp at about 25 °C
- a physiologically acceptable antioxidant e.g., bisulfite, ascorbic acid (such as sodium ascorbate), p-aminophenol, acetamol, a t-butyl ortho-substituted phenol, or any antioxidant described herein
- a physiologically acceptable crystal growth inhibitor e.g., a polycarboxylic acid, collagen, albumin, polyethylene glycol, hydroxye
- the solid dosage form can be packaged, for example, in a container (e.g., in a cartridge designed for insertion into an infusion pump, or a vial, the contents of which may be transferred to an infusion pump) of the invention for use in an infusion pump of the invention.
- a container e.g., in a cartridge designed for insertion into an infusion pump, or a vial, the contents of which may be transferred to an infusion pump
- a container e.g., in a cartridge designed for insertion into an infusion pump, or a vial, the contents of which may be transferred to an infusion pump of the invention for use in an infusion pump of the invention.
- the LD prodrug is stored in liquid form, which may be aqueous.
- the stored concentrated solution is acidic, of about pH 1.0- 2.0, pH 2.0- 3.0 (e.g., about pH 2.3), or pH 3.0-4.0, or pH 4.0-5.0.
- the preferred pH of the stored solution is 2.5 + 0.5.
- the concentration of an exemplary LDEE-HCl solution is 0.3 M to 0.35 M; 0.35 M to 0.45 M; 0.45 M to 0.55 M; 0.55 M to 0.65 M; 0.65 M to 0.75 M; 0.75 M to 1.0 M; 1.0 M to 2.0 M; 2.0 M to 3.0 M, 3.0 M to 3.5 M, or greater than 3.5 M.
- a carbidopa prodrug such as carbidopa ethyl ester hydrochloride may be optionally added in a molar amount of between about 10 % and about 40 % of the molar amount of the LDEE'HCl.
- the preferred molar amount of the carbidopa prodrug can be about 15 % and 30 % of the molar amount of LDEE'HCl, for example 1 ⁇ 4 of the molar amount LDEE'HCl.
- the first container or chamber can be impermeable to oxygen and may include the materials previously identified in this application.
- a second container or chamber contains a basic solution, such as a concentrated solution of a base, optionally forming a buffer.
- the preferred bases include a pharmaceutically acceptable potassium and/or a sodium salt of a dibasic, tribasic or tetrabasic acid.
- Exemplary salts include those of citric acid; pyrophosphoric acid; succinic acid or phosphoric acid, like trisodium citrate, tetrasodium pyrophosphate, disodium succinate or trisodium phosphate.
- citric acid pyrophosphoric acid
- succinic acid or phosphoric acid like trisodium citrate, tetrasodium pyrophosphate, disodium succinate or trisodium phosphate.
- the volume of the basic solution added to increase the pH can be between 10 ⁇ 2 -and 0.1 mL per mL of the exemplary LDEE'HCl solution; when its concentration is 0.1 M, between 0.1 mL and 1 mL may be added per mL of the exemplary LDEE'HCl solution. When its concentration is 0.02 M, between 0.5 mL and 5 mL may be added per mL of the exemplary LDEE'HCl solution.
- the present invention includes a process for manufacturing a container containing the LD prodrug (e.g., LDE or LDC) formulation by placing the solution of the LD prodrug (e.g., LDE or LDC) formulation into a container or chamber, the container or chamber including material that is substantially oxygen impermeable, eliminating substantially all of the water vapor and oxygen from the container or chamber, and sealing the container or chamber.
- the manufacturing process includes the step combining the aqueous LDE or LDC solution with a basic solution, optionally stored in a second chamber of the container.
- the aqueous liquid formulation is an oil-in-water emulsion, where the prodrug is in the oil phase.
- the liquid formulation is an emulsion (e.g., includes a lipid and/or an alcohol (e.g., glycerol))
- an LDE and/or LDA including formulation can be stored in a container of the type taught hereinabove.
- the LD prodrug (e.g., LDA, LDE, LDC or LDS or their respective salt) aqueous liquid dosage form can include one or more of the following (i) a physiologically acceptable buffer (e.g., disodium succinate or trisodium citrate); (ii) a physiologically acceptable antioxidant (e.g., bisulfite, a salt of ascorbic acid (such as sodium ascorbate), p-aminophenol, acetamol, a t-butyl ortho-substituted phenol, or any antioxidant described herein); (iii) a physiologically acceptable crystal growth inhibitor (e.g., a polycarboxylic acid, collagen, albumin, polyethylene glycol, hydroxyethyl starch, dextran, glucose, glycerol, or mannitol); (iv) a viscosity enhancing agent in an amount such that, reconstituted the infusible formulation has a viscosity of between about 1.2
- the LD prodrug can be dissolved in a lipid or in an emulsion-forming, preferably oil-in-water emulsion-forming, mixture prior to infusion.
- the present invention includes a method of preparing the infusion solution for use.
- the lipid and/or alcohol or oil-in-water emulsion including liquid may be stored in an oxygen-impermeable container or chamber, as taught hereinabove.
- the invention includes a method of preparing the lipid and/or alcohol-based or emulsion-based infusion solution for use, as well as a process for manufacturing a container containing the lipid and/or alcohol or emulsion based LD prodrug formulation by placing the lipid and/or alcohol-dissolved or emulsified LD prodrug formulation into a container or chamber, the container or chamber including material that is substantially oxygen impermeable, eliminating most of the oxygen from the container or chamber and sealing the container or chamber.
- the lipid and/or alcohol or the emulsion forming mixture may be added to the LD prodrug containing container or chamber prior to use.
- the invention also features a disposable, optionally skin adhered drug container including a pharmaceutical composition of the invention.
- the container, or a chamber of the container includes an inert atmosphere, is substantially free of water, or substantially free of oxygen.
- the formulations of the invention are placed into an infusion pump drug reservoir prior to use or may come pre-loaded in a pump reservoir.
- Reservoir volumes are typically equal to or less than 1, 2, 3, 4, 5, 7.5, 10, 12.5, 15, 17.5, or 20 mL.
- the reservoir may be reusable or disposable.
- the liquid dosage form can be packaged, for example, in a container of the invention for use in an infusion pump of the invention, or can be prepared just prior to infusion.
- Non-aqueous liquid compositions and emulsions are examples of non-aqueous liquid compositions and emulsions.
- the dosage forms of the invention can be liquid dosage forms or solid dosage forms, which can be reconstituted in a lipid and/or alcohol solution.
- the liquid dosage form can be a non-aqueous solution containing a liquid selected from ethanol, sesame oil, castor oil, cottonseed oil, benzyl benzoate, or a mixture thereof, or an emulsion.
- a liquid selected from ethanol, sesame oil, castor oil, cottonseed oil, benzyl benzoate, or a mixture thereof, or an emulsion.
- the no-aqueous compositons are infused intragastrically, intraduodenally or intrajejunally.
- the formulations of the invention are placed into a container or an infusion pump drug reservoir prior to use or may come pre-loaded in a reservoir.
- Reservoir volumes are typically equal to or less than 1, 2, 3, 4, 5, 7.5, 10, 12.5, 15, 17.5, or 20 mL.
- the reservoir may be reusable or disposable.
- the formulation is both stored and used in solution form.
- the formulation is stored as a solid and is combined with the lipid and/or alcohol-based excipient, typically a mixture of lipids and/or alcohols, prior to use.
- the container includes two separate, sealed chambers. The first chamber contains the solid formulation in a substantially dry, optionally oxygen free environment.
- the second chamber contains the lipid, such as sesame oil, castor oil, or cottonseed oil and optionally water and an emulsifier.
- the contents of the two chambers may be combined immediately prior to use either by the user or by a mechanism in the infusion pump itself. For example, a metal foil and/or alcohol or plastic barrier separating the two chambers may be pierced or crushed when an actuator is pressed in the container. The actuator may be automatically pressed when the container is inserted into the infusion pump.
- excipients used for the solid dosage forms can likewise be included in the liquid dosage forms of the invention.
- certain lipid and/or alcohol- soluble anti-oxidants such as vitamin E or tert-butyl substituted phenols may be co-dissolved in the lipid, e.g., the oil.
- the melting points and the liquidus temperatures of mixtures are lower than those of at least some of their pure components.
- Mixtures of lipids e.g., those including triglycerides that are crystalline solids at ambient temperatures
- the solidus temperature of palm or coconut oil is 20-24°C. At this temperature the oil starts scattering light because of formation of a solid phase.
- the major constituent (44 weight %) of palm oil is the triglyceride glycerol tripalmitate melting at 65°C; its second most abundant constituent (38 weight %) is glycerol trioleate, melting at - 4°C.
- the glycerol tripalmitate dissolves in the glycerol trioleate;
- glycerol trioleate suppresses the melting point of the glycerol tripalmitate.
- LD prodrugs and carbidopa prodrugs can also be soluble in alcohols like glycerol, ethylene glycol, propylene glycol, and ethanol, which can be used as solvents or co-solvents.
- the preferred alcohol solvent is glycerol.
- the lipids serve in general to lower the liquidus temperature of the mixture including the LD prodrug, the combined concentrations of which is at least 0.65 moles per liter.
- the added lipid or lipids lower the liquidus temperature to below about 30°C, preferably to below about 20°C and most preferably to below about 15°C.
- the lipids may include, for example, triglycerides of carboxylic acids.
- the preferred carboxylic acids of the triglycerides have an even number of carbon atoms.
- the number of carbon atoms is typically between 2 and 22; it is preferably between 12 and 20, e.g. 12 and/or 14 and/or 16 and/or 18 and/or 20.
- the triglycerides can be saturated, mono-unsaturated or polyunsaturated. Mono and polyunsaturated triglycerides are preferred, as are unsaturated oils with cis double bonds in their carboxylic acids, preferred over those having trans double bonds.
- the lipids may also include a low- melting cholesterol ester, such as cholesterol arachidonate, ricinoleate, linoleate, palmitoleate, and/or oleate. Typically the viscosity of the lipids is greater than about 1.2cP, usually it is greater than about 20 cP. While at higher viscosity the power consumption for pumping is greater, the rate of oxidation of the LD prodrugs, and when added, also of the carbidopa prodrugs by dissolved oxygen is reduced.
- An LD prodrug from a single container may be infused by the pump, e.g., intragastrically, intraduodenally or intrajejunally, optionally through a nasogastric, nasoduodenal, or nasojejunal tube of less than about 4 mm, 3 mm, 2 mm, 1.5 mm, 1.0 outer diameter, and/or an internal diameter of less than 1 mm, 0.7 mm, 0.35 mmfor a period of greater than or equal to about 8 hours, 12 hours, 24 hours, 48 hours, 72 hours and most preferably 96 hours.
- the container may contain between about 1 millimole and about 60 millimoles of LDE, LDC, and/or LDA. It may optionally additionally contain between about 0.2 millimoles and about 24 millimoles of carbidopa prodrug. These values correspond, in the exemplary case of LDEE, to about 225 mg and about 13.5 g of the compound.
- the container may contain between about 1 g and about 5 g of the LDEE and, if added, between about 0.2 g and about 1 g carbidopa ethyl ester.
- the corresponding volume contained in the container is between about 2.2 mL and about 11 mL.
- the liquid dosage form of the invention can be a lipid solution, such as a solution including sesame oil, or castor oil, or cottonseed oil. It may also include an alcohol like glycerol or ethanol to modify the viscosity and/or to decrease the liquidus temperature.
- a lipid solution such as a solution including sesame oil, or castor oil, or cottonseed oil. It may also include an alcohol like glycerol or ethanol to modify the viscosity and/or to decrease the liquidus temperature.
- the formulations can be administered to subjects in therapeutically effective amounts. For example, an amount is administered which prevents, delays, reduces, or eliminates the symptoms of PD.
- Typical infused dose ranges are from about 20 ⁇ to about 140 ⁇ of LD prodrug (e.g., LDA, LDE, LDC or LDS or a salt thereof), per day.
- the typical daily dose of the optionally co-infused carbidopa prodrug is between about 5 ⁇ and about 35 ⁇ .
- the typical daily dose for a subject weighing 75 kg is from about 1.5 millimoles to about 10 millimoles of LD prodrug (e.g., LDA, LDE, LDC or LDS or a salt thereof).
- the exemplary dosage of LD prodrug (e.g., LDA, LDE, LDC or LDS) to be administered is likely to depend on such variables as the stage of the PD patient (e.g., the dose/kg being higher for patients in more advanced stages of the disease), and the particular formulation of LD prodrug (e.g., LDA, LDE, LDC or LDS) being used.
- a molar amount of a carbidopa prodrug between about 10 % and about 40 % of the molar amount of the LD prodrug, for example between 15 % and 30 %, may be added.
- an enzyme inhibitor or agonist such as a DDC inhibitor, e.g., carbidopa, or carbidopa prodrug, a MAO-B agonist, and/or a COMT inhibitor can be co-infused in a systemically sub-therapeutic amount.
- the molar amount of co-infused carbidopa, carbidopa prodrug, MAO-B agonist, and/or COMT inhibitor can be between 0.1 % and 10 % of the molar amount of the infused LD-prodrug.
- the dose range of the co-infused enzyme inhibitor or agonist can be between about 20 picomole kg and about 14 ⁇ 1 ⁇ /]3 ⁇ 4.
- the typical daily dose of the optionally co-infused carbidopa or carbidopa prodrug in a subject weighing about 75 kg can be between about 1.5 ⁇ and about 1 millimole.
- Modes of delivery of the aqueous formulations are via fixed flow rate or programmed infusion, preferably continuous infusion, and for formulations in which the prodrug concentration is between 0.25M and 1.5 M, e.g., between 0.25 M and 0.8 M, or 0.4 M and 0.6 M most preferably by continuous, subcutaneous infusion.
- the preferred route of delivery of the higher concentration or non-aqueous formulations is intra-gastric, intraduodenal or intra-jejunal, e.g., via a tube, which can be optionally a nasogastric, nasoduodenal or nasojejunal tube, of less than 4 mm, 3 mm, 2 mm, 1.5 mm, 1.0 mm outer diameter.
- the LD prodrug concentration range in the subcutaneously infused solution is between 0.25 M and 1.5 M. At lesser concentrations than about 0.25 M the daily subcutaneously infused volume in a patient requiring daily 5 millimoles of LD or of the prodrug may exceed 20 mL and may cause edema or excessive swelling. Subcutaneous infusion of a solution of a concentration greater than about 1.5 M can cause the formation of subcutaneous nodules.
- the preferred concentration of the LD prodrug in the subcutaneously infused solution can be between 0.3 M and 1.0 M, more preferably 0.3 M and 0.8 M, for example, 0.4 + 0.1 M, 0.5 + 0.1 M, 0.6 + 0.1 M or 0.7 + 0.1 M, or 0.8 + 0.1 M.
- the pH of the infused solution is typically between 4.0 and 6.0, for example, 4.0 + 0.5, 4.5 + 0.5, or 5.0 + 0.5.
- the infused solution is typically stable, meaning clear and free of precipitated LD, for at least about 8 hrs at about 37°C, for example for at least about 16 hrs, 24 hrs, or 48 hrs.
- LD prodrug e.g., LDA, LDE, LDC or LDS
- an orally taken or co-infused enzyme inhibitor or agonist such as a DDC inhibitor, e.g., a carbidopa prodrug, MAO-B agonist, and/or COMT inhibitor
- anti-emetic agent such as nicotine, lobeline sulfate, pipamazine, oxypendyl hydrochloride, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate, scopolamine, metopimazine, or diphenidol hydrochloride.
- the anti-emetic into the formulation for simultaneous infusion in combination with the LD prodrug (e.g., LDA, LDE, LDC or LDS).
- the preferred route of administration of the aqueous formulations is subcutaneous infusion with a cannula or two or more cannulae, and/or with a needle or two or more needles, preferably infusion below the dermis.
- Typical depths below the surface of the skin where the solutions may be infused are between about 4 mm and about 15 mm, the preferred depth being between about 5 mm and about 11 mm.
- flow- retarding e.g., dermal or connective tissue hyaluronic acid hyaluronate can be locally, transiently hydrolyzed by hyaluronidase added to the infusate.
- Depolymerization of the hyaluronic acid/hyaluronate by hyaluronidase can accelerate the flux of the prodrug or the LD produced of the prodrug by the action of esterases to blood venules and through these to the circulatory system.
- the hyaluronidase can be optionally recombinant, i.e., human hyalorunidase-like, but bacterially produced.
- the concentrations of the subcutaneously or intramuscularly infused LD prodrug solutions generally are >0.3 M , 0.4 M, >0.5 M, >0.65 M, > 1.0 M, it is desired that the solution be rapidly diluted following its infusion. Rapid dilution reduces the likelihood and magnitude of unwanted side effects at or near the infused site or sites. It is preferred to infuse the aqueous LD prodrug solution subcutaneously or intramuscularly at sites where the tissue-fluid is not stagnant, i.e., it flows because of abundance of arterioles and venules and/or movement of voluntary muscles or involuntary muscles; and/or proximal to major lymphatic vessels.
- the distance from the infusion site at which the concentration of the infused solution is halved decreases with flow, meaning it increases with the residence time, which is the inverse of the volumetric flow-rate of the tissue's fluid.
- Table 2 shows the estimated distance from the infusing orifice over which the concentration drops to 1 ⁇ 2 of the initial when the diffusion coefficient is 3 x 10 "6 cm 2 s _1 and the infusion rate of 3 ⁇ L ⁇ min "1 .
- the distance from the orifice to points at which the concentration drops to 1 ⁇ 2 the initial is as long as 26.5 mm. Even slight flow reduces the distance.
- the residence time is typically less than 4 min and the radius of the most affected zone is less than about 820 ⁇ .
- the desired flow of the infused tissue-fluid is effectively induced by movement of proximal large voluntary muscles that are exercised during periods in which the subject is awake. Examples of such large muscles include the trapezius, deltoid, pectoralis major, triceps brachii, biceps, gluteus maximus, sartorius, biceps femoris, rectus femoris, and gastrocnemius muscles.
- the desired flow of the infused subcutaneous tissue-fluid is also induced by movement of proximal large involuntary muscles exercised during periods in which the subject is either awake or asleep, such as the diaphragm. It is therefore preferred to infuse the concentrated LD prodrug solution subcutaneously near these muscles.
- Some preferred infusion zones for example diaphragm- moved upper/central abdominal zones, can be recognized by visible movement of the skin upon the movement of the proximal muscle, e.g., of the diaphragm upon inhalation or exhalation of air.
- a skin-adhered elongated strip, of a length to width ratio of 2 or more, with two cannulae or needles typically separated by more than 1 cm, 2 cm, 3 cm, 5 cm orlO cm can be advantageously used.
- Multiple point infusion can be carried out by a pump driving the fluid in multiple tubings, and/or cannulae, and/or needles; and/or by multiple pumps, each pump driving the fluid in one or more tubing and/or cannula and/or needle.
- the infusion can be through 2 or more, 4 or more, 9 or more cannulae or needles, the tips of which may be horizontally and/or vertically separated.
- two drug pumps can be used for the subcutaneous infusion, one infusing, for example in the left arm, the second in the right arm or in the abdominal region.
- Multiple point infusion can be also carried out with a perforated plastic cannula having one or more orifices along its length.
- the orifices may have similar diameters or they may differ in their diameter, for example such that the flow through the orifices will be about the same. This can be accomplished, for example, by making orifices distal from the pump larger than orifices proximal to the pump.
- the prodrug containing aqueous solution may be delivered alternatively with a skin patch including a microneedle array in the dermis, typically at a depth of between 1 mm and about 3 mm below the epidermis.
- a skin patch including a microneedle array in the dermis, typically at a depth of between 1 mm and about 3 mm below the epidermis.
- Microneedle arrays for drug delivery are described, for example, in U.S. Patent Nos. 6,256,533, 6,379,324, 6,689,100, 6,980,555, 6,931,277, 7,115,108, 7,530,968, 7,556,821, 7,914,480, 7,785,301, 7,658,728, and 7,588,552 and in U.S. Patent Publication No. 20080269666.
- the LDEE was colorless, crystalline, melting in the temperature range of 84.5-86.5°C and contained no HPLC-UV-vis detected L-DOPA.
- the observed retention time for LD was about 3.3 minutes and the observed retention time of LDEE was about 7.8 minutes.
- EXAMPLE 2 Precipitation of LD from a 0.25 M physiological saline solution of LDEE held at 37°C for 16 hours.
- EXAMPLE 3 Precipitation of LD from a pH 6.75, 1.3 M LDEE/ LDEE-HCl solution held at 37°C for
- EXAMPLE 4 Precipitation of LD from a pH 6.87, 0.7 M LDEE/ LDEE-HCl solution held at 37°C for
- the LDEE acetate salt meaning the salt formed of LDEE and acetic acid, was prepared by adding under nitrogen 2.25 g (10 millimoles) LDEE in small portions to 2 mL of a magnetically stirred 5.0 M solution of acetic acid. The pH of the resulting colorless, clear (meaning precipitate free) solution was 5.3. After adding 0.175 mL glacial acetic acid, the pH was 4.7. The total volume was about 4.1 mL, i.e., the concentration of the acetate salt of LDEE was about 2.4 M. At this concentration the LDEE acetate equivalent molar amount of 1 g LD is dissolved in about 2.1 mL. HPLC of the solution showed that the initial % LD was between 0.22 % and 0.25 % meaning that the LDEE:LD ratio was about
- EXAMPLE 8 Precipitation of LD from 2.6 M LDEE-HCl at pH 5.5 after about 30 h.
- An about 1 M trisodium citrate solution was prepared by dissolving in 1.353 g of trisodium citrate dihydrate in 4.0 mL water.
- 1.928 g (8.57 millimoles) of LDEE were dissolved in 1.35 mL of aqueous 6.0 M HC1, then 0.25 mL of the about 1.0 M citrate solution was added to form a pH 5.1 solution of about 3.2 mL volume, in which the concentration of LDEE and its salt(s) was about 2.65 M.
- An about 2.6 M LDEE'HCl solution was prepared of 1.5 g LDEE and 1.24 mL of aqueous 5 M HC1 plus trisodium citrate and citric acid to adjust the pH to 3.3. After flushing with nitrogen, the solution was kept for 6 days at 23 + 2°C in a vial sealed with a grey elastomeric, oxygen impermeable septum. The volume was about 2.5 mL. After 6 days at 23 + 2 °C, 1.8 % of the LDEE was hydrolyzed to LD (and ethanol and HC1 which were not assayed). At this pH and temperature about 0.30 % of the LDEE* HQ was hydrolyzed daily.
- EXAMPLE 14 Estimate of the operational life of the pH 4.5 citrate buffered 2.5 M LDEE-HCl solution at 29-30°C.
- the pH 4.5, 2.5 M LDEE'HCl aqueous solution was prepared as in Example 13. After flushing with nitrogen, the solution was kept in a vial sealed with a grey elastomeric, oxygen impermeable septum. After 4 days at 29°C-30°C, 3.4 % of the LDEE-HCl was hydrolyzed, showing that the solution has an operational life, meaning time to LD saturation that might lead to some LD precipitation, of 4 days, well in excess of the required operational life of 24 hours. Projection to 37°C suggests that at body temperature the operational life is about 2 days.
- the solution would be stored, for example, for one year at 4°C, where its storage (shelf) life is projected to be greater than 4 years (per Example 18), then warmed to the 23°C ambient temperature, its residual operational life would still be longer than 4 days. If it were stored at 4°C for 18 months, then warmed to its operational ambient temperature, the solution would still have a residual operational life of more than 3 days, sufficient for infusion.
- HPLC assay showed that after 72 hours at about 23 + 2°C about 2.4 % of the LDEE'HCl was hydrolyzed to LD (plus ethanol and HC1 which were not assayed), i.e., that 0.82 % of the LDEE'HCl and/or LDEE acetate and/or LDEE was hydrolyzed per day. This is about l/5 th of the daily rate of the acetate salt of Example 6. The five-fold slower rate than that of acetate shows that the hydrolysis rate is anion- dependent and is substantially slower for the chloride of LDEE than it is for its acetate.
- Three solutions of a pH near 4.5 were prepared by adding 1 M trisodium citrate to increase the pH and 1 M HC1 to decrease the pH.
- the about 1 M trisodium citrate solution was prepared by dissolving 1.353 g of trisodium citrate dihydrate in 4.0 g of water.
- the solubility of LDEE'HCl was determined at about 25 + 1 °C.
- the first solution was prepared by dissolving 1.52 g LDEE in 1.3 mL 5 M HCl and adding 0.05 mL of about 1M citrate solution. The volume was about 2.5 mL and the LDEE'HCl concentration was about 2.7 M.
- a second solution was prepared by diluting the first solution with an equal volume of water, to form an about 1.35 M solution of LDEE'HCl.
- the third solution was made by adding to 0.6 mL of the about 1.0 M citrate solution 0.8 mL of 1.0 M HCl.
- the solubility of LD was measured in 1 mL samples of the three stirred solutions by adding sequentially small amounts of LD and watching their dissolution. In absence of LDEE'HCl, the solubility of LD was about 5.8 g per liter. In the 1.35 M LDEE-HCl solution it was about 10.2 g per liter; and in the 2.7 M LDEE-HCl solution it was as high as about 17 g per liter.
- aqueous LDEE'HCl solution was prepared of 6.002 g of LDEE and 5.2 mL of aqueous 5.0M
- HCl HCl
- An about 1 M trisodium citrate solution was prepared of 1.353 g of trisodium citrate dihydrate and 4.0 g of water.
- a pH 2.03 solution was prepared by adding 0.321 mL of 1.0 M HCl and 25 ⁇ ⁇ of the 1.0 M trisodium citrate solution. The volume was about 10.6 mL and the LDEE'HCl concentration was about 2.5 M. To about 9.8 mL of this solution 25 ⁇ ⁇ of a 1.0 M trisodium citrate solution were added to produce the pH 3.0 solution, having a concentration of LDEE'HCl of about 2.5 M.
- EXAMPLE 18 Shelf life of 2.5 M LDEE-HCl at pH 2.3 and at 4°C.
- An aqueous LDEE'HCl solution was prepared by dissolving 6.002 g of LDEE in 5.2 mL of 5.0M HCl.
- An about 1 M trisodium citrate solution was prepared of 1.353 g of trisodium citrate dihydrate and 4.0 g of water. Of this 1 M trisodium citrate solution 0.3 mL were added to the LDEE'HCl solution. The volume was about 10.6 mL and the LDEE* HQ concentration was about 2.5 M.
- the pH of the solution was 2.3. After flushing with nitrogen, each solution was kept in a vial sealed with a grey, oxygen impermeable septum.
- the solution was kept in a refrigerator at about 4°C and its LD content was determined initially daily then weekly for 21 weeks.
- the LD concentration increased from 0.17 % of that of the LDEE-HCl (i.e., from 0.0043 M) to 0.47 % of that of the LDEE'HCl (i.e., to 0.0117 M), a change of 0.0074 M.
- solubility of LD being (per Example 16) about 17 g/L or 0.086 M
- saturation in LD is expected after about 244 weeks or about 4.7 years of storage at 4°C.
- the projected shelf life of the 2.5 M solution at about 4°C is about 4.7 years. In this period the solution is expected to remain free of LD precipitate.
- An about 1 M trisodium citrate solution was prepared by dissolving in 1.353 g of trisodium citrate dihydrate in 4.0 mL water.
- 1.501 g (6.67 millimoles) of LDEE were dissolved in 1.11 mL of aqueous 6 M HC1 to form a pH 0.3 solution, the pH of which was increased to 2.3 by adding 0.055 mL of the 1 M trisodium citrate solution.
- the volume was about 2.4 and the LDEE'HCl concentration was about 2.7 M. After flushing with nitrogen, each solution was kept in a vial sealed with an elastomeric grey, oxygen impermeable septum.
- LD precipitation may occur from the 2.7 M LDEE'HCl solution at the saturation point of LD, which is according to Example 16 is greater than about 17 grams per liter at about 23 + 2°C and at a pH of 4.5. Such a concentration is reached when about 3.4 %, i.e., an additional 3.2 % of the LDEE'HCl is hydrolyzed. Considering that about 0.024 % of the LDEE'HCl is hydrolyzed daily, the projected shelf life at ambient temperature is about 128 days. EXAMPLE 20. Shelf life of 2.5 M LDEE-HCl at pH 3.0 at 4°C.
- An aqueous LDEE'HCl solution was prepared of 6.002 g of LDEE and 5.2 mL of 5.0 M HC1.
- An about 1 M trisodium citrate solution was prepared of 1.353 g of trisodium citrate dihydrate and 4.0 g of water. 300 ⁇ ⁇ of the 1 M trisodium citrate were added to the LDEE'HCl solution. The volume was about 10.6 mL and the LDEE'HCl concentration was about 2.5 M.
- To 9.1 mL of this solution 80 ⁇ ⁇ of the 1M citrate solution were added to produce about 9.2 mL of the about 2.5 M pH 3.0 solution. The solution was distributed in three vials.
- LD precipitation from an LDEE'HCl solution may occur at the saturation point, which is according to Example 16 is about 17 grams per liter at about 23 + 2°C and at pH 4.5. This concentration is reached in a 2.5 M LDEE'HCl solution when about 3.4 % of the LDEE'HCl is hydrolyzed. In the 21 week period of the experiment 0.36% of the 2.5 M LDEE'HCl was hydrolyzed in addition of the initially present 0.15% . It is projected therefore that the solution should be free of LD precipitate for about 195 weeks or 3.8 years.
- An aqueous LDEE-HCl solution was prepared of 6.002 g of LDEE and 5.2 mL of 5.0M HC1.
- An about 1 M trisodium citrate solution was prepared of 1.353 g of trisodium citrate dihydrate and 4.0 g of water. 300 ⁇ ⁇ of the 1 M trisodium citrate were added to the LDEE'HCl solution. The volume was about 10.6 mL and the LDEE'HCl concentration was about 2.5 M.
- To 9.1 mL of this solution 80 ⁇ ⁇ of the 1M citrate solution were added to produce about 9.2 mL of an about 2.5 M solution.
- To 7.7 mL of this solution 180 ⁇ ⁇ of the 1 M citrate solution were added.
- the volume of the resulting solution was about 7.9 mL and its pH was about 4.0.
- the LDEE'HCl concentration was about 2.4 M.
- the solution was distributed in three vials. After flushing with nitrogen, each solution was kept in a vial sealed with a grey, oxygen impermeable septum. The solution was kept in a refrigerator at about 4°C and its LD content was tracked for 21 weeks. The results are tabulated in Table 6.
- LD precipitation from an LDEE'HCl solution may occur at the saturation point, which is according to Example 16 is about 17 grams per liter at about 23 + 2°C and at pH 4.5. This concentration is reached in an about 2.6 M LDEE-HCl solution when about 3.4 % of the LDEE-HCl (3.2 % above that at the start of the experiment) of is hydrolyzed. In the 21 week period of the experiment 1.34 % of the 2.4 M LDEE'HCl was hydrolyzed in addition to the initially present 0.16%. It is projected therefore that the refrigerated pH 4.0 solution should be free of LD precipitate for about 50 weeks.
- EXAMPLE 22 Rapid hydrolysis of 2.1 M LDEE-HCl at 4°C and at pH 5.0.
- An aqueous LDEE'HCl solution was prepared of 6.002 g of LDEE and 5.2 mL of 5.0M HC1.
- An about 1 M trisodium citrate solution was prepared of 1.353 g of trisodium citrate dihydrate and 4.0 g of water. 300 ⁇ ⁇ of the 1 M trisodium citrate were added to the LDEE'HCl solution. The volume was about 10.6 mL and the LDEE'HCl concentration was about 2.5 M.
- To 9.1 mL of this solution 80 ⁇ ⁇ of the 1M citrate solution were added to produce about 9.2 mL of an about 2.5M solution.
- To 7.7 mL of this solution 180 ⁇ ⁇ of the 1 M citrate solution were added.
- the volume of the resulting solution was about 7.9 mL and its LDEE'HCl concentration was about 2.4 M.
- To 6.4 mL of this solution 1.14 mL of the 1M citrate solution were added to produce an about 2.1 M LDEE'HCl solution of pH 5.
- the solution was distributed in three vials. After flushing with nitrogen, each solution was kept in a vial sealed with a grey, oxygen impermeable septum. The solution was kept in a refrigerator at about 4°C and its LD content was tracked for 15 days. The results are tabulated in Table 7.
- a 2.9 M LDEE* HQ solution of about pH 2.41 was prepared. It was formed by mixing at 0-4°C (a) 20 weight % HQ; (b) LDEE and (c) trisodium citrate dihydrate at the ratio 44.9559 weight % : 54.3967 weight % : 0.0065 weight %. 2.5 mL or about 3.0 g of this solution were transferred to each vial. To a second vial 0.25 mL of 1.5 M trisodium citrate was added. 0.20 mL of the trisodium citrate solution in the second vial were then transferred with a syringe to the 2.9 M LDEE'HQ solution containing vial.
- an infusible, about 2.7 M, about pH 4.49 LDEE'HCl solution, containing the molar equivalent of about 0.532 g L-DOPA per mL was obtained.
- the typical daily dose of 1.0 g L-DOPA can be delivered by infusion of about 1.88 mL of this solution. Because the solution may be near body temperature when worn in a skin-contacting container, its operational life at 40°C was determined.
- the LD:LDEE molar ratio was 0.1 : 99.9. After 24 h at 40°C the LD:LDEE molar ratio increased to 1.8: 98.2 and after 48 h to 2.8 : 97.2. Because of the hydrolysis, the pH dropped after 24 h to 4.2 and after 48h to 4.0. Because LD does not precipitate from 2.7 M LDEE'HCl at a pH between 4.0 and 4.6 until the LD:LDEE molar ratio exceeds 3.4: 96.6, the operational life at 40°C suffices for more than the the targeted 16 h, 24 h and 48 h long infusions. EXAMPLE 24. Operational stability of subcutaneously infusible solutions.
- EXAMPLE 25 Subcutaneous Infusion in Minipigs.
- Citrate buffered LDEE'HCl solutions having a pH of 4.5-5.0 were infused into the shoulders of juvenile minipigs weighing about 10 kgs. The results are provided in Table 10.
- the concentrations and doses listed in Table 10 are LDEE (MW 225) based.
- EXAMPLE 26 High rate intramuscular infusion of 2.3 M LDEE-HCl of pH 4.5 in human.
- Example 23 About 0.45 mL of the 2.3 M LDEE-HCl citrate buffered to pH 4.5 of Example 23 were intramuscularly infused over a 45 min period in a 78 year old male volunteer using a Medronic Minimed Paradigm 522 insulin pump with the Quickset Paradigm 23 inch (60 cm) infusion set. The cannula was inserted intramuscularly in the right upper arm' s side facing away from the chest at about 5 mm depth. The infused solution was colorless and clear (meaning precipitate-free) after being kept for about 3 days at room temperature and for about 3 months in a refrigerator. The infused solution contained about 1 millimoles of LDEE'HCl, the equivalent of about 0.2 g LD.
- the flow rate was 0.6 mL/h. After the infusion there was a small nodule which spread after 4 hours into an about 1 mm high, 2-3 cm radius protrusion. There was no pain, inflammation, color change or sensitivity at the protruding site. The protrusion disappeared after 2 days.
- EXAMPLE 27 Painless subcutaneous infusion 2.3 M LDEE-HCl of pH 4.5 in human.
- Example 23 0.24 mL of the 2.3 M LDEE'HCl citrate buffered to pH 4.5 of Example 23 was subcutaneously infused in a 78 year old male volunteer over an about 90 min period in 8 boluses spaced 12 min apart. Each bolus was about 3 min long; during the 8 infusion periods of 3 min the flow rate was about 10 ⁇ / ⁇ .
- a Medronic Paradigm insulin pump with the Quickset Paradigm 23 inch (60 cm) infusion set was used for infusion. The set had an about 1 cm long needle and cannula, which was used to insert the cannula. The cannula was inserted with its tip about 9 mm deep vertically just left of the center of the abdomen, about 5 cm below the diaphragm, probably in the abdominal fat.
- the infused solution was colorless and clear (meaning precipitate-free) after being kept for 2.5 days at room temperature and for 7 weeks in a refrigerator. Even though the pH was mildly acidic and the solution was hypertonic, the volunteer felt no pain or irritation during or after the infusion, and the infusion did not change the appearance of the skin, nor did it cause the formation of a nodule.
- the 240 ⁇ infused over the 90 min period contained the equivalent of about 110 mg of LD, meaning that the dose rate was equivalent of 73 mg hr LD.
- EXAMPLE 28 Abdominal subcutaneous infusion of 2.7 M LDEE'HCl in human.
- a healthy 49 year old male volunteer took one Lodosyn (carbidopa), 25 mg pill, at each of the morning, midday and evening of the day preceding the infusion, and in the morning, midday and evening of the day of the infusion.
- a stored solution of pH 2.4 and 2.5 mL volume of 2.9 M LDEE'HCl After adjusting the pH of a stored solution of pH 2.4 and 2.5 mL volume of 2.9 M LDEE'HCl by adding to it 0.16 mL of 1.5 M trisodium citrate solution to about pH 4.6 + 0.1, a 2.7 M LDEE'HCl solution was obtained.
- the volunteer infused 0.67 mL of the 2.7 M LDEE'HCl solution into his abdomen over a period of 9 hours.
- the infusion site was 7-8 cm below the ribs.
- the initial 4 hr infusion was at a rate of 0.062 mL/hr (37.5 mg of LDEE/hr), followed by 0.082 mL/hr (50 mg of LDEE/hr) in the next 5 hours.
- the total infused volume contained 406 mg LDEE, the equivalent to 356 mg L-DOPA.
- Mild swelling was observed and an induration of approximately 2.5 cm diameter developed under the infusion site. After 24 hours the induration became diffuse and partly, but not completely, subsided. There were no other adverse events.
- EXAMPLE 29 Subcutaneous infusion of 2.7 M LDEE'HCl in the exercised upper arm of a volunteer.
- a healthy 49 year old male volunteer took one Lodosyn (carbidopa), 25 mg pill, at each of the evening preceding the infusion, and in the morning, midday and evening of the day of the infusion.
- a stored solution of pH 2.4 and 2.5 mL volume of 2.9 M LDEE'HCl After adjusting the pH to about pH 4.7 + 0.3 of a stored solution of pH 2.4 and 2.5 mL volume of 2.9 M LDEE'HCl by adding 0.16 mL of 1.5 M trisodium citrate solution, a 2.7 M LDEE'HCl solution was obtained.
- the a volunteer infused 0.67 mL of the 2.7 M LDEE'HCl solution into the frequently exercised and occasionally massaged outside of the upper arm over a period of 9 hours.
- the initial 4 hr infusion was at a rate of 0.062 mL/hr (37.5 mg of LDEE/hr), followed by 0.082 mL/hr (50 mg of LDEE/hr) in the next 5 hours.
- the total infused volume contained 400 mg LDEE, the equivalent to 351 mg L-DOPA.
- EXAMPLE 30 Subcutaneous infusion of 0.95 M LDEE'HCl in the exercised upper arm of a volunteer.
- a healthy 49 year old male volunteer took one Lodosyn (carbidopa), 25 mg pill, at each of the evening of the day preceding the infusion, and in the morning, mid-day and evening of the day of the infusion.
- 1 mL of the 2.9 M LDEE'HCl stored solution of pH 2.4, 0.04 mL of a 1.5 M trisodium citrate solution and 2 mL sterile water were syringed into the reservoir of a Medtronic Minimed Paradigm 723 pump.
- This pump and a Medtronic Minimed Silhouette, 43 inches, 17 mm cannula infusion set inserted with a Medtronic Minimed Sil-Serter infusion set insertion system were used.
- the volunteer periodically exercised his arm and gently massaged the infusion site. There was no pain or redness during or inflammation after the infusion. At the infusion site there was a very slightly swollen region of about 4 cm diameter at the end of the infusion, which disappeared gradually in about three days. There were no other adverse events.
- EXAMPLE 31 Subcutaneous infusion of 0.58 M LDEE'HCl in the upper arm of a volunteer.
- the pump, a Medtronic Minimed Silhouette, 43 inches, 17 mm cannula infusion set, and a Medtronic Minimed Sil-Serter infusion set insertion system were used.
- the volunteer infused 3 mL, or 400 mg LDEE (equivalent to 350 mg L-DOPA) of the now 5x diluted (i.e. 0.58 M) LDEE solution into his upper arm over a period of 9 hours at a flow rate of 0.33 mL/hr.
- the volunteers felt no pain during the infusion.
- the volunteer had no pain and only very slight reddening of a 2x4 cm skin area and a very slightly harder than normal 2 cm diameter zone under the skin at the infusion site.
- the infusion ended at 7:30 pm. On the following morning at 5:30 am, the skin and infused tissue appeared normal, i.e., they could not be distinguished from those of the contra-lateral, non-infused arm. There were no adverse events.
- EXAMPLE 32 Subcutaneous infusion of 5.1 millimoles of 0.48 M LDEE'HCl in the upper arm.
- the pump, a Medtronic Minimed Silhouette, 43 inches, 17 mm cannula infusion set, and a Medtronic Minimed Sil-Serter infusion set insertion system were used.
- EXAMPLE 33 Long shelf life two vial system, one with solid LDEE, the other with HC1.
- a first glass vial would contain 1.5 g (6.67 millimoles) of dry LDEE and 20 mg (0.0.78 millimoles) of anhydrous trisodium citrate.
- a second vial would contain aqueous 0.5 M HC1 (13.4mL, 06.67 millimoles).
- the expected LDEE'HCl concentration in the solution resulting of mixing the contents of the vials would be about 0.5M and the pH of the solution would be about 4.7 + 0.5.
- a shelf life of at least 1 year at 25 °C is expected for the unmixed constituents of the vials. After mixing the operational life is expected to exceed 24 hrs at 37 °C.
- EXAMPLE 34 Exemplary two-vial embodiment for subcutaneous infusion.
- Vial A contains 3 mL of the 2.5 M LDEE'HCl aqueous solution.
- the LDEE'HCl solution is acidic (has an about 0.45 millimole excess of HC1).
- Enough 1 M trisodium citrate is added to increase the pH to about 2.5 + 0.5.
- the solution can be stored when refrigerated, according to Example 18, for several years.
- the 7.5 millimoles of LDEE'HCl contained in Vial A are the equivalent of 1.5 g of LD.
- Vial B contains a trisodium citrate solution of about 0.1 M concentration in the amount needed for raising the pH in Vial A from about pH 2.5 + 0.5 to about 4.5, typically about 10 micromoles or about 0.1 mL.
- Prior to infusion the solutions stored in the two vials are made operational by their mixing.
- EXAMPLE 35 Exemplary single-vial embodiment for subcutaneous infusion.
- the vial may contain 10 mL of a 0.5 M LDEE'HCl pH 4 citrate buffered aqueous solution.
- the 5 millimoles of LDEE* HQ contained in the vial are the equivalent of about lg of LD.
- the vial would be refrigerated at 5 + 3°C. The user or caregiver would be instructed to infuse the solution, as is, within about 6 months of its production and refrigerated storage.
- EXAMPLE 36 2.9 M LDEE'HCl of pH 2.5 + 0.5 for intragastric, intraduodenal or intrajejunal infusion.
- a vial may contain 3.7 mL of 2.9 M
- LDEE'HCl its pH adjusted by monosodium citrate and HC1 to 3.0 + 0.2.
- the vial would contain about 10.7 millimoles of LDEE'HCl, enough for 2 days for a patient requiring about 1 g of LD per day.
- the vial may be stored refrigerated for at least 12 month and additionally kept at the body temperature of about 37°C for at least 2 days. Its content may be infused as is, without raising the pH, using a tubing of less than 1 mm internal diameter and less than 2 mm outer diameter.
- EXAMPLE 37 Water free LDEE linoleate salt for intragastric, intraduodenal or intrajejunal infusion.
- the viscous solution could be stored refrigerated at 5 + 3 °C for at least 3 months. It could be intragastrically or intrajejunally infused for managing PD. To reduce its viscosity it could be diluted with an edible oil or with an edible liquid carboxylic acid, such as linoleic acid or oleic acid.
- a solid formulation of the invention can include the components tabulated in Table 11 below.
- a non-aqueous liquid salt of LDEE for subcutaneous or intragastric or intrajejunal infusion can include a liquid or liquid crystalline ricinoleic acid, or oleic acid, or palmitic acid addition salt of L- DOPA ethyl ester (0-10 mole % excess acid), and may also include
- EXAMPLE 40 Non-aqueous glycerol solution of LDEE.
- a non-aqueous glycerol solution of LDEE for subcutaneous or intragastric or intrajejunal infusion can include 25 weight % LDEE, and some or all of the components below.
- the components are placed in a 10 mL container and stored at ambient temperature under nitrogen.
- EXAMPLE 41 Co-infusion of concentrated aqueous solutions containing prodrugs of carbidopa and LD.
- a vial containing 2.5 mL of an aqueous solution having a pH of 2.5 + 0.5 and containing the hydrochloride salts of ethyl esters of both LDEE and carbidopa at respective molar concentrations of 2.4 + 0.6 M and 0.6 + 0.2 M could be stored refrigerated at 5 + 3°C for at least 6 months. It would be infused as is intraduodenally or intrajejunally or intragastrically. Prior to subcutaneous infusion its pH could be raised to between 4 and 6 by adding 0.3 + 0.03 millimoles of trisodium dissolved in 12.5 mL water.
- EXAMPLE 42 Pharmacokinetic study of infusion of LDEE'HCl formulation in minipigs.
- Citrate buffered LDEE'HCl solutions having a pH of 4.5-5.0 were infused into the neck/shoulder regions of juvenile minipigs weighing about 10 kgs. Two minipigs were treated. On each minipig, the solutions were simultaneously infused at two infusion sites, one on the left neck/shoulder and one on the right neck/ shoulder. A total of 5.24 mL of solution containing 218 mg/mL LDEE was infused into each minipig over a period of 16 hours, delivering a total dose of 1,142 mg LDEE to each minipig. The dose was split equally between the two infusion sites, with each infusion site receiving 571 mg LDEE in 2.62 mL over 16 hours.
- Blood samples were collected at times 0 (pre-dose), 30 minutes, and 1, 2, 4, 8 and 16 hours after the start of the infusion. Approximately 3mL whole blood was collected from the jugular vein. The whole blood was collected into tubes containing K2 EDTA as the anticoagulant. Immediately after collection the samples were centrifuged for -15 minutes at -3000 RPM, at -4 ° C. Each plasma sample was then transferred to a plastic cryovial containing sodium metabisulfite and sodium fluoride as preservatives. After the samples were processed they were placed on dry ice until movement to storage at —70 degrees Celsius. The samples were analyzed for LDEE using LC-MS.
- the minipigs experienced mild swelling in an area of about 1x2 cm at the infusion sites at the end of the infusion that resolved over 24 hours, and subsequent development of small subcutaneous nodules of about lxl cm that resolved over a period of about one week.
- the measured concentrations of LDEE and LD in the two minipigs are shown in Table 12.
- minipigs were administered a dose of 1,142 mg LDEE over 16 hours, equivalent to the administration of 1.0 g of LD.
- This dosing equates to 114.2 mg/kg for the 10 kg minipigs, versus 16.3 mg/kg for a typical 70 kg patient.
- the dose received by the minipigs is therefore a factor of seven higher, on a mg/kg basis, than a typical dose administered to patients with advanced PD.
- the circulating plasma LDEE concentration did not exceed 15 ng/mL. It may be expected that at the lower doses (on a mg/kg basis) typically administered to PD patients, the circulating plasma LDEE concentration during the infusion will not exceed 100, 50, 30, 15, 10 or 5 ng/mL.
- the data demonstrate that a circulating plasma LD concentration greater than 1,600 ng/mL was continuously maintained for a period of at least 8 hours during the infusion. This demonstrates that a circulating plasma LD concentration exceeding 400, 800, 1200, or 1600 ng/mL can be continuously maintained for a period of at least 8 hours during the infusion.
- the plasma LD concentrations achieved is sufficient to turn on a patient.
- the data demonstrate that a circulating plasma LD concentration less than 5,000 ng/mL was continuously maintained for a period of at least 8 hours during said infusion. It may be expected that at the lower doses (on a mg/kg basis) typically administered to PD patients, the circulating plasma LD concentration during the infusion will not exceed 5000, 2500, or 2000 ng/mL.
- concentration greater than 400 ng/mL was achieved within 60 minutes of the initiation of the infusion.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011341316A AU2011341316A1 (en) | 2010-12-10 | 2011-12-12 | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
US13/992,105 US20140088192A1 (en) | 2010-12-10 | 2011-12-12 | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
KR1020137018033A KR20140035325A (en) | 2010-12-10 | 2011-12-12 | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
CA2823642A CA2823642A1 (en) | 2010-12-10 | 2011-12-12 | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
JP2013543406A JP2014508113A (en) | 2010-12-10 | 2011-12-12 | Levodopaprodrug composition capable of subcutaneous injection and injection method |
EP11847546.6A EP2648716A4 (en) | 2010-12-10 | 2011-12-12 | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
SG2013044565A SG191090A1 (en) | 2010-12-10 | 2011-12-12 | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
BR112013014304A BR112013014304A2 (en) | 2010-12-10 | 2011-12-12 | subcutaneously infusible levodopa prodrug compositions and method of infusion |
CN201180066952.8A CN103648493A (en) | 2010-12-10 | 2011-12-12 | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42190210P | 2010-12-10 | 2010-12-10 | |
US61/421,902 | 2010-12-10 | ||
US201161431256P | 2011-01-10 | 2011-01-10 | |
US61/431,256 | 2011-01-10 | ||
US201161492227P | 2011-06-01 | 2011-06-01 | |
US61/492,227 | 2011-06-01 | ||
US201161538449P | 2011-09-23 | 2011-09-23 | |
US61/538,449 | 2011-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012079072A2 true WO2012079072A2 (en) | 2012-06-14 |
WO2012079072A3 WO2012079072A3 (en) | 2014-02-27 |
Family
ID=46207787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/064398 WO2012079072A2 (en) | 2010-12-10 | 2011-12-12 | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
Country Status (10)
Country | Link |
---|---|
US (1) | US20140088192A1 (en) |
EP (1) | EP2648716A4 (en) |
JP (1) | JP2014508113A (en) |
KR (1) | KR20140035325A (en) |
CN (1) | CN103648493A (en) |
AU (1) | AU2011341316A1 (en) |
BR (1) | BR112013014304A2 (en) |
CA (1) | CA2823642A1 (en) |
SG (1) | SG191090A1 (en) |
WO (1) | WO2012079072A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103932986A (en) * | 2014-04-17 | 2014-07-23 | 河北师范大学 | Method for preparing nano-liposome marked by colloidal gold and loaded with PD (pharmacodynamics) medicine |
US9446059B2 (en) | 2014-10-21 | 2016-09-20 | Abbvie Inc. | Carbidopa and L-dopa prodrugs and methods of use |
EP3075723A1 (en) * | 2015-03-30 | 2016-10-05 | Berlirem GmbH | Highly soluble L-DOPA glycerol esters |
WO2016155888A1 (en) * | 2015-03-30 | 2016-10-06 | Berlirem Gmbh | Water-soluble l-dopa esters |
JP2017500990A (en) * | 2013-11-05 | 2017-01-12 | シンアジャル コーポレイション | Devices and methods for continuous drug delivery through the mouth |
US9901561B2 (en) | 2015-05-06 | 2018-02-27 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
WO2018059739A1 (en) | 2016-09-29 | 2018-04-05 | Berlirem Gmbh | L-dopa derivatives for the treatment of neurological diseases |
US10117843B2 (en) | 2015-01-20 | 2018-11-06 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
WO2019097120A1 (en) | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
WO2020115753A1 (en) * | 2018-12-05 | 2020-06-11 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | L-dopa and/or dopa decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders |
EP4223288A1 (en) * | 2022-02-07 | 2023-08-09 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2432454T (en) | 2009-05-19 | 2017-07-10 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
NZ610911A (en) | 2010-11-15 | 2015-02-27 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
US10112040B2 (en) | 2011-11-15 | 2018-10-30 | Neurometrix, Inc. | Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode arrangement |
US11247040B2 (en) | 2011-11-15 | 2022-02-15 | Neurometrix, Inc. | Dynamic control of transcutaneous electrical nerve stimulation therapy using continuous sleep detection |
US11259744B2 (en) * | 2011-11-15 | 2022-03-01 | Neurometrix, Inc. | Transcutaneous electrical nerve stimulator with automatic detection of leg orientation and leg motion for enhanced sleep analysis, including enhanced transcutaneous electrical nerve stimulation (TENS) using the same |
PT2780073T (en) | 2011-11-15 | 2017-12-18 | Neurometrix Inc | Apparatus for relieving pain using transcutaneous electrical nerve stimulation |
US9474898B2 (en) | 2013-03-29 | 2016-10-25 | Neurometrix, Inc. | Detecting cutaneous electrode peeling using electrode-skin impedance |
US10940311B2 (en) | 2013-03-29 | 2021-03-09 | Neurometrix, Inc. | Apparatus and method for button-free control of a wearable transcutaneous electrical nerve stimulator using interactive gestures and other means |
WO2014172381A1 (en) | 2013-04-15 | 2014-10-23 | Neurometrix Inc. | Transcutaneous electrical nerves stimulator with automatic detection of user sleep-wake state |
US10109377B2 (en) * | 2013-12-03 | 2018-10-23 | Cura Technologies Inc. | System and method for facilitating delivery of patient-care |
HRP20231716T1 (en) | 2014-03-13 | 2024-03-15 | Neuroderm Ltd. | Dopa decarboxylase inhibitor compositions |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
RU2018119194A (en) * | 2015-11-24 | 2019-12-25 | Нейродерм Лтд. | PHARMACEUTICAL COMPOSITIONS CONTAINING AMEO LEVODOPA AND THEIR APPLICATIONS |
GB201521541D0 (en) * | 2015-12-07 | 2016-01-20 | Proximagen Ltd | New therapeutic uses of enzyme inhibitors |
RU2019119439A (en) | 2016-12-23 | 2021-01-26 | ДжиЭсКей Консьюмер Хелткер С.А. | "Intelligent" electrode node for transcutaneous electrical nerve stimulation (TESN) |
US11058877B2 (en) | 2017-05-30 | 2021-07-13 | Neurometrix, Inc. | Apparatus and method for the automated control of transcutaneous electrical nerve stimulation based on current and forecasted weather conditions |
US20230123806A1 (en) | 2017-07-07 | 2023-04-20 | Neuroderm, Ltd. | Device for subcutaneous delivery of fluid medicament |
KR102510743B1 (en) | 2017-07-07 | 2023-03-15 | 뉴로덤 엘티디 | Device for subcutaneous delivery of fluid medicament |
US11883661B2 (en) | 2018-12-07 | 2024-01-30 | Neurometrix, Inc. | Intelligent determination of therapeutic stimulation intensity for transcutaneous electrical nerve stimulation |
WO2020128831A2 (en) * | 2018-12-17 | 2020-06-25 | Endopump Ltd. | Subcutaneously implanted device for gastrointestinal administration of substances |
US20230174690A1 (en) * | 2019-12-26 | 2023-06-08 | Rutgers, The State University Of New Jersey | Compositions and methods for single-step multipurpose surface functionalization |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE76747T1 (en) * | 1986-06-10 | 1992-06-15 | Chiesi Farma Spa | PHARMACEUTICAL COMPOSITIONS CONTAINING LEVODOPA METHYL ESTER, THEIR PREPARATION AND THERAPEUTIC USES. |
US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
WO2005121070A1 (en) * | 2004-06-04 | 2005-12-22 | Xenoport, Inc. | Levodopa prodrugs, and compositions and uses thereof |
SE0401842D0 (en) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
US7709527B2 (en) * | 2006-12-21 | 2010-05-04 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use |
NZ601248A (en) * | 2008-04-14 | 2014-06-27 | Halozyme Inc | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
-
2011
- 2011-12-12 WO PCT/US2011/064398 patent/WO2012079072A2/en active Application Filing
- 2011-12-12 CA CA2823642A patent/CA2823642A1/en not_active Abandoned
- 2011-12-12 AU AU2011341316A patent/AU2011341316A1/en not_active Abandoned
- 2011-12-12 CN CN201180066952.8A patent/CN103648493A/en active Pending
- 2011-12-12 KR KR1020137018033A patent/KR20140035325A/en not_active Application Discontinuation
- 2011-12-12 BR BR112013014304A patent/BR112013014304A2/en not_active IP Right Cessation
- 2011-12-12 JP JP2013543406A patent/JP2014508113A/en active Pending
- 2011-12-12 EP EP11847546.6A patent/EP2648716A4/en not_active Withdrawn
- 2011-12-12 US US13/992,105 patent/US20140088192A1/en not_active Abandoned
- 2011-12-12 SG SG2013044565A patent/SG191090A1/en unknown
Non-Patent Citations (1)
Title |
---|
See references of EP2648716A4 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020203914A (en) * | 2013-11-05 | 2020-12-24 | シンアジャル コーポレイション | Devices and methods for continuous drug delivery via mouth |
JP2017500990A (en) * | 2013-11-05 | 2017-01-12 | シンアジャル コーポレイション | Devices and methods for continuous drug delivery through the mouth |
JP2019063574A (en) * | 2013-11-05 | 2019-04-25 | シンアジャル コーポレイション | Devices and methods for continuous drug delivery via mouth |
CN103932986B (en) * | 2014-04-17 | 2016-01-20 | 河北师范大学 | A kind of method being mounted with the nanometer liposome of PD medicine preparing colloid gold label |
CN103932986A (en) * | 2014-04-17 | 2014-07-23 | 河北师范大学 | Method for preparing nano-liposome marked by colloidal gold and loaded with PD (pharmacodynamics) medicine |
US10730895B2 (en) | 2014-10-21 | 2020-08-04 | Abbvie Inc. | Carbidopa prodrug |
US9446059B2 (en) | 2014-10-21 | 2016-09-20 | Abbvie Inc. | Carbidopa and L-dopa prodrugs and methods of use |
US11091507B2 (en) | 2014-10-21 | 2021-08-17 | Abbvie Inc. | Methods of treating Parkinson's disease |
US10174061B2 (en) | 2014-10-21 | 2019-01-08 | Abbvie Inc. | Carbidopa and L-dopa prodrugs and methods of use |
US10117843B2 (en) | 2015-01-20 | 2018-11-06 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
US11046640B2 (en) | 2015-03-30 | 2021-06-29 | Berlirem Gmbh | Water-soluble L-DOPA esters |
CN107848954A (en) * | 2015-03-30 | 2018-03-27 | 伯里兰有限责任公司 | Water-soluble L DOPA esters |
WO2016155888A1 (en) * | 2015-03-30 | 2016-10-06 | Berlirem Gmbh | Water-soluble l-dopa esters |
EP3075723A1 (en) * | 2015-03-30 | 2016-10-05 | Berlirem GmbH | Highly soluble L-DOPA glycerol esters |
US10786474B2 (en) | 2015-05-06 | 2020-09-29 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US10588882B2 (en) | 2015-05-06 | 2020-03-17 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US10328044B2 (en) | 2015-05-06 | 2019-06-25 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US10300033B2 (en) | 2015-05-06 | 2019-05-28 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US9901561B2 (en) | 2015-05-06 | 2018-02-27 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US11135191B2 (en) | 2015-05-06 | 2021-10-05 | Synagile Corporation | Devices for the administration of pharmaceutical suspensions |
US11426376B2 (en) | 2015-05-06 | 2022-08-30 | Synagile Corporation | Devices for the administration of pharmaceutical suspensions |
WO2018059739A1 (en) | 2016-09-29 | 2018-04-05 | Berlirem Gmbh | L-dopa derivatives for the treatment of neurological diseases |
WO2019097120A1 (en) | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
WO2020115753A1 (en) * | 2018-12-05 | 2020-06-11 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | L-dopa and/or dopa decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders |
EP3890713A4 (en) * | 2018-12-05 | 2023-01-04 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | L-dopa and/or dopa decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders |
EP4223288A1 (en) * | 2022-02-07 | 2023-08-09 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
WO2023148401A1 (en) * | 2022-02-07 | 2023-08-10 | Berlirem Gmbh | Novel kit of pharmaceutical preparations for the treatment of neurodegenerative diseases |
Also Published As
Publication number | Publication date |
---|---|
WO2012079072A3 (en) | 2014-02-27 |
CA2823642A1 (en) | 2012-06-14 |
BR112013014304A2 (en) | 2016-07-19 |
AU2011341316A1 (en) | 2013-07-04 |
CN103648493A (en) | 2014-03-19 |
JP2014508113A (en) | 2014-04-03 |
EP2648716A2 (en) | 2013-10-16 |
SG191090A1 (en) | 2013-07-31 |
EP2648716A4 (en) | 2015-05-20 |
KR20140035325A (en) | 2014-03-21 |
US20140088192A1 (en) | 2014-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012079072A2 (en) | Subcutaneously infusible levodopa prodrug compositions and methods of infusion | |
US20150217046A1 (en) | Dosing regimens for subcutaneously infusible acidic compositions | |
CA2574437C (en) | Infusion and injection solution of levodopa | |
ES2227301T3 (en) | INJECTABLE PHARMACEUTICAL COMPOSITION FOR THE SYSTEMATIC ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE PRINCIPLES CONTAINING MEDIUM CHAIN TRIGLICERIDES. | |
AU2013318146B2 (en) | Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium | |
JP2003500119A (en) | Dosing device and administration method of small molecule insulin-like substance | |
US20140128355A1 (en) | Baclofen solution for low-volume therapeutic delivery | |
US11672863B2 (en) | Enhanced solubility drug-containing formulations | |
US20190224153A1 (en) | L-dopa derivatives for the treatment of neurological diseases | |
Pravika et al. | The Impact of Manually Controlled Portable Duodopa Pump on Levodopa Pharmacokinetics and Pharmacodynamics | |
JP2021506933A (en) | Treatment of Exercise-Induced Hypoglycemia in Type 1 Diabetes and Insulin Use Type 2 Diabetes | |
KR20200136008A (en) | Continuous administration of pharmaceutical compositions for the treatment of neurodegenerative disorders | |
US20230338647A1 (en) | Subcutaneously implanted device for gastrointestinal administration of substances | |
CN116172943B (en) | Injectable sustained-release gel preparation and application thereof | |
WO2022175973A1 (en) | An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof | |
CN100435788C (en) | Inhibitor for perioperative blood sugar elevation | |
Wallace et al. | Characteristics of Distribution of Morphine and Metabolites in Cerebrospinal Fluid and Plasma With Chronic Intrathecal Morphine Infusion in Humans | |
UA102195U (en) | METHOD OF POSTOPERATIVE ANALYSIS OF PATIENTS WITH TUMOR TUMORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11847546 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2013543406 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011847546 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2823642 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2011341316 Country of ref document: AU Date of ref document: 20111212 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20137018033 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13992105 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013014304 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013014304 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130607 |